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Summary:  
Each year, over 5 million people die as a consequence of stroke worldwide, and 
at least 1 in 6 patients who survive a stroke will suffer another stroke within 5 
years1. Yet, even validated clinical prognostic models are not sufficiently precise 
to predict outcome in patients with stroke2. In this context blood biomarkers may 
add to improve prognostic accuracy for risk stratification, decision-making and 
thus ultimately patient outcome. Our research focus was to identify and assess 
different blood biomarkers to improve risk stratification and identification of stroke 
etiology. We selected the most promising neuroendocrine candidate biomarkers.  
 During stress, vasopressin is a potent synergistic factor of corticotropin 
releasing hormone (CRH) as a hypothalamic stimulator of the hypothalamo-
pituitary-adrenal (HPA)- axis3-7. Measurements of CRH and vasopressin levels 
are cumbersome because of their instability and short half-life8-10. In contrast, 
copeptin is a more stable peptide, which is stoichiometrically released from the 
vasopressin precursor molecule11.  
 The aim of our first study was to evaluate copeptin as a new “stress 
marker” and to compare it to cortisol levels in different stress situations (i.e. 
healthy controls, medical patients and patients after heart surgery). Copeptin 
showed a more pronounced increase upon substantial physical stress as 
compared to cortisol levels. It reflected even moderate stress more subtly as 
compared to cortisol. Thus, copeptin appeared to be a new promising stress 
marker (study I)12.  
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 After identifying copeptin as a stress biomarker, we determined its value 
as a prognostic marker in patients with acute ischemic stroke. In this cohort 
study, copeptin was measured on admission in consecutive stroke patients and 
neurological outcome was assessed at 3 months.  Copeptin remained highly 
predictive even after adjusting for risk factors and it improved the prognostic 
accuracy of the established National Institute of Health Stroke Score (NIHSS). 
Thus, we concluded that copeptin is a novel, independent prognostic marker 
improving currently used risk stratification of stroke patients (study II)13.  
 The predictive value of copeptin persisted also when assessed for long-
term functional outcome and mortality one year after the index stroke (study III)14. 
 In the same stroke cohort we evaluated the prognostic value of cortisol, 
triiodothyronine (T3), free thyroxine (fT4), thyroid- stimulating hormone (TSH) 
and growth hormone (GH) simultaneously. We found that the prognostic 
accuracy of cortisol was higher compared to the other anterior pituitary axis 
hormones. Cortisol was an independent prognostic marker of functional outcome 
and death within 90 days and one year but, unlike copeptin, cortisol contributed 
only limited additional predictive value to the NIHSS score (study IV)15. 
 To validate the incremental value of copeptin in the prediction of outcome 
compared to established clinical variables, we performed an independent 
multicenter cohort study. We demonstrated that in patients with ischemic stroke, 
copeptin is the first validated blood biomarker that added predictive information 
for functional outcome and mortality at three months beyond established 
prognostic models including, vascular risk factors, age, comorbidities, imaging 
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information and the NIHSS. In addition, copeptin also showed to be a new 
promising blood biomarker for prediction of in-hospital complications (study V)16. 
 As copeptin was an accurate prognostic marker in acute ischemic stroke 
we aimed at assessing its reliability for risk stratification in patients with transient 
ischemic attacks (TIAs). We thus conducted a prospective study in TIA patients. 
Copeptin but not cortisol improved the prognostic accuracy of the routinely used 
ABCD2 risk score. We concluded that if validated in an independent cohort, 
routine copeptin measurement may be an additional tool for risk stratification and 
targeted resource allocation after TIA (study VI)17. 
Besides their application as a prognostic tool, serum biomarkers may also 
enhance etiologic classification and thus improve patient allocation to the 
appropriate therapy. A-type natriuretic peptides (ANP) have been associated with 
the activation of the sympathetic nervous system and have been proposed as 
biomarkers of atrial fibrillation (AF)18,19. So we assessed the diagnostic value of 
mid-regional pro ANP in acute ischemic stroke patients and found that it was a 
new independent and reliable diagnostic marker for cardioembolic etiology (study 
VII)20.  
Early predictors for the development of stroke-associated infection may identify 
high-risk patients and reduce post-stroke infection and mortality. We found that 
among ischemic stroke patients, copeptin, procalcitonin, white blood cell count 
and CRP measured on admission were predictors of infection within 5 days after 
stroke. The combination of these biomarkers improved the prediction of patients 
who developed an infection (study VIII)21.   
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UTI Urinary Tract Infections 
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1. Introduction 
1.1. Prognosis after acute ischemic stroke  
Stroke is the third leading cause of death and the leading cause of chronic 
serious disability22. Each year, more than 5 million people die as a consequence 
of stroke, and at least 1 in 6 patients who survive a stroke will suffer another 
stroke within 5 years1. Thus many patients fear the disabling consequences of 
stroke even more than those of coronary heart disease. However, stroke risk 
factors and outcome predictors have generally received less attention. Thus, the 
development of a credible evidence base of prognostic information for outcomes 
that are meaningful to patients and clinicians, including level of independency, is 
required. However, even currently available, validated clinical prognostic models 
are still in need for further improvement2. In this context blood biomarkers may 
add to improve prognostic accuracy for risk stratification, decision-making and 
thus ultimately patient outcome. 
 
1.2. Blood biomarkers in the setting of stroke  
A blood biomarker in the setting of acute stroke can be any quantifiable entity 
that assesses the manifestation of a stroke-related process. There may be 
markers for example to guide risk stratification, to characterize stroke size and 
clinical severity, to reveal stroke etiology, to select appropriate treatment options, 
to identify patients that may benefit most from interventions, to monitor treatment 
efficacy, and to recognize the risk of worsening or complications in the short term 
or the risk of unfavorable long term outcome. To address these questions, 
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stroke-related biomarkers need to be associated with diverse pathophysiological 
processes immediately preceding stroke or processes during and after stroke.  
Brain injury following transient or permanent focal cerebral ischemia results from 
a complex cascade of pathophysiological events that evolve in time and space23. 
In ischemic stroke the inciting event is the embolic or thrombotic obstruction of 
arterial flow to the brain. In brief, sudden cerebral hypoperfusion leads to cellular 
bioenergetic failure, excitotoxicity, and oxidative stress with subsequent blood 
brain barrier dysfunction, inflammation, perturbation of haemostasis, activation of 
neuroendocrine axes, and eventually apoptosis and necrosis of neuronal, glial 
and endothelial cells23-27. Outcome after ischemic stroke depends on all these 
factors, which contribute to break the balance either towards a favorable or 
unfavorable outcome (figure 1). 
Figure 1. Ischemic cascade and Prognosis after stroke (slide by Mira Katan 2009) 
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1.3. Implementation and selection of stroke biomarkers 
The most fruitful implementation for stroke biomarkers is in areas where 
information from traditional clinical sources is currently limited such as:  
A) Risk stratification and prediction of adverse outcomes since they are 
prerequisites for safe decision-making for interventions, the degree of monitoring 
(intensive care unit, intermediate care or normal ward), the need for 
hospitalization versus outpatient management. 
B) Determination of stroke etiology, since this has also direct implications for 
treatment decisions. 
Our main research focus over the past 5 years was to identify and assess 
different blood biomarkers to improve risk stratification and the identification of 
stroke etiology. Instead of picking the largely investigated brain tissue or 
coagulation markers such as astroglial S100beta or d-dimeres, we chose an 
innovative, more holistic approach and selected the most promising candidate 
biomarkers of the neuroendocrine system. Activation of the hypothalamo-
pituitary-adrenal- axis or “stress- axis” is among the first measurable 
physiological response to cerebral ischemia28-31. Neuroendocrine markers act 
and interact to preserve overall homeostasis after acute tissue damage. Each 
“stressor” such as the impact of neuronal cell death or the impact of 
comorbidities, even social factors, influences the final “stress” marker level. As 
such they reflect the ‘global threat’ to the body and thus they may indicate when 
the threshold to return to homeostasis is crossed and the outcome of the 
individual shifts towards an unfavorable outcome. Besides the advantage of 
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incorporating information from different systems, acting and interacting 
systemically as well as within the brain, some of these neuroendocrine markers 
are easily accessible and can be measured reliably. 
 
1.4. Neuroendocrine biomarkers 
The hormonal cascade initiated by a “stressor“ through brain stem and limbic 
pathways involves the release of CRH from parvocellular neurons in the 
paraventricular nucleus of the hypothalamus32. CRH stimulates the release of 
ACTH from the anterior pituitary gland. Another hypothalamic hormone, which is 
stimulated by different stressors and probably different pathways, is arginine- 
vasopressin. AVP seems to exert a potentiating action on CRH and these two 
agents together are considered the main secretagogues of ACTH3-7 (figure 2).  
Figure 2.  Main secretagogues of ACTH 
 
    Adapted from Katan et al. Swiss Med Wkly. 201033 
CRHAVP
Cortisol
ACTH
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ACTH, in turn, stimulates the adrenal cortex to produce cortisol. Cortisol is the 
“classical” stress hormone at a peripheral level and easy to measure. However, 
the assessment and interpretation of cortisol levels to assess the integrity of the 
HPA-axis is dependent on an intact anterior pituitary and adrenal gland. For a 
direct assessment of recognition of a stressor at the level of the central nervous 
system, the measurement of CRH or AVP has theoretical advantages as these 
hypothalamic hormones are produced in the brain but are directly released in the 
systemic circulation. They may, therefore, be optimal blood biomarkers for 
several neurological illnesses since they do not require blood brain barrier 
disruption to be systemically measurable. Thus they can be considered directly 
reflective of brain disease activity even without major destruction. However, the 
measurement of circulating CRH or AVP levels is challenging. Both CRH and 
AVP are released in a pulsatile pattern, are unstable (especially at room 
temperature), and are rapidly cleared from plasma within minutes8-10,34. AVP 
derives from a larger precursor peptide (pre-provasopressin) along with two other 
peptides, neurophysin II and copeptin. Copeptin is released in an equimolar ratio 
to AVP and is more stable in the circulation and easy to measure. Copeptin 
levels closely mirror the production of AVP34 (figure 3). 
We hence believed that copeptin may reflect the individual “stress-burden” or 
degree of disruption of “homeostasis” on a hypothalamic level while elegantly 
bypassing the blood brain barrier due to direct systemic release. 
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Figure 3. Pre-provasopressin 
 
 
2. Methods and Results 
2.1.  Evaluation of Copeptin as a new neuroendocrine biomarker 
Based on the fact that AVP is involved in the stress response and based on the 
findings that copeptin mirrors AVP levels we first evaluated copeptin under the 
influence of different physical stressors. To evaluate the discriminatory value of 
copeptin as compared to cortisol and to assess different stress-levels we 
performed an observational study including patients with presumed increasing 
levels of stress. We hypothesized that copeptin as a brain-derived stress 
hormone provides a more direct and subtle measure of the individual stress level 
compared to cortisol.  
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  2.1.1. Study I 
To gather pilot data12 we intended to test three categories (group A-C) of 
patients, all without prior evidence for HPA- axis dysfunction, in different levels of 
stress caused by the severity of the underlying illness. Ethical approval was 
obtained, and the patients or their legal representatives gave written informed 
consent. Group A (no stress) contained 20 healthy control subjects, without 
apparent stress. Group B (moderate stress) consisted of 25 patients 
consecutively recruited from a wide and representative variety of patients having 
been hospitalized on the medical ward for at least 48 hours. In Group C, 29 
stable surgical patients were consecutively recruited undergoing elective 
coronary bypass grafting under general anaesthesia. Peak cortisol levels are 
achieved in the immediate postoperative period, around the time of 
extubation35,36. Therefore, large surgery can serve as a standardized 
physiological model for studying major stress37. Indeed, copeptin showed a 
gradual increase with increasing levels of stress and, in contrast to cortisol levels, 
differentiated between healthy control subjects without apparent stress and 
medical patients with a moderate degree of stress12,32. In addition, copeptin 
showed a more pronounced increase upon major stress as compared to cortisol 
(the increase in cortisol was 265 ± 34% and in copeptin 1430 ± 157%, 
p<0.001)12. 
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2.2.  Neuroendocrine biomarkers for the prediction of functional 
outcome and mortality in stroke patients 
Many publications have reported an association of different biomarkers (e.g. C 
reactive protein, matrix metalloproteinase 9, neuron specific enolase) with stroke 
severity or outcome. However, none of these publications reported that the 
analyzed biomarker provided additional prognostic information compared to 
established clinical variables (e.g. age, blood pressure, nicotine, dyslipidemia, 
co-morbidities such as heart failure and lesion size) or whether the biomarker 
increased the predictive power of validated clinical prognostic scores38 such as 
the NIHSS Score. We thus conducted a prospective cohort study to assess the 
incremental value of copeptin in the prognosis after stroke and TIA. The study 
was approved by the local ethics committee. From 605 screened patients with 
suspected cerebrovascular events, in 362 patients an ischemic stroke, in 40 
patients a hemorrhagic stroke and in 107 patients a TIA was diagnosed 
according to the World Health Organization Criteria39 . At baseline we recorded 
vital signs and vascular risk factors. Co-morbidities were assessed by the 
modified Charlson Comorbidity Index40. Severity of stroke was determined on 
admission by the NIHSS41. In TIA patients we recorded the ABCD2 Score. 
Computed tomography or magnetic resonance imaging was performed on 
admission on each patient. Detailed information such as cardiac and 
neurovascular ultrasound and 24-hour ECGs were collected to define stroke 
etiology according to the TOAST classification42. The clinical stroke syndrome 
was determined by applying the criteria of the Oxfordshire Community Stroke 
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Project; i.e. total anterior circulation syndrome, partial anterior circulation 
syndrome, lacunar syndrome, and posterior circulation syndrome43. Blood 
samples were collected within 72 h hours from symptom onset and categorized 
into 0-3h (window for thrombolysis at the time the study was conducted); 3-12h; 
12-24h and 24-72h. Plasma was frozen at – 70 °C. Copeptin measurement was 
done in a single batch with a commercial sandwich immunoluminometric assay 
with a lower detection limit of 0.4 pmol/L and a functional assay sensitivity (< 20 
% inter assay coefficient of variance) of < 1 pmol/L44.  
  2.2.1. Study II 
The primary end point of this study13 was unfavorable functional outcome after 90 
days from baseline, defined as modified Rankin Scale of 2 to 6 points. The 
secondary end point was death from any cause within 90-days follow-up13.  
In this prospective, observational study, the median age of patients with ischemic 
stroke was 75 (IQR 63-83) years and 41% were women. An unfavorable 
functional outcome was found in 151 patients (42%) with a median mRS score of 
4 (IQR 3-6). Forty-four patients died and mortality rate was thus 12%. We found 
copeptin to be a novel, strong, and independent prognostic marker for functional 
outcome and death (table 1). 
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Table 1. Multivariate analyses for the primary and secondary outcome 
 
In addition, copeptin had a superior discriminatory value if compared to CRP ( 
AUC 0.61; 95% CI 0.55-0.68; p<0.001), white blood cell count (AUC 0.55; 95% 
CI 0.49-0.62; p<0.0001) and glucose (AUC 0.57; 95% CI 0.50-0.63; p<0.001). 
Importantly, copeptin improved the prognostic accuracy of the NIHSS score. The 
combination of the clinical score with the biomarker revealed a significantly 
higher AUC of 0.79 (95% CI 0.75-0.84) to predict functional outcome if compared 
to the clinical score or the marker alone. The combined AUC of 0.89  (95% CI 
0.84-0.94) predicting death was even higher. To further estimate the incremental 
prognostic information of copeptin levels to the traditional outcome predictor (i.e. 
NIHSS), we calculated the net reclassification improvement, which has recently 
been proposed as a statistical method to evaluate prognostic biomarkers45. This 
statistic examines whether the addition of a blood marker moves those with 
unfavorable outcome to higher risk categories more often than to lower risk 
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categories and those with a favorable outcome to lower risk categories more 
often than to higher risk categories. We used a priori risk groups based on risk 
classification by Adams et al. and Goldstein et al.46,47. The NRI for functional 
outcome was 39% and for mortality 48% thus copeptin helped in 39 %, 
respectively 48% of patients to improve classification if compared to the NIHSS 
alone. Further, time to death was analyzed by Kaplan Meier survival curves. 
Patients in the lower two quartiles had a minimal risk of death, in contrast to 
patients with copeptin levels in the 3rd and 4th quartile (p<0.0001).  
To strengthen the assumption that copeptin is an accurate marker in the very 
acute phase we analysed the subgroup of patients with symptom onset between 
0–3 hours (n = 78) and the prognostic accuracy for functional outcome and 
mortality was very similar to the overall sample (data not shown). 
  2.2.2. Study III 
Next we performed a long-term follow-up study14 in the aforementioned cohort 
aiming to evaluate copeptin levels as a potential marker to predict long-term 
functional outcome and mortality in acute stroke patients one year after 
admission to the emergency department14. From 362 patients, 341 (94.2%) 
completed the one-year follow-up. Multivariate logistic regression analysis 
adjusted for age and NIHSS showed that copeptin was an independent predictor 
for functional outcome (OR 4.00, 95%CI 1.94-8.19) and death (OR 2.68, 95%CI 
1.24-5.82). The AUC of copeptin for functional outcome was 0.72 (95%CI 0.67-
0.77) and for mortality 0.74 (95%CI 0.69-0.78). Copeptin levels significantly 
improved the AUC of NIHSS for functional outcome from 0.70 (95%CI 0.64-0.74) 
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to 0.76 (95%CI 0.71-0.82, p=0.002) and for mortality from 0.74 (95%CI 0.69-
0.78) to 0.78 (95%CI 0.71-0.85, p=0.04). In addition we calculated Kaplan Meier 
curves and stratified patients based on copeptin tertiles. As demonstrated in 
Figure 4, we found an increased risk for mortality with increasing copeptin 
tertiles, particularly from the second to the third tertile. 
Figure 4. Copeptin and stroke mortality  
 
Urwyler S. et al. Stroke 2010.14 
 
  2.2.3. Study IV 
To assess if other markers of the anterior pituitary axis hormones namely 
cortisol, T3, fT4, TSH and GH are associated with functional outcome and 
mortality within 90 days and one year after stroke we measured these hormones 
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in blood samples of the same stroke cohort which were obtained from an 
indwelling venous catheter the first morning after admission. For this study15 
blood was collected at 7am the day after admission for standardized 
measurement of hormones. Hormone measurements on day one were not 
available in the whole cohort, either because patients had died or were already 
discharged on day one thus for the final analysis 281 ischemic stroke patients 
were included. Cortisol was measured with a competitive chemiluminescence 
immunoassay (IMMULITE 2000; Siemens Medical Solution Diagnostics, Los 
Angeles, CA, USA) with a calibration range from 28 to 1380 nmol/l. T3 (nmol/l), 
fT4 (pmol/l) and TSH (mIU/l) were measured by an electro-chemistry-
luminescence immuno-assay (ECLIA, Roche Diagnostics, Mannheim, Germany). 
Growth hormone was measured using a high-sensitivity chemiluminescence 
immunoassay with a functional assay sensitivity of 0.027 ng/ml as described 
recently48. For all measurements, levels that were not detectable were 
considered to have a value equal to the lower limit of detection of the assay.  
In this study15 we found that in the receiver operating characteristic curve 
analysis, the prognostic accuracy of cortisol was higher compared to all other 
measured hormones and that it was in the range of the NIHSS, similarly to 
copeptin. Cortisol was also an independent prognostic marker of functional 
outcome and death (OR 1.23 (95% CI 1.07–1.43) and 1.43 (95%CI 1.17–1.75), 
respectively, p < 0.01 for both), adjusted for age and the NIHSS, by contrast, the 
other anterior pituitary axis hormones i.e. TSH, peripheral thyroid hormones and 
GH were only of minor value to predict outcome in stroke (table 2).   
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Table 2. Univariate and multivariate association between hormone levels 
and outcome
 
Neidert S and Katan M. et al. J Intern Med 201115 
 
Cortisol unlike copeptin (in our previous study13) however added no significant 
additional predictive value to the clinical NIHSS score. Moreover, the magnitude 
of association in terms of odds ratios was also less impressive if compared to 
copeptin. 
  2.2.4. Study V 
Before implementing copeptin in clinical practice, we wanted to validate the 
prognostic potential of copeptin in a prospective, independent, large multi-center 
study49. Validation of biomarker study results is crucial, as a recent meta-analysis 
suggested that pilot studies on blood biomarkers typically report higher effect 
sizes than subsequent larger validation studies of the same blood biomarker50. 
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Moreover, it was unclear whether copeptin predicts outcome in patients with 
ischemic stroke treated differently, that is, conservatively or with thrombolysis 
and if copeptin might also predict in hospital complications such as malignant 
cerebral edema, seizures etc. The CoRisk study aimed at validating the accuracy 
of copeptin in predicting functional outcome, mortality, and complications as 
compared to established clinical variables in a multicenter, international setting49. 
For the analysis of this study16 we included 788 patients older than 18 years with 
an acute ischemic stroke within 24 hours of symptom onset, admitted 
consecutively to the emergency department of each tertiary care center (Berne, 
Basel, Frankfurt and Berlin) between March 24, 2009 and April 8, 2011. The two 
primary endpoints were unfavorable functional outcome (mRS 3-6 points) and 
mortality within 90 days. Secondary endpoint was any of the following five pre-
specified complications during hospitalization: (1) symptomatic intracerebral 
hemorrhage according to the SITS-MOST criteria51 (parenchymal hematoma 
type 2 accompanied by a four-point increase in the NIHSS score or leading to 
mortality), (2) space-occupying cerebral edema, (3) pneumonia (defined as 
auscultatory respiratory crackles combined with body temperature ≥ 38 °C, 
purulent sputum, or positive chest x-ray), (4) seizures (clinical diagnosis of focal 
and/or generalized seizure in a previously non-epileptic patient)52 or (5) mortality 
within 10 days from admission. We found that higher copeptin levels again 
independently predicted unfavorable outcome (adjusted OR 2.17 [95% CI, 1.46–
3.22], p<0.001) and mortality (adjusted OR 2.69 [95% CI, 1.64–4.41], p<0.001). 
Additionally we could demonstrate that copeptin was also predictive of in house 
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complications (adjusted OR 1.93 [95% CI, 1.33–2.80], p<0.001). The 
discriminatory accuracy, calculated with the area under the receiver operating 
characteristics curve improved significantly for all endpoints when adding 
copeptin to different prognostic models including the strongest clinical predictors 
such as the NIHSS score and age (table 3). Moreover, the combination of 
copeptin with a validated score encompassing both the NIHSS and age led to a 
net reclassification improvement of 11.8% for functional outcome and of 37.2% 
for mortality. Finally the predictive value of copeptin regarding functional outcome 
and mortality was consistent across all subgroups. We did not identify any 
significant effect modifiers (figure 6). 
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Table 3. Area under the Curve for Functional Outcome and Mortality 
Functional Outcome 
Predictors ROC Area 95% CI P* 
Copeptin [pmol/l] 0.71 0.67 – 0.75 - 
NIHSS 0.81 0.78 – 0.84 
<0.001 
NIHSS + Copeptin [pmol/l] 0.83 0.80 – 0.86 
      
Model 1 0.86 0.84 – 0.89 
<0.001 
Model 1 + Copeptin [pmol/l] 0.87 0.85 – 0.90 
Mortality 
Predictors ROC Area 95% CI P* 
Copeptin [pmol/l] 0.75 0.71 – 0.80 - 
NIHSS 0.80 0.77 – 0.84 
<0.001 
NIHSS + Copeptin [pmol/l] 0.83 0.79 – 0.86 
      
Model 2 0.86 0.82 – 0.90 
<0.001 
Model 2 + Copeptin [pmol/l] 0.87 0.83 – 0.91 
      
 
Footnote: Model 1 was the multivariate logistic regression model including all 
significant predictors of the univariate analysis (i.e. age, hypertension, diabetes 
mellitus, atrial fibrilation, modified charlson index, kidney impairment, NIHSS, 
TACS, Glucose, CRP, gender, DWI lesion size, unknown aetiology of stroke, 
time from symptom onset) and Model 2 was the cox regression model including 
the same predictors.*To test the statistical significane of the comparison of 
nested versus whole models we used the liklihood ratio test.  
DeMarchis and Katan et al., Neurology 201316 
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Figure 6. Interaction analyses 
 
DeMarchis and Katan et al., Neurology 201316 
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2.3. Prediction of re-events after transient ischemic attacks 
There is much interest in identifying clinical prognostic indicators that can be 
used to estimate stroke risk after transient ischemic attacks. The high short-term 
risk of stroke following TIA has been emphasized, but the ability to identify high 
risk patients is suboptimal53. Thus, comparably cheap, reliable and rapidly 
measureable prognostic blood markers measured in the Emergency Department 
may be helpful in early risk stratification and potentially improve clinical decision 
making in TIA patients.  
2.3.1. Study VI 
The present study17 evaluated the two stress-markers copeptin and cortisol as 
new prognostic tools for the risk- stratification of re-events in a sub-cohort of 
patients with TIA derived from the aforementioned large prospective cohort (see 
paragraph 2.2.). The primary endpoint of this analysis was a subsequent 
cerebrovascular event (i.e. ischemic and hemorrhagic stroke, TIA) in the first 90 
days in patients with a TIA, assessed by a structured follow up telephone 
interview.  Stroke was defined as an acute deficit of focal neurological function 
with symptoms lasting more than 24 hours, resulting from intracranial vascular 
disturbance (ischemia or haemorrhage) occurring within 90 days after the index 
event. TIA was defined as an acute loss of focal cerebral or ocular function with 
symptoms lasting less then 24 hours of presumed ischemic origin following 
adequate investigations54.  
From all patients (n= 605) with a suspected cerebrovascular event, a total of 107 
patients were diagnosed with a TIA on admission. All patients with acute 
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transient neurological dysfunction, in whom diagnostic workup suggested a non-
vascular disorder, were classified as TIA mimics54. Risk-stratification according to 
the currently used ABCD2- score55 was performed. All patients underwent a 
standardized diagnostic work up including specification of stroke etiology 
according to the TOAST classification56, and routine laboratory testing. All 
plasma blood samples were obtained on admission within 72 hours of symptom 
onset. Copeptin was measured with a new chemiluminescence sandwich 
immunoassay34 and Cortisol was measured with a competitive 
chemiluminescence immunoassay (IMMULITE 2000; Siemens Medical Solution 
Diagnostics, Los Angeles, CA, USA). 
 
We found cerebrovascular re-events after a TIA within 90 days in ten (9%) 
patients, eight (8%) out of the ten patients presented with a new TIA and two 
(2%) had an ischemic stroke. One patient with an ischemic stroke died. Patients 
with a cerebrovascular re-event had higher median copeptin levels than patients 
without a re-event (11.25 (IQR 9.11-24.78) pmol/L) vs. 4.55 (IQR 2.8-7.8) pmol/L, 
p=0.016). In contrast, median basal cortisol levels in patients developing a 
cerebrovascular re-event compared to those without a re-event were similar 
(382.0 (IQR 331.0-437.5) nmol/L vs. 408 (IQR 317-557) nmol/L, p=0.53). The 
AUC for copeptin to predict a re-event was 0.73 (95% CI 0.545- 0.922). At a 
copeptin cut- off of 9.0 pmol/L, sensitivity was 80% with a specificity of 76% to 
diagnose a re-event. Combining copeptin and the ABCD2- score in a combined 
logistic regression model showed an AUC of 0.77 (95% CI 0.596- 0.949). This 
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combination of the clinical score and the biomarker showed a higher overall 
prognostic accuracy than the ABCD2- score alone (0.43 (95% CI 0.291-0.570), 
p= 0.002). Patients with copeptin levels below 4.60 pmol/L had a minimal risk of 
cerebrovascular re-events, in contrast to patients with copeptin levels above 4.60 
pmol/L, who were at higher risk to develop a new cerebrovascular event (log rank 
p=0.02) (See Fig 7) 
Figure 7.  Time to re-event analysis after TIA 
 
              Mira Katan et. al. Neurology 201117 
In the MRI subgroup of patients (n=88) presenting with ischemia compatible DWI 
lesions (n=7) (6%) copeptin levels were higher than in patients without DWI 
lesions (12.65 (3.75-43.55) pmol/l vs. 4.50 (2.70-7.57) pmol/l, p=0.045). 
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2.4. Identification of stroke etiology 
At least 1 in 6 patients who survives a stroke will suffer another stroke within 5 
years1. For optimal secondary prevention directed at the underlying mechanism, 
an etiological classification of stroke is critical. Even with a thorough evaluation, 
the etiology of ischemic stroke remains “undetermined” (i.e. classified as 
cryptogenic stroke according to the classical TOAST criteria56) or only “possible” 
or “probable”  (according to the SSS TOAST-criteria57). Thus in 25-39% of 
patients a specific secondary prevention cannot be initiated58. The highest rates 
of stroke recurrence and mortality are seen in patients with cardioembolic and 
cryptogenic stroke59. The use of rapidly measurable serum biomarkers for 
etiologic diagnostic assessment on admission may enhance etiologic 
classification and thus improve the implementation of optimal secondary 
prevention, patient outcome and benefit-cost ratio.  
 2.4.1. Natriuretic peptides as cardioembolic markers 
Interesting candidates for etiological biomarkers in acute stroke are natriuretic 
peptides. These peptides belong to a group of vasoactive peptide hormones 
whose release in part is stimulated by the sympathetic nervous system. Their 
physiological role is generally to maintain hemodynamics, by their natriuretic, 
diuretic and vasodilating actions. A-type natriuretic peptides have been proposed 
as biomarkers in determining atrial fibrillation and MRproANP plasma levels 
correlate with the duration of AF episodes18,19. Recently a new assay has been 
designed for ANP to detect the mid-region of the prohormone60. The mid-regional 
fragment of proANP is more stable than the N- or C-terminal part of the precursor 
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in vivo and in blood ex vivo, which renders it generally more applicable to clinical 
practice61.  
 2.4.2. Study VII 
In the earlier described stroke cohort (n=362, see also paragraph 2.2.), we thus 
investigated MRproANP level on admission20. When dividing patients into 4 
subgroups based on stroke etiology, 18 % (n=65) of patients were allocated to 
the large artery atherosclerosis group, 36% (n=131) to the cardioembolic group, 
15% (n=55) to the small vessel occlusion group, 4% (n=16) to the group of other 
etiologies (e.g. dissection) and 26% (n=92) to the group with cryptogenic 
etiology. MRproANP levels were highest in patients with CE etiology (206pmol/L 
(IQR 119-326), significantly higher as compared to other etiologies (124pmol/L 
(IQR 73-207), p<0.0001). In an adjusted logistic regression analysis MRproANP 
was independently associated with CE stroke etiology. To estimate if MR-
proANP improved the diagnosis of CE etiology by already known clinical 
information, we calculated logistic models based on clinical information (age, 
known heart failure and AF on admission) and combined models based on 
clinical information plus MRproANP levels. The model including MRproANP 
(AUC 0.81 (95%CI 0.77-0.86)) was significantly better than the model based on 
clinical information alone (AUC 0.76 (95%CI 0.71-0.81), p<0.001). 
 
2.5. Prediction of infections after stroke  
Infection during the first days after ischemic stroke occurs in 25-65% of 
patients62,63. Pneumonia and urinary tract infection are the most common 
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infectious complications after ischemic stroke64. It has been suggested that the 
predominance of infections during the acute phase of stroke is due to stroke-
induced immunosuppression65. The central nervous system modulates the 
activity of the immune system through complex pathways that include the HPA- 
axis, the vagus nerve, and the sympathetic nervous system66,67. Several studies 
found an independent association between stroke associated infections and poor 
functional outcome after ischemic stroke68. 
Therefore, early initiation of antibiotic treatments is recommended if bacterial 
infection is present69. However, gold-standard clinical diagnostics are time-
consuming and delay early antibiotic therapy. Thus, accurate and readily 
available prognostic markers for optimal risk stratification are needed. We 
therefore selected C-reactive protein, white blood cells, monocytes, as they 
represent the most commonly measured and well-established inflammatory 
markers in clinical routine. Procalcitonin was selected to better discriminate 
bacterial infections from viral infections or general inflammation70. Copeptin, as 
reliable stress marker33 was selected because stroke related immunosuppression 
may be mediated by changes in the neuroendocrine system. All these 
biomarkers are immediately available due to rapid analytic procedures. We 
hypothesize that these blood markers are predictive for the development of 
stroke associated infections.  
2.5.1. Study VIII 
In the above described stroke cohort (see paragraph 2.2.) we assessed time 
point and type of stroke associated infections21 (i.e. pneumonia, urinary tract 
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infections, other infections). Infections were diagnosed according to the criteria of 
the U.S. Centre for Disease Control and Prevention71 and stroke associated 
infection was defined as any infection occurring within the first 5 days of hospital 
admission. Time point of diagnosis was referred to the beginning of clinical 
symptoms, which led to diagnostic work-up and resulted in the diagnosis of 
infection. 
In order to exclude acute infections preceding stroke, patients with admission 
temperature ≥ 38°C, or patients reporting an infection lasting up to 3 days before 
onset of stroke or patients who required mechanical intubation were not included 
in the study. Blood samples were collected on admission, and days 1, and 3 to 
assess white blood cells, monocytes, C- reactive protein, procalcitonin, and 
copeptin. Of 383 patients with stroke or TIA, who had at least 2 time points of 
measurements, 66 (17.2%) developed an infection within 5 days after onset of 
stroke. Twenty (5.2%) patients suffered from pneumonia, 25 (6.5%) patients had 
urinary tract infections and 21 (5.5%) patients had other infections (sepsis: 7 
patients; phlebitis: 6 patients; gastroenteritis: 4 patients, erysipelas: 1 patient; 
panniculitis: 1 patient, colpitis: 2 patients). We found that copeptin, procalcitonin, 
white blood cells and C- reactive protein levels on admission predicted any 
infection, pneumonia and urinary tract infections in the acute phase of stroke in 
univariate analyses. After adjusting for age, NIHSS or the Charlson comorbidity 
index or infarct localization (infra-/supratentorial) in a bivariate model all 
biomarkers remained significant predictors (see table 4). The combination of the 
biomarkers including either white blood cells, C- reactive protein and copeptin 
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(AUC: 0.92) or white blood cells, C- reactive protein and procalcitonin (AUC: 
0.90) showed better predictive accuracy concerning the development of 
pneumonia during hospitalization compared to each marker alone (p <0.0001). 
Table 4. Bivariate analyses  
  
         Fluri F et al. PlosONE 201221 
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3. Discussion  
The use of blood biomarkers is becoming increasingly popular in different fields 
of medicine. Several biomarkers are widely accepted in specific clinical 
situations, including troponin for the diagnosis of myocardial infarction and BNP 
to guide diuretic therapy in heart failure. Numerous biomarkers have also been 
evaluated in neurological conditions72. Potential clinical applications have been 
considered for biomarkers in vascular neurology, including:  characterizing stroke 
size and clinical severity, identifying stroke etiology, estimating short term risk of 
progression or worsening, risk of vascular and overall mortality, and long term 
functional outcome. But at present only few studies have shown additional 
information on an individual basis beyond that gained from standard clinical 
evaluation and neuroimaging38. Thus none of these blood biomarkers have yet 
been implemented into clinical routine in the field of stroke. In order to increase 
successful performance of blood biomarker studies we have to comply to certain 
quality standards. For instance we have to use well-defined cohorts instead of 
case-control studies and to define a realistic and adequate number of outcome 
events and apply ideal statistical methods (e.g. C-statistics, goodness of fit test, 
net reclassification index). Furthermore, the selection process of potential 
candidates is crucial and should focus on a specific clinical question. 
In this context my goal was to first identify and then evaluate different blood 
biomarkers to particularly improve risk stratification and identification of stroke 
etiology. In the search of new blood biomarkers for risk stratification I tried to find 
a marker, which is produced in the brain, which is independent of blood-brain 
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barrier disruption and at the same time easily accessible in the systemic 
circulation. The marker should as a prognostic marker ideally incorporate as 
much information on the body’s actual condition as possible. In other words the 
marker should reflect to some degree the damage that has already been 
produced by ischemia (e.g. neuronal death), the damage that might arise 
(penumbra) as well as the bodies capacity to restore the damage (extend of 
comorbidities). Since the body has its own “alarm-system”, which is mediated by 
the neuroendocrine-system to recognize all kinds of threats and then react and 
adapt, it seemed reasonable to use markers of this “alarm-system”. As outlined in 
section 1.4, copeptin appeared to be an ideal and promising candidate and was 
selected for further study.  
 
Hence, we could demonstrate for the first time in study I12 that copeptin was a 
subtle marker of the individual physical stress level in a population consisting of 
healthy controls (no apparent physical stress), hospitalized medical patients 
(moderate physical stress) and surgical patients during the peri- and 
postoperative period (high physical stress). Specifically, copeptin showed a 
gradual increase with increasing levels of stress and, in contrast to cortisol levels, 
differentiated between healthy control subjects without apparent physical stress 
and medical patients with a moderate degree of stress. In addition, copeptin 
showed a more pronounced increase upon major stress compared to cortisol 
levels. The correlation between copeptin and cortisol concentrations in our study 
suggested that copeptin measurements are associated with the activity of the 
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HPA-axis. We thus concluded that copeptin is a new stress marker.  Copeptin 
levels may reflect the stress degree at a higher, i.e. the hypothalamic-pituitary 
level, whereas cortisol concentrations might mirror the more peripheral stress 
response of the adrenal glands. If confirmed in a larger study, copeptin might 
provide a novel tool for the assessment of the individual stress level at the 
hypothalamic level. 
 
In study II13 we found in a large prospective stroke cohort that copeptin measured 
at a uniform time after stroke onset is a novel, strong, and independent 
prognostic marker for functional outcome and death in patients with ischemic 
stroke. Since no single statistical method provides all the information needed to 
assess a novel marker73, we determined its discriminatory ability (using C-
statistics), its accuracy (calibration by a goodness of fit test74) as well as the 
improvement of risk classification. The prognostic accuracy of copeptin in stroke 
patients was superior to that of other commonly measured laboratory 
parameters, as well as clinical measures. Importantly, copeptin is the first 
reported circulating biomarker that improves the prognostic accuracy of the 
NIHSS score significantly not only in terms of discrimination but also in terms of 
better risk classification. Hence copeptin if validated in an external cohort could 
be helpful in identifying those patients with a high risk for poor outcome, in whom 
more intensive neuromonitoring might be considered, as well as closer blood 
pressure, body temperature, and glucose adjustment. From a public health point 
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of view, accurate prognosis helps ensure availability of adequate resources to 
meet the needs of numerous stroke survivors. 
 
In study III14 we confirmed that copeptin is prognostic not only for short term 
outcome but also for long term outcome, the same magnitude of association was 
found and we could again demonstrate that copeptin added clinical relevant 
information for risk stratification according to published criteria for the evaluation 
of blood biomarkers in cardiovascular disease including stroke45. 
 
In study IV15 we wanted to simultaneously assess hormonal markers of the 
anterior pituitary axis i.e. cortisol, triiodothyronine, free thyroxine, thyroid- 
stimulating hormone and growth hormone in patients with acute ischemic stroke 
with regard to their accuracy to predict functional outcome and mortality. Cortisol 
was found to be an independent prognostic marker of functional outcome and 
mortality. Conversely, triiodothyronine, free thyroxine, thyroid- stimulating 
hormone and growth hormone add only limited or no prognostic information to 
currently used measures and scores. Cortisol improved the classification of 
patients for functional outcome and for death in net reclassification statistics as 
evidenced by significant net reclassification improvements. However, the lack of 
significance in the combined receiver operating characteristic curve analysis 
suggests that these findings need to be interpreted with caution. The prognostic 
performance of cortisol within the same population was similar to that of 
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copeptin, but showed no significant additional predictive value to the NIHSS in 
contrast to copeptin. 
Thus copeptin remained the most interesting neuroendocrine candidate as 
prognostic marker in the acute stroke setting. However before studying copeptin 
in an interventional trial to assess its value regarding patient management and 
ultimately cost-effectiveness we validated our results in an independent larger 
cohort study.  
 
In this validation study (i.e. study V), copeptin improved the discriminatory ability 
of the NIHSS and multivariate models as shown by an increase in the respective 
AUCs. Copeptin added prognostic information to validated prognostic scores 
such as the index by König75 et al, encompassing NIHSS and age. Moreover, 
copeptin improved reclassification compared to the multivariate models including 
demographic factors, cardiovascular risk factors, lesion size in MRI, 
comorbidities, and admission laboratory variables such as C- reactive protein 
and glucose. In addition, we also found that (1) copeptin independently predicted 
complications, and (2) that the prognostic ability of copeptin was consistent 
across subgroups including different acute treatments (conservative vs. 
thrombolysis). Study V confirmed and extended the conclusions of the previously 
published derivation study II. While several markers, such as NT-BNP, CRP, D-
Dimers, interleukin-6, von Willebrand factor, S-100β, and neuron specific 
enolase, have been associated with functional outcome or mortality, only very 
few biomarkers contributed additional prognostic information on top of clinical 
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assessment76,77. None of these markers, however, were fully evaluated including 
assessment of accuracy, discriminatory ability, reclassification improvement, and 
performance in an external validation study according to the recommendations of 
the American Heart Association for studies evaluating biomarkers in 
cardiovascular research45.  
 
In study VI17 we still considered stress markers namely cortisol and copeptin but 
in a different population (i.e. patients with transient ischemic attacks), having 
another clinical question in mind with thus another clinical endpoint (i.e. 
cerebrovascular re-events). As principal finding of this study, we found that 
copeptin, but not cortisol levels may provide additional prognostic information 
beyond the ABCD2-score in patients with a TIA to predict cerebrovascular re-
events within 90 days.  
Again copeptin performed better then cortisol for risk stratification. This was in 
line with our findings in study III were cortisol was not as helpful compared to 
copeptin concerning the prognosis in acute stroke patients or in study I, where 
we demonstrated that copeptin levels - even better than cortisol levels - 
differentiated the "no stress"- situation from "moderate stress"- situations. We 
hypothesized that the release of copeptin in patients suffering from a more 
severe “ischemic threat” (reflected also by the presence of DWI lesions in this 
clinically defined TIA cohort) might be more pronounced.  Since this patient 
group is per se known to have a higher risk for cerebrovascular re-events78 and 
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mortality, copeptin also seemed to be a good candidate marker for the prediction 
of re-events.  
In study VII we assessed MRproANP besides its value as prognostic marker for 
functional outcome and mortality also as marker for cardioembolic stroke 
etiology. We hypothezised that increased MRproANP levels might mirror not only 
manifest heart failure but also a beginning cardiac pathology (e.g. subclinical 
heart failure) in which intracardial thrombus development might be more likely. 
This would explain the additional diagnostic value of MRproANP levels to 
differentiate a cardioembolic etiology from others in our study. It is essential to 
identify the CE etiology in stroke because recurrent stroke occurs within 2 weeks 
in up to 12% of patients who initially experience embolic stroke from cardiac 
sources79. Atrial fibrillation may be no longer present when patients are examined 
by 24-hours-electrocardiography-monitoring. Thus, anticoagulant therapy might 
be delayed even when the neurologist suspects an embolic origin due to distinct 
patterns of lesions. Using biomarkers may be a reasonable strategy to improve 
the identification of CE stroke already in the acute phase, as this supports the 
need of more extensive diagnostic tests and accelerating the start of optimal 
secondary prevention80. 
 
In study VIII we sought to identify early predictors for the development of stroke-
associated infection. We evaluated routine inflammatory markers (i.e. white blood 
cells, monocytes, C-reactive protein) as well as procalcitonin and copeptin. The 
value of rapidly available blood markers as predictors of stroke associated 
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infections have not been studied extensively, although white blood cells CRP and 
monocytes are routinely measured within the first hours of admission. 
Procalcitonin has been evaluated in the setting of acute stroke for the prediction 
of stroke associated infections, however, in these studies the time point of 
diagnosis in relation to biomarker measurements was not taken into account. 
Copeptin so far was never assessed as a predictor of stroke associated 
infections. We found that each laboratory parameter remained a strong predictor 
after adjusting for NIHSS, age, Charlson comorbidity index and infarct 
localization. This is an unexpected finding because age and stroke severity may 
also contribute to stroke related immunosuppression and thus infection after 
acute ischemic stroke81. However, these biomarkers seem to add prognostic 
information beyond age, stroke severity and a higher Charlson comorbidity index 
as well as infarct localization. The predictive value of copeptin in respect to 
stroke associated infections was similar to that of established biomarkers of 
infection (i.e. WBC, CRP). This finding might be due to the association of 
copeptin with the activation of the HPA axis: increased copeptin-levels probably 
indicate a high degree of stress and stroke induced immunosuppression, which 
means a higher susceptibility to develop an infection. The prognostic value of 
procalcitonin was also in the range of white blood cells and CRP. The 
combination of established inflammatory makers (WBC, CRP) combined with a 
biomarker of stress, i.e. copeptin or a biomarker of bacterial infection, i.e. 
procalcitonin improves prediction of stroke-associated infections compared to the 
strongest prognostic marker alone. The combination of biomarkers probably 
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reflects better the complexity of an infection than one biomarker alone and may 
lead to a more accurate prediction of a beginning but not yet clinically apparent 
infection. The investigated biomarkers seem to detect infections before clinical or 
paraclincal signs prompt further diagnostic work-up leading to the diagnosis of 
infection. Thus these markers may help in risk stratification and may select high-
risk patients for intervention studies. If validated in larger prospective studies the 
combination of these 3 biomarkers with best AUC values may add significant 
information for the early identification of high-risk patients. Future intervention 
studies could select patients with high-risk profiles according to these biomarker 
levels and these high-risk patients may proof to benefit from prophylactic 
antibiotic treatment. 
 
In conclusion, there is need to develop a credible evidence base of prognostic 
information for outcomes that are meaningful to stroke patients and physicians to 
optimize care and allocation of health care resources. We discovered that with 
the use of neuroendocrine biomarkers, risk stratification, as well as accurate 
etiologic classification of stroke patients in the emergency setting, can be 
significantly improved. We newly identified copeptin and MRproANP as the most 
promising markers. 
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Abstract BACKGROUND: During stress, vasopressin is a potent synergistic factor of CRH 
as a hypothalamic stimulator of the HPA axis. The measurements of CRH and 
vasopressin levels are cumbersome because of their instability and short half-life. 
Copeptin is a more stable peptide stoichiometrically released from the same pre-
cursor molecule. The aim of our study was to compare copeptin and cortisol levels 
in different stress situations. 
METHODS: Three groups of patients with increasing stress levels were investigated: 
a) healthy controls without apparent stress (n=20), b) hospitalized medical patients 
with moderate stress (n=25) and c) surgical patients 30 minutes after extubation, 
with maximal stress (n=29). In all patients we assessed cortisol and copeptin 
levels. Copeptin levels were measured with a new sandwich immunoassay. 
RESULTS: Cortisol levels in controls were (median, IQ range, 486 [397–588] nmol/
L), not significantly different as compared to medical patients (438 [371–612] 
nmol/L, p=0.69). Cortisol levels in surgical patients after extubation were higher 
(744 [645–1062] nmol/L p<0.01 vs controls and medical patients). Copeptin levels 
in controls were 4.3 [3.2–5.5] pmol/L, which was lower as compared to medical 
patients (17.5 [6.4–24.1], pmol/L, p<0.001) and surgical patients after extubation 
(67.5 [37.8–110.0] pmol/L, p<0.001). The correlation between copeptin levels and 
cortisol was r=0.46, p<0.001.
CONCLUSION: Copeptin is a novel marker of the individual stress level. It more 
subtly mirrors different stress levels as compared to cortisol values.
1.
2.
3.
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INtroduCtIoN 
The two major peripheral limbs of the stress system are 
the hypothalamic-pituitary-adrenal (HPA) axis and the 
sympathetic nervous system [1,2]. Corticotropin- re-
leasing hormone (CRH) and arginin vasopressin (AVP) 
also termed antidiuretic hormone (ADH), are the main 
secretagogues of the HPA-axis to produce ACTH and 
cortisol, respectively. Importantly, serum cortisol levels 
have been reported to be proportionate to the degree 
of stress, if the HPA axis is intact [3,4]. For a direct as-
sessment of the individual stress level at a cerebral level, 
the measurement of CRH or AVP might offer an alter-
native. Unfortunately, the measurement of circulating 
AVP levels and CRH is challenging. Both, CRH and 
AVP are released in a pulsatile pattern, are unstable and 
rapidly cleared from plasma within minutes. AVP de-
rives from a larger precursor peptide (pre-provasopres-
sin) along with two other peptides, neurophysin II and 
copeptin. Copeptin is released in an equimolar ratio to 
AVP and is more stable in the circulation and easy to 
determine. Copeptin levels were found to closely mir-
ror the production of AVP [5]. 
Large surgery can serve as a standardized physio-
logical model for studying major stress [4]. Peri- and 
postoperative basal cortisol levels reflect the degree of 
surgical stress [6,7]. Peak cortisol levels are achieved in 
the immediate postoperative period, around the time of 
extubation [3,8]. The assessment and interpretation of 
cortisol levels is dependent on an intact anterior pitu-
itary and adrenal gland, respectively.
This study compares copeptin levels with the cortisol 
response in order to identify subtle marker of the indi-
vidual stress level at a hypothalamic level. 
MetHods
Setting and Study population
The details of the study population with different lev-
els of physical stress have been previously described 
[4,9,10]. Briefly we obtained ethical approval and the 
patients or their legal representatives gave written in-
formed consent to participate in the study. The study 
population was divided in to three groups; Group A (no 
stress) contained 20 healthy control subjects, without 
apparent stress. Group B (moderate stress) consisted 
of 25 patients consecutively recruited from a wide and 
representative variety of patients having been hospital-
ized on the medical ward. They were on the medical 
ward for various reasons (i.e. acute diabetic complica-
tions [hyperglycemic crisis, hypoglycemia], infections 
[urosepsis, exacerbation of chronic obstructive lung 
disease, pneumonia], inflammations [acute pancreati-
tis or myocarditis], hypoventilation syndrome, myocar-
dial infarction, congestive heart failure, unstable angina 
pectoris, cerebrovascular insult, decompensated liver 
cirrhosis, and ocular neuropathy). None of the patients 
showed clinical or laboratory features of acute or chron-
ic adrenal insufficiency. In Group C, 29 stable surgical 
patients were consecutively recruited from the division 
of cardiothoracic surgery undergoing elective coro-
nary bypass grafting under general anesthesia. These 
patients served as a standardized model for maximal 
stress, which is generally experienced after extubation 
[3,8]. For premedication midazolam 7.5mg was used in 
all patients. Anesthesia was induced with thiopentone 
(2–4mg/kg) and fentanyl (2–4ug/kg). Etomidate was 
not used for any patient. Intubation was facilitated with 
pancuronium (0.15 mg/kg). Before and during cardio-
pulmonary bypass anesthesia was maintained with iso-
flurane (0.5–1.5 MAC) and fentanyl. Antibiotic pro-
phylaxis consisted of cefuroxime (1,5g, t.i.d.) for 48h. 
Surgery was done under normothermic conditions (i.e. 
resulting in cooling not lower than 35° Celsius). Car-
diopulmonary bypass was started after heparin (350 
IU/kg) and cylocapron 30 mg/kg. No blood transfu-
sions were required. None of the patient’s received cor-
ticosteroid treatment.
Exclusion criteria were as follows: patients who re-
ceived drugs that influence the hypothalamo-pituitary 
adrenal axis in the last 3 months [11]; patients with dis-
eases affecting the adrenal or the pituitary gland; patients 
with known or suspected primary or secondary adrenal 
insufficiency; and patients receiving etomidate. 
In Group A and Group B, patients were tested once 
between 6–9 a.m. Surgical patients in Group C were 
evaluated at three different time points - the morning 
(6-9 a.m.) before operation (no apparent stress) and 30 
minutes after extubation (with maximal stress) as well 
as on the day after the operation.
Adrenal function in each participant was assessed 
by either low or standard ACTH tests performed be-
tween 0600–0900 h. Thereby, in all subjects, blood 
samples were taken at 0 min for the basal measurement 
of cortisol and ACTH and again at 30 and 60 min for 
the measurement of serum cortisol concentration after 
iv administration of 1 or 250 μg Synacthen (synthetic 
ACTH1–24), respectively. 
Assay
We measured Copeptin serum levels with a new sand-
wich immunoassay as recently described in detail [12]. 
Briefly, this sandwich immunoluminometric assay 
works with two polyclonal antibodies which bind to 
the C-terminal region of pre-pro-AVP. One antibody is 
attached to polystyrene tubes and the other is labeled 
with acridinium ester for chemiluminescence detec-
tion. For the assay 50 µl of either serum or plasma are 
required, no extraction steps or other pre-analytical 
procedures like addition of protease inhibitors are nec-
essary. The analytical detection limit is 1.7 pmol/L and 
the total precision of the assay (inter laboratory CV) 
was < 20% for copeptin concentrations across the cali-
bration curve (up to 405 pmol/L). In 359 healthy indi-
viduals Copeptin plasma concentration had a median of 
4.2 pmol/L (range, 1–13.8 pmol/L). The 97.5th percen-
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tile was 11.25 pmol/L, and the 2.5th percentile was 1.7 
pmol/L. Of all 359 tested volunteers, only nine (2.5%) 
had a plasma copeptin concentration below the detec-
tion limit of the assay of 1.7 pmol/L. It is important to 
note that in contrast to mature AVP, copeptin is more 
stable in plasma or serum ex vivo. Ex vivo stability of 
copeptin (< 20% loss of recovery) was shown for serum 
and plasma for at least seven days at room temperature 
and 14 days at 4° C[12].
Statistical Analysis
We expressed discrete variables as counts (percentage) 
and continuous variables as means ± standard devia-
tion (SD) or median [interquartile range] unless stated 
otherwise. Two-group comparison of normally distrib-
uted data was performed by Students t-test. For multi-
group comparisons, one-way analysis of variance with 
least square difference for posthoc comparison was ap-
plied. For data not normally distributed, we performed 
the Mann-Whitney-U test. The Kruskal-Wallis one-way 
analysis of variance was used if more than two groups 
were being compared. Correlation analyses were per-
formed by using Spearman rank correlation. All testing 
was two-tailed and P values less than 0.05 were consid-
ered to indicate statistical significance.
results
Demographic data
table 1 shows demographic and other characteristics of 
the subjects in Group A-C.
We investigated 20 healthy controls, 25 medical pa-
tients and 29 patients undergoing surgical treatment. 
Twenty-one subjects (28.4%) were female. In the sur-
gical group, all except one patient were male. There 
was no significant difference between the three groups 
concerning age, body mass index, blood pressure, and 
electrolytes. 
Cortisol levels in different stress situations
Cortisol levels in controls were 486 [397–588] nmol/L 
not significantly different as compared to medical pa-
tients (basal cortisol 438 [371–612], p=0.69). Cortisol 
levels in surgical patients 30 minutes after extubation 
were significantly higher (744 [645–1062], p<0.01) as 
compared to controls and medical patients (Figure 
1A). 
Copeptin levels in different stress situations
Copeptin levels in controls were 4.3 [3.2–5.5] pmol/L, 
which was significantly lower as compared to medical 
patients (17.5 [6.4–24.1], p<0.001) and surgical patients 
after extubation (67.5 [37.8–110.0] pmol/L, p<0.001) 
(Figure 1B). 
Percentage increase and decrease of cortisol and 
copeptin levels in different stress situations in surgical 
patients (Group C)
The percentage increase in cortisol from baseline to the 
extubation period (i.e. major stress) was 265 ± 34%, and 
the respective increase for copeptin was significantly 
higher with 1430 ± 157% (p<0.001) (Figure 2). 
Cortisol levels the day after the operation decreased 
to 82.3 ± 46.2% compared to the immediate extubation 
period, defined as maximal stress (p=0.01), whereas co-
peptin levels decreased to 65.5% ± 34.1 (p<0.001). The 
decrease for copeptin levels tended to be more pro-
nounced as compared to the decrease in cortisol levels 
(p=0.09). 
Copeptin levels and gender 
In control subjects, copeptin levels were significant-
ly lower in females (4.56± 2.36 pmol/L) compared to 
copeptin levels in males (6.16 ± 2.30; p=0.025) .In the 
group of medical patients copeptin levels were not sig-
nificantly different between men and women. 
Table 1: Characteristics of the study group (Group A-C) 
Healthy controls
(Group A, n=20)
Medical patients
(Group B, n=25)
Surgical patients undergoing CABG 
(Group C, n=29)
preoperative postoperative
Age (yr) 51(35–57) 64(56–79) 67(59–75)
Sex (m/f ) 10/10 15/10 28/1
BMI (kg/m2) 23(21–24) 29.7(25–31) 27(24–28)
Mean blood pressure (mmHg) 89(86–97) 90(83–93) 85(77–90)
Sodium (mmol/l) 141(138–144) 141(139–143) 138(136–138)
Potassium (mmol/l) 4.0( 3.6–4.3) 4.0(3.7–4.3) 4.3(4.2–4.7)
Glucose (mmol/l) 5.8(5.3–7.8) 5.9(5.3–7.7) 7.8(7–9.1)
Demographic and laboratory characteristics of healthy controls (group A), medical patients (group B), and surgical patients 
undergoing coronary artery bypass grafting (CABG) (group C) before the operation and after surgery. To convert glucose from 
mmol/liter into mg/dl, multiply by 18. m, male; f, female. BMI denotes body mass index. 
344 Copyright © 2008 Neuroendocrinology Letters ISSN 0172–780X • www.nel.edu
Mira Katan, Nils Morgenthaler, Isabelle Widmer, Jardena J. Puder, Caroline König, Beat Müller and Mirjam Christ-Crain
The study results remained similar when perform-
ing the analyses only in the male subpopulation (Fig-
ure 1C).
The correlation between copeptin levels and cortisol 
was r=0.46, p<0.001 There was no correlation between 
copeptin levels and age or between copeptin and sodi-
um values. No patient had dysnatremia. 
dIsCussIoN
In our cohort, copeptin was found to be a more subtle 
marker of the individual stress level. Specifically, co-
peptin shows a gradual increase with increasing levels 
of stress and, in contrast to cortisol levels, differenti-
ates between healthy control subjects without apparent 
stress and medical patients with a moderate degree of 
stress. In addition, copeptin shows a more pronounced 
increase upon major stress as compared to cortisol 
levels. 
The significant correlation between copeptin and 
cortisol concentrations in our study indicates that both 
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Figure 1. Total cortisol (A) and copeptin (B) levels in controls, 
medical patients and surgical patients after extubation, mirroring 
three different levels of physical stress. Copeptin levels (C) in the 
male controls, male medical patients and male surgical patients.  
Data show means ± SEM with scatter plots representing the 
absolute values. * denotes p<0.05; ** denotes p<0.01; *** denotes 
p<0.001
Figure 2. (A)Percentage increase of total cortisol and copeptin 
levels from before operation (no apparent stress) to after 
extubation (major stress). (B) Percentage decrease of total 
cortisol and copeptin levels from after extubation (major stress) 
to the day after operation. 
Data present mean ± SEM. * denotes p<0.05; ** denotes 
p<0.01; *** denotes p<0.001
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Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level
measurements mirror the activity of the HPA-axis. Co-
peptin levels reflect the stress degree at a higher, i.e. the 
hypothalamic-pituitary level, whereas cortisol concen-
trations mirror the more peripheral stress response of 
the adrenals. 
Presently, in clinical routine, cortisol levels are con-
sidered to predict the ability of our body to produce an 
adequate stress response [10]. However, cortisol levels 
only mirror the peripheral endocrine response of the 
adrenals to stress, whereas the hypothalamic response 
to stress is not detected. CRH and AVP might play a 
crucial role in conducting the perception of stress at the 
central hypothalamic level. There is an emerging view 
that AVP is the principal regulated variable that imparts 
situation specific drive on the HPA axis, whereas CRH 
serves mainly to impose stimulatory tone [13]. Since 
AVP measurement is problematic, measurement of co-
peptin in this regard provides a novel and valuable lab-
oratory tool. 
Our study is observational in nature. Thus, we can 
not make a conclusion about the clinical impact of the 
higher increase in copeptin levels compared to serum 
cortisol values upon major stress. Possibly, copeptin 
provides a more direct and earlier mirror of the stress 
level as compared to cortisol. Our finding that copeptin 
levels, but not cortisol levels, increase in medical pa-
tients with a moderate stress level compared to healthy 
subjects without stress strengthens this assumption.
AVP levels mirror fluid balance. Since copeptin is 
stoichiometrically produced with AVP, one could argue 
that the increase of copeptin levels may be explained by 
a change in water balance. However, plasma sodium as 
main parameter of osmolality was not different between 
medical and surgical patients at the time-point where 
we measured copeptin. This suggests that changes in 
osmolality were not the main stimulus for the increase 
in copeptin. As a limitation, we did not assess serum 
osmolality or detailed fluid balance in our patients. 
We found significantly lower baseline copeptin lev-
els in female versus male control subjects which is in 
accordance with the published literature. Morgenthaler 
et al. found also that copeptin values in healthy indi-
viduals differed significantly between men and women 
[12]. In contrast, we found no significant difference in 
the copeptin levels upon increasing stress level between 
men and women. In addition, analyzing only male 
study subjects showed a similar gradual increase of co-
peptin upon increasing levels of stress compared to the 
whole study population. Thus, in situations of more se-
vere stress, the baseline gender differences are overrid-
den by the increasing stress response. 
Another well known stimulus of AVP secretion is a 
drop in blood volume and, thus, blood pressure. This 
might have influenced the pronounced increase of co-
peptin in patients after extubation and is part of a se-
vere stress response of the body. However a small re-
duction in blood pressure usually has little or no effect 
on plasma vasopressin levels [14]. In our study popu-
lation blood pressure between medical patients and 
surgical patients was not significantly different; thus, 
a drop in blood pressure can not explain the increase 
of copeptin levels in medical patients, again suggesting 
that the increase in copeptin levels was predominantly 
stress-related. 
Copeptin has already been evaluated in critically ill 
patients with septic shock [15–17], in patients with re-
spiratory infections [18,19] as well as upon changes in 
osmolality [20] and in patients with diabetes insipidus 
[21]. In the acute state, copeptin, similarly to cortisol, 
has been shown to be an independent marker for re-
duced survival in critically ill patients as well as in pa-
tients with heart insufficiency [22]. Measurement of 
plasma copeptin concentrations in critically ill patients 
deserves to be evaluated as an indirect laboratory pa-
rameter to assess stress and therefore outcome in future 
studies. 
Our study has limitations. First, this is a preplanned 
posthoc analysis of an observational study evaluating 
cortisol levels in different stress situations and the di-
agnostic performance of low dose and standard ACTH 
tests. Our findings should, therefore, be regarded as 
hypothesis-generating. Second, our study population 
included patients with intact adrenal function, as as-
sessed by the ACTH-test and can therefore only yield 
information about the acute stress level in patients with 
preserved adrenal function. Therefore, we can not draw 
conclusions about the impact of adrenal insufficiency 
on copeptin levels. For example patients with complete 
or relative adrenal insufficiency might provoke a hyper-
sensitivity to a stressor resulting in higher basal levels 
of copeptin and possibly predicting a worse outcome. 
We further did not perform serial blood sampling al-
though cortisol levels show large variations during the 
day. However, during critical illness and severe stress, 
the circadian pattern of cortisol is usually lost [23]. 
Nevertheless, serial cortisol measurements would most 
probably have given more reliable results.
In conclusion, copeptin subtly mirrors the individ-
ual stress level in a population consisting of healthy 
controls, hospitalized medical patients and surgical 
patients during the peri- and postoperative period. It 
shows a more gradual increase with increasing stress as 
compared to total cortisol levels. If confirmed in a larg-
er subset of patients, copeptin might provide a novel 
tool for the assessment of the individual stress level at 
the hypothalamic level. 
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Copeptin: A Novel, Independent Prognostic
Marker in Patients with Ischemic Stroke
Mira Katan, MD,1,2 Felix Fluri, MD,2 Nils G. Morgenthaler, MD, PhD,3 Philipp Schuetz, MD,1
Christian Zweifel, MD,4 Roland Bingisser, MD,5 Klaus Mu¨ller, MD,6 Stephan Meckel, MD,6
Achim Gass, MD,2,6 Ludwig Kappos, MD,2 Andreas J. Steck, MD,2 Stefan T. Engelter, MD,2
Beat Mu¨ller, MD,1,7 and Mirjam Christ-Crain, MD1
Objective: Early prediction of outcome in patients with ischemic stroke is important. Vasopressin is a stress hormone. Its
production rate is mirrored in circulating levels of copeptin, a fragment of provasopressin. We evaluated the prognostic value of
copeptin in acute stroke patients.
Methods: In a prospective observational study, copeptin was measured using a new sandwich immunoassay on admission in
plasma of 362 consecutive patients with an acute ischemic stroke. The prognostic value of copeptin to predict the functional
outcome (defined as a modified Rankin Scale score of 2 or 3), mortality within 90 days, was compared with the National
Institutes of Health Stroke Scale score and with other known outcome predictors.
Results: Patients with an unfavorable outcomes and nonsurvivors had significantly increased copeptin levels on admission (p
0.0001 and p 0.0001). Receiver operating characteristics to predict functional outcome and mortality demonstrated areas
under the curve of copeptin of 0.73 (95% confidence interval [CI], 0.67–0.78) and 0.82 (95% CI, 0.76–0.89), which was
comparable with the National Institutes of Health Stroke Scale score but superior to C-reactive protein and glucose (p 0.01).
In multivariate logistic regression analysis, copeptin was an independent predictor of functional outcome and mortality, and
improved the prognostic accuracy of the National Institutes of Health Stroke Scale to predict functional outcome (combined
areas under the curve, 0.79; 95% CI, 0.74–0.84; p 0.01) and mortality (combined areas under the curve, 0.89; 95% CI,
0.84–0.94; p 0.01).
Interpretation: Copeptin is a novel, independent prognostic marker improving currently used risk stratification of stroke
patients.
Ann Neurol 2009;66:799–808
Acute ischemic stroke is a devastating disease; it is the
third leading cause of death and the leading cause of
acquired disability in developed countries.1 In 2008, an
estimated 780,000 persons in the United States will
suffer from a stroke, and 15 to 30% of stroke survivors
will be permanently disabled. The direct and indirect
cost of stroke is expected to amount to approximately
$65.5 billion.2 An early risk assessment with estimate
of the severity of disease and prognosis is pivotal for
optimized care and allocation of healthcare resources.3
A prompt identification of patients at increased risk for
adverse outcome interventions could be targeted to
those most likely to benefit. In this context, rapidly
measurable markers predicting mortality and functional
outcome in stroke would be clinically helpful.
Abnormalities in endocrine function have been re-
ported in ischemic stroke with activation of the
hypothalamo-pituitary-adrenal axis being one of the
first measurable physiological responses to cerebral
ischemia.4–6 Vasopressin (AVP) is a potent synergistic
factor of corticotropin-releasing hormone as hypotha-
lamic stimulator of the hypothalamo-pituitary-adrenal
axis. Small studies found increased AVP levels in pa-
tients with ischemic stroke,7 correlating with stroke se-
verity.8 However, the measurement of AVP levels is
cumbersome because of its instability and short half-
life. AVP derives from a larger precursor peptide (pro-
vasopressin) together with two other peptides, neuro-
physin II and copeptin. Copeptin is released in an
equimolar ratio to AVP, and is more stable in the cir-
culation and easy to measure.9 This study aimed at
prospectively evaluating the prognostic value of copep-
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tin levels in a large cohort of patients with an acute
ischemic stroke and comparing it with other known
outcome predictors.
Subjects and Methods
Study Design and Setting
We conducted a prospective cohort study at the University
Hospital Basel, Basel, Switzerland. From November 2006 to
November 2007, all patients with an acute ischemic cerebro-
vascular event were included. The Ethics Committee of
Basel, Switzerland, approved the trial protocol. Informed
consent was obtained from patients before enrolment; other-
wise, the consent was obtained from the patients’ next of kin
or a physician not involved in the study, in case next of kin
were absent. This report adheres to the consolidated stan-
dards for the reporting of observational trials.10
Patients
Patients were eligible for inclusion if they were admitted to
the emergency department with an acute ischemic stroke de-
fined according to the World Health Organization criteria11
and with symptom onset within 72 hours.
Clinical Variables
On admission (ie, during the first 24 hours), the following
items were recorded: vital signs; relevant comorbidities as as-
sessed by the Charlson comorbidity index (CCI) adjusted for
stroke (the CCI is a comorbidity scoring system that includes
weighting factors by disease severity according to the ICD-
9-CM system)12; medication before stroke; thrombolysis (in-
travenous/intraarterial) as acute stroke treatment; risk factors
(ie, age; sex; smoking history; hypercholesterolemia; history
of hypertension, diabetes mellitus, previous ischemic stroke,
or transient ischemic attack, respectively; positive family his-
tory for myocardial infarction, stroke, or transient ischemic
attack); and severity of stroke as assessed by the National
Institutes of Health Stroke Scale (NIHSS) score13 (scores
range from 0 to 42, with greater scores indicating increasing
severity), performed by a stroke neurologist certified in the
use of this scale. The clinical stroke syndrome was deter-
mined applying the criteria of the Oxfordshire Community
Stroke Project, that is, total anterior circulation syndrome
(TACS), partial anterior circulation syndrome, lacunar syn-
drome, and posterior circulation syndrome.14 Patients under-
went the following standardized diagnostic workup to ex-
clude intracranial hemorrhage and to identify the cause of
cerebral infarction: brain computer tomography, magnetic
resonance imaging (MRI), or both; standard 12-lead electro-
cardiography; 24-hour electrocardiography; echocardiogra-
phy; and neurosonographic studies of the extracranial and
intracranial arteries. Routine laboratory testing was always
done. Stroke cause was determined according to the criteria
of the TOAST (Trial of Org 10172 in Acute Stroke Treat-
ment) classification,15 which distinguishes large-artery arte-
riosclerosis, cardioembolism, small-artery occlusion, other
causative factor, and undetermined causative factor.
Blood Sampling and Follow-up
Blood samples were collected on admission (within 0–3
[n  78], 3–12 [n  189], 12–24 [n  55], and 24–72
[n  40] hours from symptom onset). In patients who died
within 24 hours after admission or in patients who were dis-
charged, data from admission or until discharge were col-
lected. The NIHSS score was assessed on admission and day
5. Functional outcome was obtained on days 5 and 90 ac-
cording to the modified Rankin Scale (mRS)16 blinded to
copeptin levels.
End Points
The primary end point of this study was favorable functional
outcome of stroke patients after 90 days from baseline, de-
fined as an mRS score of 0 to 2 points. Secondary end point
in stroke patients was death from any cause within a 90-day
follow-up. Outcome assessment was performed by two
trained medical students blinded to copeptin levels with a
structured follow-up telephone interview with the patient or,
if not possible, with the closest relative or family physician.
Neuroimaging
CCT was performed in all patients on admission mainly to
exclude intracranial hemorrhage. Thereafter, MRI was per-
formed on a clinical 1.5-Tesla MR Avanto system (Siemens,
Erlangen, Germany) using a stroke protocol, including T1-,
T2-, and diffusion-weighted imaging (DWI) sequences, and
a magnetic resonance angiography. MRI with DWI was
available in 197 stroke patients (55%). In those patients,
DWI lesion volumes were determined by consensus of two
experienced raters unaware of the clinical and laboratory re-
sults. The lesion size was calculated by the commonly used
semiquantitative method.17 Lesions were ranked into three
sizes to represent typical stroke patterns: (1) small lesion with
a volume of less than 10ml, (2) medium lesion of 10 to
100ml, and (3) large lesion with a volume of more than
100ml.18
Assays
Blood was obtained from an indwelling venous catheter. Re-
sults of the routine blood analyses were recorded. Plasma was
frozen at 70°C. Measurement was done in a single batch
with a commercial sandwich immunoluminometric assay
(B.R.A.H.M.S LUMItest CT-proAVP, B.R.A.H.M.S AG,
Hennigsdorf/Berlin, Germany), as described in detail else-
where.19 Since this initial publication, the assay was modified
as follows: The capture antibody was replaced by a murine
monoclonal antibody directed to amino acids 137 to 144
(GPAGAL) of provasopressin. This modification improved
the sensitivity of the assay. The lower detection limit was
0.4pmol/L, and the functional assay sensitivity (20% inter-
assay coefficient of variance) was less than 1pmol/L. Median
copeptin levels in 200 healthy individuals was 3.7pmol/L,
and the 97.5 percentile was 16.4pmol/L. The median in
healthy individuals using this modification was similar as
published in other studies (4.2pmol/L in Morgenthaler and
colleagues19 and 3.8pmol/L in Khan and colleagues20).
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Statistical Analysis
Discrete variables are summarized as counts (percentage),
and continuous variables as medians and interquartile ranges
(IQRs). Two-group comparison of not normally distributed
data was performed using Mann–Whitney U test, and a
Kruskal–Wallis one-way analysis of variance was used for
multigroup comparisons.
To investigate whether copeptin allows predicting of both
functional outcome and death after 3 months, we used dif-
ferent statistical methods. First, the relation of copeptin with
the two end points was investigated with the use of logistic
regression models. Therefore, common logarithmic transfor-
mation (ie, base 10) was performed to obtain normal distri-
bution for skewed variables (ie, copeptin concentrations) as
the resulting model yielded smaller Akaike Information Cri-
terion, which was chosen to compare the results. We used
crude models and multivariate models adjusted for all signif-
icant outcome predictors and report odds ratios (ORs). Note
that the OR corresponds to a one-unit increase in the ex-
planatory variable; for the log-transformed copeptin values,
this corresponds to a 10-fold increase.
Second, we compared different prognostic risk scores from
different predictive models by calculating receiver operating
characteristic analysis. Thereby the area under the receiver
operating characteristic curve (AUC) is a summary measure
over criteria and cut-point choices. The AUC summary
equals the probability that the underlying classifier will score
a randomly drawn positive sample higher than a randomly
drawn negative sample. To test whether the copeptin level
improves score performance, we considered the two nested
logistic regression models with NIHSS and copeptin as com-
pared with NIHSS only. Under the lower-dimensional sub-
model, the difference in deviance between the two models
has a 2 distribution with 1 degree of freedom. Furthermore,
care was taken to adjust for the optimistic bias of in-sample
prediction error estimates using a fivefold cross-validation
scheme. Letting Y be the indicator of the event of interest
and X the covariate vector of a given risk score, high utility
corresponds to accurately modeling the regression E(Y  X 
x). We used the Brier’s score as the quadratic scoring rule to
measure predictive performance, where the fitted values of
the predictive probabilities Pr(Y  1  X  x) are contrasted
with the actually observed values.
Third, to assess the calibration of the predictive models,
we compared the number of events that are observed with
those that are expected by estimation from the models within
different a priori risk groups based on Goldstein and col-
leagues’21,22 data.
Fourth, we calculated reclassification tables to further in-
vestigate the benefit of copeptin level as compared with the
NIHSS score alone on risk as proposed by, for example,
Cook23 and Pencina and coauthors.24 Regarding so-called
net reclassification improvement, only those changes in esti-
mated prediction probabilities that imply a change from one
risk category to another were considered. For estimating
meaningful a priori risk categories, we used predicted prob-
abilities based on Goldstein and colleagues’21,22 data.
Finally, to study the ability of copeptin for mortality pre-
diction, we calculated Kaplan–Meier survival curves and
stratified patients by copeptin tertiles.
All testing was two tailed, and p values less than 0.05 were
considered to indicate statistical significance. All calculations
were performed using STATA 9.2 (Stata Corp, College Sta-
tion, TX), R version 2.8.1 and the ROCR package (version
1.0–2), which is available from CRAN repository (http://
cran.r-project.org/), for evaluating and visualizing the perfor-
mance of scoring classifiers.25
Results
Patients
From 605 screened patients, ischemic stroke was diag-
nosed in 362 patients, and 359 completed follow-up
and were included in the analysis (Fig 1). Furthermore,
we excluded 11 patients from the analysis because of
missing values for copeptin.
Descriptive Characteristics of Stroke Patients
The median age of patients with ischemic stroke in-
cluded in this study was 75 (IQR, 63–83) years and
41% were women. On admission, the median NIHSS
score was 5 (IQR, 2–10) points. Median body temper-
ature was 37.0°C (IQR, 36.5–37.4°C), and the median
systolic blood pressure was 160mm Hg (IQR, 140–
180mm Hg). A total of 275 patients (77%) had a his-
tory of hypertension, 93 (26%) had hypercholesterol-
Fig 1. Study profile/flow sheet of the study.
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emia, 71 (20%) had a history of diabetes mellitus, 124
(35%) were smokers, 75 (21%) were diagnosed with
atrial fibrillation, 88 (25%) had a history of a previous
vascular event, and 91 (25%) had coronary heart dis-
ease. An unfavorable functional outcome was found in
151 patients (42%) with a median mRS score of 4
(IQR, 3–6). Forty-four patients died, and the mortal-
ity rate was thus 12%. The principal baseline charac-
teristics of all patients grouped according to their func-
tional outcome are provided in Table 1.
Main Results
COPEPTIN AND SEVERITY OF STROKE ACCORDING TO THE
NATIONAL INSTITUTES OF HEALTH STROKE SCALE AND
LESION SIZE. Copeptin levels increased with increas-
ing severity of stroke as defined by the NIHSS score.
Copeptin concentrations in patients with an NIHSS
score of 0 to 6 points (n  210) were 8.6 (IQR, 5.2–
15.3) pmol/L, in patients with an NIHSS score of 7 to
15 points (n  86) were 15.8 (IQR, 7.7–28.7)
pmol/L, and in patients with an NIHSS score greater
than 15 points (n  52) were 30.1 (IQR, 9.0–67.9)
pmol/L. In the subgroup of patients (n  197) in
whom MRI was available, copeptin levels paralleled le-
sion size. Median copeptin levels in patients with a
small lesion were about half the levels than in patients
with medium lesions (8.4 [IQR, 4.4–13.7] vs 14.9
[IQR, 6.6–26.0] pmol/L), whereas levels were greatest
in patients with a large lesion (18.3 [IQR, 5.3–51.9]
pmol/L).
COPEPTIN AND FUNCTIONAL OUTCOME AFTER 3
MONTHS. Copeptin levels in patients with an unfa-
vorable outcome were significantly greater than those
in patients with a favorable outcome (19.4 [IQR, 8.7–
36.6] vs 8.2 [IQR, 4.5–14.5] pmol/L; p 0.0001; Fig
2A).
In univariate logistic regression analysis, we calcu-
lated the ORs of log-transformed copeptin levels as
compared with the NIHSS score and other risk factors
as presented in Table 2. With an unadjusted OR of 6.9
(95% CI, 3.89–12.33), copeptin had a strong associa-
tion with functional outcome. After adjusting for all
other significant outcome predictors, copeptin re-
mained an independent outcome predictor with an ad-
justed OR of 2.53 (95% CI, 1.26–5.07). In addition,
age, CCI, presence of TACS, and the NIHSS score
remained significant outcome predictors, unlike all
others assessed (Table 3). In the subgroup of patients
(n  197) in whom MRI evaluations were performed,
copeptin was an independent outcome predictor with
an OR of 2.89 (95% CI, 1.14–7.34; p  0.026) after
adjustment for both lesion size (OR, 1.01; 95% CI,
1.00–1.02; p  0.043) and the NIHSS score (OR,
1.07; 95% CI, 1.01–1.14; p  0.027).
With an AUC of 0.73 (95% CI, 0.67–0.78), copep-
tin showed a significantly greater discriminatory ability
as compared with CCI, sex, and the presence of TACS,
and was within the range of the NIHSS score and age
(Table 4). In addition, copeptin was superior to
C-reactive protein (CRP) (AUC, 0.61; 95% CI, 0.55–
0.68; p 0.001), white blood cell count (AUC, 0.55;
95% CI, 0.49–0.62; p 0.0001), and glucose (AUC,
0.57; 95% CI, 0.50–0.63; p 0.001). Copeptin im-
proved the NIHSS score (AUC of the combined
model, 0.79; 95% CI, 0.74–0.84; p 0.001). This
improvement was stable in an internal 5-fold cross-
validation that resulted in an average AUC (standard
error) of 0.748 (0.036) for the NIHSS and 0.789
(0.028) for the combined model, corresponding to a
difference of 0.041 (0.014). The 5-fold cross-validated
mean squared prediction error decreased from 0.197
(0.012) in the model with NIHSS to 0.181 (0.012) in
the model with NIHSS and copeptin, corresponding to
an average decrease of 0.016 (0.002). Moreover, a
model combining copeptin level, age, sex, and the CCI
with the NIHSS score showed an AUC of 0.85 (95%
CI, 0.81–0.89), which was greater than all predictors
alone (p 0.0001) (see Table 4).
COPEPTIN AND DEATH WITHIN 90 DAYS. Copeptin lev-
els in 41 of the 44 patients who died were more than
3 times greater as compared with patients who survived
(9.5 [IQR, 5.3–19.1] vs 35.6 [IQR, 19.4–93.7]
pmol/L; p 0.001; see Fig 2B). Univariate analysis
identified copeptin levels, age, presence of TACS, and
the NIHSS score as the main predictors associated with
death (see Table 2). After adjustment for these param-
eters, copeptin level remained an independent predic-
tor for mortality with an OR of 4.23 (95% CI, 1.605–
11.152; see Table 3).
Receiver operating characteristic curves demon-
strated the greatest discriminatory accuracies for copep-
tin level (AUC, 0.83; 95% CI, 0.76–0.89) and the
NIHSS score (AUC, 0.85; 95% CI, 0.78–0.91). The
combination of copeptin level and the NIHSS score
had a higher discriminatory accuracy (AUC, 0.89; 95%
CI, 0.84–0.94) than the NIHSS score alone (p 
0.02). In addition, the combination of age, copeptin,
TACS, and the NIHSS score showed the greatest ac-
curacy (AUC, 0.92; 95% CI, 0.88–0.95), greater than
all individual parameters alone (p 0.01) (see Table
4).
Again, this improvement was stable in an internal
5-fold cross-validation with an AUC (standard error) of
0.837 (0.018) for the NIHSS and 0.886 (0.019) for
the combined model. Thus, the average difference
across cross-validation runs was 0.049 (0.020). Im-
provement in the fitted values of the predictive proba-
bilities for 5-fold cross-validated Brier’s score was 0.071
(0.009) for the logistic model with copeptin as com-
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Table 1. Baseline Characteristics of Stroke Patients
Baseline Characteristics All Good Outcome
(mRS 0–2)
Poor Outcome
(mRS 3–6)
pa
n 359 208 151
Demographic data
Median age, yr (IQR) 75 (63–83) 71 (59–80) 80 (71–86) 0.001
Female sex (n) 41% (149) 35% (73) 49% (76) 0.01
Stroke severity, median NIHSS score (IQR) 5 (2–10) 4 (2–6) 8 (4–17) 0.001
DWI lesion size 197 139 58
Small 136 74% (103) 56% (33) 0.001
Medium 50 24% (33) 30% (17) 0.001
Big 11 2% (3) 14% (8) 0.001
Laboratory findings 359 208 151
Median copeptin level, pmol/L (IQR)b 11.6 (5.6–21.2) 8.2 (4.5–14.5) 19.4 (8.7–36.6) 0.0001
Median glucose level, mmol/L (IQR) 6.1 (5.5–7.4) 6.0 (5.3–7.2) 6.3 (5.6–7.7) 0.05
Median C–reactive protein concentration,
mmol/L (IQR)
3.6 (3.0–9.9) 3.0 (3.0–6.5) 4.90 (3.0–19.9) 0.001
Median white blood cell count (IQR) 8.2 (6.5–9.9) 8.1 (6.5–9.6) 8.3 (6.6–10.1) NS
Vital parameters on admission 359 208 151
Median arterial pressure, mm Hg (IQR)
Systolic 160 (140–180) 162 (143–180) 159 (132–180) NS
Diastolic 90 (80–100) 91 (81–102) 90 (79–98) NS
Median body temperature, °C (IQR) 37.0 (36.5–37.4) 37.0 (36.7–37.5) 37 (36.4–37.4) NS
Stroke causative factorsc 359 208 151
Small-vessel occlusive (n) 15% (55) 18% (38) 11% (17) NS
Large-vessel occlusive (n) 18% (65) 18% (38) 18% (27) NS
Cardioembolic (n) 36% (131) 36% (75) 37% (56) NS
Other (n) 4% (16) 5% (11) 3% (5) NS
Unknown (n) 26% (92) 22% (46) 30% (46) NS
Therapies before admission 359 208 151
Antihypertensive (n) 59% (213) 57% (119) 62% (94) NS
ASS (n) 37% (133) 36% (74) 39% (59) NS
Clopidogrel (n) 5% (18) 3% (7) 7% (11) NS
Anticoagulant (n) 11% (38) 9% (18) 13% (20) NS
Statins (n) 22% (78) 23% (47) 21% (31) NS
Comorbidity 359 208 151
Median Charlson Index (IQR) 1 (0–2) 0 (0–2) 1 (0–2) 0.0001
Vascular risk factors 359 208 151
Hypertension (n) 77% (275) 73% (152) 81% (123) 0.05
Atrial fibrillation (n) 21% (75) 16% (34) 27% (41) 0.05
Smoking history (n) 35% (124) 38% (79) 30% (45) NS
Hypercholesterolemia (n) 26% (93) 28% (58) 23% (35) NS
Diabetes mellitus (n) 20% (71) 19% (39) 21% (32) NS
Coronary heart disease (n) 25% (91) 23% (48) 28% (43) NS
Prior stroke (n) 25% (88) 23% (48) 26% (40) NS
Family history for stroke and/or myocardial
infarction (n)
30% (106) 32% (67) 26% (39) NS
Stroke syndrome 359 208 151
TACS (n) 11% (41) 5% (11) 20% (30) 0.0001
PACS (n) 45% (162) 44% (92) 47% (69) NS
LACS (n) 21% (74) 23% (47) 18% (27) NS
POCS (n) 23% (83) 28% (58) 16% (24) 0.01
ap value was assessed using Mann-Whitney U test.
bIn 11 patients, values for copeptin were missing.
cSome had two causative agents at the same time and because of rounding, percentages may not sum to 1.
mRS  modified Rankin Scale; IQR  interquartile range; NIHSS  National Institutes of Health Stroke Scale; DWI  diffusion-
weighted imaging; NS  not significant; TACS  total anterior circulation syndrome; PACS  partial anterior circulation syndrome;
LACS  lacunar syndrome; POCS  posterior circulation syndrome.
pared with 0.076 (0.013) for NIHSS only. This corre-
sponds to an average decrease of 0.005 (0.005).
The time to death was analyzed by Kaplan–Meier
survival curves based on copeptin tertiles. Patients in
the lowest tertile (copeptin 7.2pmol/L) had a mini-
mal risk for death, in contrast with patients with
copeptin levels in the 2nd and 3rd tertiles (copeptin
between 7.2 and 17.8pmol/L and copeptin 
17.8pmol/L, respectively) (p 0.0001) (Fig 3).
Reclassification
In-sample reclassification behavior for patients with
good functional outcome and patients with poor func-
tional outcome (see Supplementary Table 5A) and for
patients who died and for those who did not die (see
Supplementary Table 5B) was calculated (see supple-
mentary material). Forty patients with poor outcome
were classified in higher risk categories using the model
with the NIHSS and copeptin. Twenty patients with
poor outcome were classified in lower risk categories
using the model with the NIHSS and copeptin as com-
pared with the model with the NIHSS score as the
only predictor variable. Thus, the estimated net reclas-
sification improvement for functional outcome was
0.3935. Similarly, 10 patients who died were classified
in higher risk categories and 2 patients who died were
classified in lower risk categories using the model with
the NIHSS score and copeptin level as compared with
the model with the NIHSS score as the only predictor
variable. The estimated net reclassification improve-
ment for mortality was 0.4818.
Discussion
In this prospective, observational study, we found that
copeptin is a novel, strong, and independent prognos-
tic marker for functional outcome and death in pa-
tients with ischemic stroke. The prognostic accuracy of
copeptin in stroke patients is superior to that of other
commonly measured laboratory parameters, as well as
clinical measures. It is in the range of the commonly
used clinical NIHSS score. Importantly, copeptin is the
first reported circulating biomarker that improves the
prognostic accuracy of the NIHSS score significantly.
The NIHSS is a standardized measure of stroke se-
verity and is used to predict 3-month outcome. How-
ever, it has some limitations. The use of the NIHSS
implies special training and there remains a notable in-
terobserver variability.26 In addition, left hemispheric
stroke syndromes show greater NIHSS scores than
right hemispheric syndromes, and the NIHSS is less
reliable in patients with posterior compared with ante-
rior circulation syndromes.27 Early and adequate risk
assessment is pivotal for optimized care of stroke pa-
tients. In this context, readily measurable biomarkers,
such as copeptin, are additionally helpful in predicting
the severity level and outcome of patients with isch-
emic stroke.
When recorded on admission, different variables are
allegedly associated with poor outcome in stroke pa-
tients, for example, body temperature,28 blood glu-
cose,29 CRP,30 and white blood cell count.31 Com-
pared with control subjects, CRP levels were greater in
patients with stroke than in healthy control subjects in
all stroke subtypes, both in the acute phase and after a
3-month follow-up.32 It has been demonstrated that
high-sensitive CRP was an accurate prognostic marker
for mortality.33 However, other studies found no dif-
ferences in CRP concentrations in a mixed stroke pop-
ulation,34 and pretreatment CRP failed to predict out-
come in stroke patients treated with intravenous
thrombolysis.35 All of these parameters were modest
predictors of functional outcome and unable to im-
prove the prognostic accuracy of the NIHSS.
Other mediators involved in the ischemic cascade are
protein S-100,36 interleukin-6,37 matrixmetallo-
proteinase-9,38 myelin basic protein, and neuron-
specific enolase.39 Although these biomarkers reliably
mirror the initial stroke severity (NIHSS and lesion
size) and some even bear an association with outcome,
they were not able to independently predict functional
Fig 2. (A) Copeptin levels in stroke patients with favorable
and unfavorable functional outcome. (B) Copeptin levels in
survivors and nonsurvivors of stroke. Mann–Whitney U Test.
All data are medians and interquartile ranges (IQR), with
dot plots representing all values.
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outcome or death within 3 months or to improve the
predictive value of the NIHSS, in the earlier men-
tioned studies. It has been demonstrated that brain na-
triuretic peptide and its N-terminal peptide (NT-
proBNP) are excellent markers for vascular mortality
and re-events.40 However, baseline levels of NT
proBNP were not significantly associated with func-
tional outcome within 3 months.41
AVP, together with corticotropin-releasing hormone,
is the main secretagogue of the hypothalamo-pituitary-
adrenal axis to produce adrenocorticotropic hormone
and cortisol. Serum cortisol levels have been reported
to increase proportionately with the degree of stress
and to predict outcome in several diseases42 including
ischemic stroke43; however, it has not been shown that
cortisol is able to improve the prognostic accuracy of
the NIHSS. We have recently shown that copeptin lev-
els mirror different levels of stress more subtly than
cortisol.44 In addition, cortisol shows cross-reactivity
with other steroids,45 varies with the amount of
hormone-binding proteins, underlies a circadian
rhythm,46 and changes with food intake,47 thus limit-
ing its prognostic accuracy in the acute phase of stroke.
Copeptin is known to have prognostic value in non-
neurological diseases. For example, copeptin levels are
independent predictors of survival in critically ill pa-
tients suffering from hemorrhagic and septic shock.48
Furthermore, copeptin levels have prognostic implica-
tions in patients with acute heart failure49 and in pa-
tients with acute myocardial infarction.20
We assume that the close and reproducible relation
of copeptin levels to the degree of activation of the
Table 2. Univariate Analysis
Predictors Functional Outcome Mortality
ORa 95% CIa p OR 95% CIa p
Copeptin (increase per log unit)b 6.93 3.89–12.33 0.0001 16.11 6.95–37.35 0.0001
CRP (increase per unit) 1.01 1.00–1.02 0.01 1.10 0.99–1.21 0.05
Glucose (increase per unit) 1.07 0.97–1.18 0.15 1.01 1.00–1.02 0.009
Age (increase per unit) 1.06 1.04–1.08 0.0001 1.09 1.05–1.13 0.0001
Temperature (increase per unit) 0.87 0.61–1.24 0.44 0.86 0.50–1.48 0.59
Systolic blood pressure (increase per unit) 0.99 0.99–1.01 0.45 0.99 0.98–1.00 0.15
Female sex 1.78 1.17–2.74 0.01 1.35 0.72–2.54 0.93
NIHSS (increase per unit) 1.16 1.12–1.21 0.0001 1.19 1.14–1.25 0.0001
Risk factors
Charlson Index (increase per unit) 1.34 1.15–1.56 0.0001 1.16 0.96–1.40 0.13
Hypertension 1.62 1.00–2.70 0.06 1.75 0.75–4.09 0.19
Atrial fibrillation 1.91 1.14–3.19 0.01 3.16 0.92–6.15 0.09
Smoking history 0.69 0.44–1.08 0.11 0.61 0.29–1.24 0.16
Hypercholesterolemia 0.78 0.48–1.27 0.32 0.96 0.47–1.97 0.90
Diabetes mellitus 1.17 0.70–2.00 0.57 1.06 0.48–2.31 0.89
Coronary heart disease 1.33 0.82–2.14 0.25 2.07 1.07–4.00 0.03
Prior stroke 1.20 0.75–1.95 0.46 0.66 0.29–1.48 0.31
Family history for stroke and/or MI 0.74 0.46–1.17 0.19 0.89 0.44–1.80 0.756
Stroke syndrome and causative factors
TACS 4.44 2.15–9.19 0.0001 6.67 3.39–13.99 0.0001
PACS 1.12 0.74–1.69 0.74 0.81 0.41–1.54 0.53
LACS 0.75 0.44–1.26 0.28 0.35 0.12–1.02 0.054
POCS 0.489 0.287–0.831 0.01 0.500 0.200–1.231 0.202
Small-vessel occlusive 0.58 0.30–1.05 0.07 0.113 0.015–0.843 0.033
Large-vessel occlusive 0.97 0.56–1.68 0.93 0.55 0.21–1.45 0.23
Cardioembolic 1.05 0.68–1.62 0.84 1.54 0.82–2.92 0.43
Other 0.61 0.21–1.80 0.37 0.47 0.06–3.64 0.46
Unknown 1.54 0.96–2.49 0.08 1.96 1.02–3.79 0.05
aNote that the odds ratio corresponds to a unit increase in the explanatory variable; for copeptin, this corresponds to an increase per
unit of the log transformation of copeptin (thus, a log-transformed increase of 1 corresponds to a copeptin increase of 10pmol/L).
bIn 11 patients, values for copeptin were missing.
OR  odds ratio; CI  confidence interval; CRP  C-reactive protein; NIHSS  National Institutes of Health Stroke Scale; MI 
myocardial infarction; TACS  total anterior circulation syndrome; PACS  partial anterior circulation syndrome; LACS  lacunar
syndrome; POCS  posterior circulation syndrome.
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stress axis, and thus disease severity, is the basis of its
unique usefulness as a biomarker. Seemingly, copeptin
allows tapping an endogenous information system of
our body at a hypothalamic level that, through mech-
anisms still poorly understood, accurately assesses the
severity of damage. Copeptin mirrors somehow the in-
dividual “stress burden” of patients. If the individual
threshold, that is, to ensure homeostasis, is crossed, it is
most likely that a less favorable outcome occurs.
The following limitations of our study must be
taken into account. First, we analyzed patients within a
rather large time frame of 72 hours of symptom onset,
representing a heterogeneous stroke population. We in-
tended to reflect a general, unselected population as it
occurs in clinical routine, and results remained similar
when analyzing only patients with symptom onset
within 0 to 12, 12 to 24, and 24 to 72 hours. Fur-
thermore, in the subgroup of patients who underwent
thrombolysis (symptom onset 0–3 hours; n  78),
copeptin levels measured on admission were greater in
Table 3. Multivariate Analysis
Predictor OR 95% CIa p
Multivariate Analysis for Functional Outcome
Copeptin (increase per log unit) 2.57 1.27–5.17 0.01
Age (increase per unit) 1.06 1.04–1.09 0.0001
Female sex 1.43 0.82–2.49 0.21
Stroke severity, NIHSS (increase per unit) 1.17 1.10–1.23 0.0001
Charlson Index (increase per unit) 1.31 1.09–1.58 0.004
TACS 1.51 0.55–4.15 0.42
Multivariate Analysis for Mortality
Copeptin (increase per log unit) 4.31 1.65–11.25 0.003
Age (increase per unit) 1.07 1.03–1.12 0.002
Stroke severity, NIHSS (increase per unit) 1.16 1.09–1.23 0.0001
TACS 1.52 0.51–4.55 0.458
OR  odds ratio; CI  confidence interval; NIHSS  National Institutes of Health Stroke Scale; TACS  total anterior circulation
syndrome.
Table 4. Prediction of Functional Outcome and Mortality
Parameter AUC 95% CI p
Prediction of Functional Outcome
Copeptin 0.73 0.67 0.78
NIHSS 0.75 0.70 0.80 0.46
Age 0.70 0.64 0.76 0.47
Charlson Index 0.63 0.58 0.69 0.01
Sex 0.58 0.52 0.63 0.001
TACS 0.57 0.54 0.61 0.0001
Combined score (NIHSS/copeptin) 0.79 0.75 0.84 0.01
Prediction of Mortality
Copeptin 0.82 0.76 0.89
NIHSS 0.85 0.78 0.91 0.59
Age 0.74 0.67 0.81 0.08
TACS 0.64 0.57 0.72 0.001
Combined score (NIHSS/copeptin) 0.89 0.84 0.94 0.01
AUC  area under the curve; CI  confidence interval; NIHSS  National Institutes of Health Stroke Scale; TACS  total anterior
circulation syndrome.
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patients with unfavorable outcome compared with pa-
tients with favorable outcome, and the prognostic ac-
curacy for functional outcome and mortality was sim-
ilar to the overall sample. Second, we performed DWI
in only a subset of patients. However, this mirrors clin-
ical routine where MRI testing is not yet widely avail-
able within this time window in the emergency setting.
Despite its inherent limitations, outcome predictors
are helpful in identifying those patients with a high
risk for poor outcome, in whom more intensive neu-
romonitoring might be considered, as well as closer
blood pressure, body temperature, and glucose adjust-
ment.
Moreover, it is important to develop a credible evi-
dence base of prognostic information for outcomes that
are meaningful to patients and relatives, including level
of independency. From a public health point of view,
accurate prognosis helps ensure availability of adequate
resources to meet the needs of numerous stroke survi-
vors.
It is customary to base the prognostic assessment and
treatment decisions on several parameters that each
mirror different pathophysiological aspects. In this con-
text, copeptin appears to have an interesting potential
as a new prognostic biomarker and makes it a promis-
ing candidate also for a multimarker panel. This may
allow improved risk stratification and allocation of tar-
geted therapies for stroke patients in the future. How-
ever, before broad implementation, additional studies
are needed for external validation.
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Prognostic Value of Copeptin
One-Year Outcome in Patients With Acute Stroke
Sandrine A. Urwyler, BMed; Philipp Schuetz, MD; Felix Fluri, MD; Nils G. Morgenthaler, MD, PhD;
Christian Zweifel, MD; Andreas Bergmann, PhD; Roland Bingisser, MD; Ludwig Kappos, MD;
Andreas Steck, MD; Stefan Engelter, MD; Beat Mu¨ller, MD; Mirjam Christ-Crain, MD; Mira Katan, MD
Background and Purpose—An accurate long-term outcome prediction may improve management of stroke patients. We
investigated the ability of copeptin to predict 1-year outcome in stroke patients.
Methods—In this preplanned post hoc analysis, the National Institutes of Health Stroke Scale score and copeptin levels
were measured on admission in a cohort of patients with ischemic stroke. The primary end point was functional outcome
(modified Rankin Scale score 3 or 3–6) after 1 year. The secondary end point was all-cause mortality.
Results—Of 362 patients, 341 (94.2%) completed the 1-year follow-up, 146 (43%) patients had an unfavorable functional
outcome, and 66 (20%) died. Multivariate logistic-regression analysis adjusted for age and National Institutes of Health
Stroke Scale score showed that copeptin was an independent predictor of functional outcome (odds ratio4.00; 95% CI,
1.94–8.19) and death (odds ratio2.68; 95% CI, 1.24–5.82). The area under the receiver operating characteristic curve
of copeptin was 0.72 (95% CI, 0.67–0.77) for functional outcome and 0.74 (95% CI, 0.69–0.78) for mortality. Copeptin
improved the area under the receiver operating characteristic curve of the National Institutes of Health Stroke Scale
score for functional outcome from 0.70 (95% CI, 0.64–0.74) to 0.76 (95% CI, 0.71–0.82; P0.002) and for mortality
from 0.74 (95% CI, 0.69–0.78) to 0.78 (95% CI, 0.71–0.85; P0.04).
Conclusions—Copeptin levels are a useful, complementary tool to predict functional outcome and mortality 1 year after
stroke.
Clinical Trial Registration—ISCTRN 00390962; clinicaltrials.gov No. NCT00390962.
(Stroke. 2010;41:1564-1567.)
Key Words: biomarkers  copeptin  1-year outcome  stroke
Stroke ranks second to ischemic heart disease as a causeof death worldwide and is the leading cause of serious
disability.1 Mortality after 1 year ranges between 21% and
27%; 15% to 30% of survivors are permanently disabled.1
Costs of long-term care account for 50% of total costs.2
Early treatment and adequate rehabilitation are known to
reduce dependency at 6 months and may improve long-
term outcome.2 Prediction of long-term outcome at stroke
onset based on clinical deficits only is difficult3; therefore,
rapid measurement of blood biomarkers predicting long-
term functional outcome and mortality could prove useful.
We recently demonstrated in a prospective cohort study
that the biomarker copeptin predicted outcome 90 days
after stroke onset and improved the prognostic accuracy of
the National Institutes of Health Stroke Scale (NIHSS)
score.4 This follow-up study evaluated copeptin as a
marker to predict functional outcome and mortality in
acute stroke patients 1 year after admission.
Patients and Methods
Setting
This study was based on a prospective cohort study (ClinicalTrials.gov
number, NCT00390962).4 A complete description has been reported
previously.4 In brief, vital signs, relevant comorbidities, risk factors,
and stroke severity on admission as assessed by the NIHSS were
recorded. Copeptin was measured with a sandwich immunolumino-
metric assay.5 For follow-up, we used structured telephone inter-
views performed by 1 trained medical student, blinded to copeptin
levels.6 The primary end point of this study was functional outcome
in patients 1 year after stroke, defined by a modified Rankin Scale
score (unfavorable outcomemodified Rankin Scale score 2). The
secondary end point was death from any cause within the
1-year follow-up.
Statistical Analysis
Discrete variables are expressed as counts (percentages) and
continuous variables as medians and interquartile ranges (IQRs).
Two-group and multigroup comparisons were performed with the
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Mann–Whitney U test and Kruskal-Wallis 1-way ANOVA, re-
spectively. The relation of copeptin to outcomes was assessed in
logistic-regression models. For multivariate analysis, we included
confounders, known risk factors, and other outcome predictors as
assessed in univariate analysis. Receiver-operating-characteristic
curves were calculated to assess discrimination. To estimate the
additive benefit of copeptin to the NIHSS score, we used
likelihood ratio tests. Kaplan–Meier survival curves were con-
structed for mortality prediction. All testing was 2 tailed, and
probability values 0.05 were considered statistically significant. Cal-
culations were performed with STATA 9.2 (Stata Corp, College Station,
Tex) and Graphpad Prism 5 (Graphpad Software).
Results
Patients
Of the original 362 ischemic stroke patients,4 341 (94.2%)
completed the 1-year follow-up. In 5 patients, copeptin values
were missing, leaving 336 patients for the final analysis.
Baseline characteristics have been reported previously.4 The
median age of the patients was 75 (IQR, 65 to 83) years, 40%
were women, and the median NIHSS score on admission was
5 points (IQR, 2 to 10).
Primary End Point
In the 146 patients (43%) with an unfavorable functional
outcome, copeptin levels were higher compared with those in
patients with a favorable outcome (19.30; IQR, 9.60 to 36.98
pmol/L vs 8.12; IQR, 4.58 to 14.65 pmol/L; P0.0001).
Univariate and multivariate logistic-regression analyses
showed that copeptin was associated with functional outcome
(Table). The area under the curve (AUC) of copeptin was
0.72 (95% CI, 0.67 to 0.77) and significantly higher than for
white blood cell count (WBC), C-reactive protein (CRP), and
glucose but similar to the AUC for NIHSS score (0.70; 95%
CI, 0.64 to 0.76).
We stratified patients into copeptin tertiles and com-
pared outcome within 6 predefined NIHSS risk catego-
ries.7 Increasing copeptin tertiles were associated with
Table. Univariate and Multivariate Analyses
One-Year Functional Outcome One-Year Mortality
Predictor
Univariate
Odds Ratio (95% CI)* P
Multivariate
Odds Ratio (95% CI)* P
Univariate
Odds Ratio (95% CI)* P
Multivariate
Odds Ratio (95% CI)* P
Copeptin† 7.1 (3.9–12.8) 0.0001 4.0 (1.9–8.2) 0.0001 7.8 (4.0–15.3) 0.0001 2.7 (1.2–5.8) 0.01
CRP 1.0 (0.9–1.0) 0.32 1.0 (1.0–1.0) 0.08
Age 1.1 (1.1–1.1) 0.0001 1.1 (1.0–1.1) 0.0001 1.1 (1.1–1.2) 0.0001 1.1 (1.1–1.1) 0.0001
Systolic blood pressure 1.0 (1.0–1.0) 0.27 1.0 (1.0–1.0) 0.47
Female sex 1.7 (1.1–2.6) 0.05 1.2 (0.7–2.1) 0.49 1.9 (1.1–3.3) 0.05
Stroke severity, NIHSS
score
1.1 (1.1–1.2) 0.0001 1.1 (1.1–1.2) 0.0001 1.1 (1.1–1.2) 0.0001 1.1 (1.1–1.2) 0.0001
Risk factors
Hypertension 1.3 (0.8–2.2) 0.31 1.5 (0.8–3.1) 0.21
Atrial fibrillation 2.1 (1.2–3.5) 0.01 0.7 (0.3–1.4) 0.29 3.4 (1.9–6.1) 0.0001 1.3 (0.6–2.7) 0.56
Smoking history 0.6 (0.4–1.0) 0.05 1.0 (0.6–1.8) 0.93 0.4 (0.2–0.8) 0.01 0.8 (0.4–1.8) 0.63
Hypercholesterolemia 0.7 (0.4–1.1) 0.16 0.7 (0.4–1.4) 0.34
Diabetes mellitus 1.4 (0.8–2.3) 0.24 0.9 (0.5–1.8) 0.85
Coronary heart disease 1.2 (0.8–2.0) 0.39 1.2 (0.7–2.2) 0.56
Prior stroke 1.2 (0.7–2.0) 0.42 1.0 (0.5–1.8) 0.91
Family history of stroke/
myocardial infarction
0.5 (0.3–0.8) 0.01 0.6 (0.3–1.1) 0.11 0.6 (0.4–1.2) 0.17
Stroke syndrome
TACS 3.3 (1.6–6.8) 0.01 1.3 (0.5–3.6) 0.65 3.3 (1.7–6.8) 0.01 0.9 (0.3–2.7) 0.87
PACS 1.0 (0.6–1.5) 0.98 1.5 (0.9–2.5) 0.15
LACS 0.8 (0.5–1.4) 0.42 0.4 (0.2–0.9) 0.05
POCS 0.6 (0.4–1.1) 0.08 0.5 (0.2–1.0) 0.05
Stroke etiology
Small-vessel occlusive 0.6 (0.3–1.1) 0.09 0.2 (0.1–0.7) 0.05
Large-vessel occlusive 0.8 (0.5–1.5) 0.55 0.5 (0.2–1.1) 0.07
Cardioembolic 1.0 (0.6–1.5) 0.89 1.4 (0.8–2.4) 0.25
Other 0.9 (0.3–2.5) 0.77 0.6 (0.1–2.8) 0.52
Unknown 1.8 (1.1–2.9) 0.05 1.5 (0.8–2.8) 0.20 2.3 (1.3–4.1) 0.01
TACS indicates total anterior circulation syndrome; PACS, partial anterior circulation syndrome; LACS, lacunar circulation syndrome; and POCS, posterior circulation
syndrome.
*Note that the odds ratio corresponds to a unit increase in the explanatory variable; †for copeptin, this corresponds to an increase per unit of the log transformation
of copeptin (thus, a log-transformed increase of 1 corresponds to a copeptin increase of 10 pmol/L).
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higher risk for adverse outcome (Figure 1a). Similarly, the
combination of copeptin and NIHSS score in a combined
logistic-regression model improved the NIHSS score
(AUC of the combined model0.78; 95% CI, 0.72 to
0.84; P0.01). This was not true for glucose, CRP, or
WBC.
Secondary End Point
Sixty-six patients (20%) died. Copeptin levels in nonsur-
vivors (28.10 pmol/L; IQR, 13.20 to 60.88) were higher
compared with those in survivors (9.34 pmol/L, IQR, 5.37
to 19.00; P0.0001). In univariate and multivariate anal-
yses, copeptin was an independent predictor for mortality.
Receiver-operating-characteristic analysis showed similar
results for the NIHSS score (AUC0.74; 95% CI, 0.66 to
0.81) and copeptin (AUC0.74; 95% CI, 0.69 to 0.78) but
inferior results for WBC, CRP, and glucose. Stratification
of patients into copeptin tertiles confirmed increased
mortality risk in 6 predefined NIHSS risk groups (Figure
1b). The combination of NIHSS score and copeptin im-
proved the AUC to 0.79 (95% CI, 0.71 to 0.87; P0.05).
We found an increased risk for mortality with increasing
copeptin tertiles, particularly from the second to the third
tertile (Figure 2).
Discussion
The ability to use biochemical markers to improve the
prognostic accuracy after acute ischemic stroke is attrac-
tive.8 Several biomarkers were evaluated previously: brain
natriuretic peptide, CRP, WBC, and glucose have a signif-
icant association with outcome in stroke patients.8 How-
ever, most studies were small and did not adjust the blood
markers for age and stroke severity in multiple logistic-
regression models.8 None of these markers increased the
predictive power of the NIHSS score nor accuracy for
long-term outcome.8
This study shows that copeptin is a reliable and inde-
pendent marker to predict long-term outcome in patients
with ischemic stroke. Importantly, copeptin improved the
prognostic value of the NIHSS score for long-term mor-
tality and functional outcome at 1 year and was a better
prognostic marker compared with other markers. Copeptin
remained a significant predictor even after adjusting for
age and stroke severity and added information for risk
stratification beyond the NIHSS score.
Copeptin, though not a specific biomarker, is an attrac-
tive tool for routine clinical use because it is easy and
quick to measure. In contrast to other brain markers, it
directly mirrors intracerebral processes and is released into
the systemic circulation, thus bypassing the blood-brain
barrier. The strengths of this study are the prospective,
consecutive inclusion of well-characterized stoke patients,
blinded outcome assessment, and thorough follow-up in-
terviews. As a limitation, our results need validation in an
independent cohort of patients.
Figure 2. Kaplan–Meier survival curves
for copeptin.
Figure 1. Bar graph of NIHSS score in combination with copep-
tin for (a) functional outcome and (b) mortality prediction.
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In conclusion, we believe that copeptin levels may reliably
predict long-term stroke prognosis at its onset. This will allow
identification of high-risk patients for whom secondary pre-
vention and intensive rehabilitation can be directed to im-
prove their outcome.
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Anterior pituitary axis hormones and outcome in acute
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Abstract.NeidertS,KatanM,SchuetzP,FluriF,ErnstA,
BingisserR, Kappos L, Engelter ST, SteckA,Mu¨ller B,
Christ-Crain M (University Hospital Basel, Basel,
Switzerland;SphingoTecGmbH,Borgsorf,Germany;
Kantonsspital Aarau, Aarau, Switzerland) Anterior
pituitary axis hormones and outcome in acute
ischaemicstroke.J InternMed2011;269: 420–432.
Background. Early and accurate prediction of outcome
in acute stroke is important and influences risk-opti-
mized therapeutic strategies. Endocrine alterations
of the hypothalamic–pituitary axis are amongst the
firstmeasurable alterationsafter cerebral ischaemia.
We therefore evaluated the prognostic value of corti-
sol, triiodothyronine (T3), free thyroxine (fT4), thy-
roid-stimulating hormone (TSH) and growth hor-
mone (GH) in patients with an acute ischaemic
stroke.
Methods. In an observational study including 281 pa-
tients with ischaemic stroke, anterior pituitary axis
hormones (i.e. cortisol, T3, fT4, TSH and GH) were
simultaneously assessed to determine their value to
predict functional outcome and mortality within
90 daysand1 year.
Results. In receiver operating characteristic curveanal-
ysis, the prognostic accuracy of cortisol was higher
compared to all measured hormones and was in the
rangeof theNational InstitutesofHealthStrokeScale
(NIHSS). Cortisol was an independent prognostic
marker of functional outcome and death [odds ratio
(OR) 1.0 (1.0–1.01) and 1.62 (1.37–1.92), respec-
tively, P < 0.0002 for both, adjusted for age and the
NIHSS] in patients with ischaemic stroke, but added
no significant additional predictive value to the clini-
calNIHSSscore.
Conclusion. Cortisol is an independent prognostic mar-
ker for death and functional outcome within 90 days
and1 year in patientswith ischaemic stroke. By con-
trast, other anterior pituitary axis hormones such as
peripheral thyroid hormones andGHare only ofmin-
orvalue topredictoutcome instroke.
Keywords: cortisol,hypothalamic–pituitaryaxis,stroke.
Introduction
Stroke is the third commonest cause of mortality
worldwide and a major cause of long-term disability
[1]. Stroke strongly influences an individual’s emo-
tional and socio-economic quality of life [1]. It is esti-
mated that 795 000 people suffered an acute stroke
in the United States of America in 2009, of whom15–
30% remain permanently disabled [2]. An early risk
assessmentwithanestimateof theseverity ofdisease
andprognosis ispivotal foroptimizedcareandalloca-
tion of healthcare resources. The National Institutes
of Health Stroke Scale (NIHSS) is a standardized and
widely used assessmentmeasure to predict 3-month
outcome in acute cerebrovascular events but its use
implies special training and there is inter-observer
variability [3]. In this context, rapidly measurable
markers to predict illness development, outcomeand
mortality might improve the prognostic accuracy of
clinical scoresandtraditional risk factors.
Theclassical ‘stress response’ of thebodyoccursafter
stimulation of the hypothalamic–pituitary axis (HPA
axis) by a stressor. It is characterized by an increase
incortisol levels, depressionof thyroid functionanda
functional deficit of anabolic hormones such as
growth hormone (GH) and insulin [4]. Anabolic resis-
tance might contribute to the prolonged whole-body
protein breakdown with increased susceptibility
for infections and delayed recovery. In cerebral
ischaemia, endocrinechangesof theHPAaxisareone
of the first measurable alterations [5, 6]. In addition,*Theseauthorscontributedequally.
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low triiodothyronine (T3) levels, as in the ‘low T3 syn-
drome’, have been described as a prognostic risk fac-
tor for death and functional outcome in stroke pa-
tients [7]. We therefore evaluated the prognostic
value of cortisol, T3, free thyroxine (fT4), thyroid-
stimulatinghormone (TSH) andhumanGHonhospi-
tal admission in a well-described cohort of 281 pa-
tientswith ischaemicstroke.
Material and methods
Study design and setting
Thedesignof thisprospectivecohort studyat theUni-
versity Basel, Switzerland (Clinical Trials.gov num-
ber, NCT00390962), has been described in detail
elsewhere [8, 9]. Briefly, from November 2006 until
November 2007, consecutive patients presenting
with acute ischaemic stroke were included. Informed
consent was obtained from the patient if possible,
otherwise from a relative or from the patient’s physi-
cian in theabsenceofa relative.Thisstudyadheres to
the consolidated standards for the reportingof obser-
vational trials [10] and was approved by the Ethics
CommitteeofBasel,Switzerland.
Patients
Patientswere eligible for the study if theywere admit-
ted with acute ischaemic stroke according to the
World Health Organization criteria [11], with symp-
tomonsetwithin72 h.
Of a total of 362 eligible patients, blood was collected
on day 1 after admission for standardized measure-
ment of cortisol, thyroidhormonesandGH in281pa-
tients; thesemeasurementscouldnotbeperformedin
81 patients (two patients died, 68were discharged to
another institution before the standardized blood
sampling on the day after admission could be per-
formedandbloodsamplingwasomittedin11patients
bymistake).However, these281patientsweresimilar
in terms of baseline characteristics [age (P = 0.50),
gender (P = 0.82), NIHSS (P = 0.65) and weight
(P = 0.89)]comparedtotheoverallcohort.Oftheorigi-
nal281strokepatients,268completed the1-year fol-
low-upandwereavailableforlong-termanalysis.
Clinical variables
Within the first 24 h after admission, the following
data were recorded: vital signs; relevant co-morbidi-
ties assessed by the Charlson comorbidity index
(CCI) adjusted for stroke (the CCI is a comorbidity
scoring system that includesweighting factors on the
basis of disease severity according to the ICD-9-CM
system) [12]; medication; traditional risk factors (i.e.
age, gender, smokinghabits, hypercholesterolaemia,
history of hypertension, diabetes mellitus or tran-
sient ischaemic attack (TIA) ⁄ ischaemic stroke, or po-
sitive family history of myocardial infarction, stroke
or TIA); and severity of stroke as assessed by the NI-
HSS [13] by a neurologist certified in the use of this
scale. The clinical stroke syndrome was determined
by applying the criteria of the Oxfordshire Commu-
nity Stroke Project: total anterior circulation syn-
drome (TACS); partial anterior circulation syndrome
(PACS); lacunar syndrome (LACS); and posterior cir-
culation syndrome (POCS) [14]. Patients underwent
routine laboratory testing and standardized diagnos-
tic work-up to evaluate stroke aetiology. Stroke aeti-
ology was determined according to the criteria of the
TOAST classification [15], which distinguishes be-
tween large-artery arteriosclerosis, cardioembolism,
small-artery occlusion and other or undetermined
aetiologies.
Neuroimaging
To exclude intracranial haemorrhage, cranial com-
puted tomography was performed in all patients on
admission. Thereafter magnetic resonance imaging
(MRI) was performed on a clinical 1.5 T MR Avanto
system (SIEMENS,Erlangen,Germany)usinga stroke
protocol, including T1-, T2- and diffusion-weighted
imaging (DWI) sequences, and magnetic resonance
angiography. MRI with DWI data was available for
169 patients (60.1%). In these patients, DWI lesion
volumes were determined by consensus of two expe-
riencedneuroradiologistsunaware of the clinical and
laboratory results. The lesion size was calculated by
the commonly used semi-quantitative method [16].
Lesions were classified into three sizes to represent
typical stroke patterns: (i) small lesions with a vol-
ume of <10 mL; (ii) medium lesions of 10–100 mL;
and (iii) large lesions with a volume of more than
100 mL[17].
Assays
Blood samples were obtained from an indwelling ve-
nous catheter thefirstmorningafter admission.Rou-
tine blood count and C-reactive protein (CRP) levels
were measured in all patients. Plasma was collected
at the timeofbloodsampling inplastic tubes contain-
ing ethylenediaminetetraacetic acid. The tubes were
placed on ice and centrifuged at 3000 g, and plasma
wasstoredat)70 Cuntil required forassay.
S. Neidert et al. | Pituitary axis hormones and outcome in stroke
ª 2011 The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine 269; 420–432 421
Cortisol was measured with a competitive chemilu-
minescence immunoassay (IMMULITE 2000; Sie-
mens Medical Solution Diagnostics, Los Angeles,
CA, USA) with a calibration range from 28 to
1380 nmol L)1. T3 (nmol L)1), fT4 (pmol L)1) and
TSH (mIU L)1) were measured by an electrochemical
luminescence immunoassay (Roche Diagnostics,
Mannheim, Germany). GH was measured using a
high-sensitivity chemiluminescence immunoassay
with a functional assay sensitivity of 0.027 ng mL)1
asdescribed recently [18]. Forallmeasurements, lev-
els thatwere not detectablewere considered tohave a
valueequal to the lower limitofdetectionof theassay.
Outcomes
The primary end-point was functional outcome on
day 90. It was assessed by two trained medical stu-
dents, blinded to hormone levels, with a structured
follow-up telephone interview with the patient or, if
not possible, with the closest relative or family doctor
if no close relatives were available. Functional out-
come was assessed by the modified Rankin Scale
(mRS) [19]. A favourable functional outcome was de-
fined as anmRS of 0–2 points, whereas an unfavour-
able outcome was defined as an mRS of >2 points.
Secondary end-points were all-cause mortality with-
in 90 days, as well as long-term functional outcome
andmortalityafter1 year.
Statistical analysis
First, to assess the association between hormones
and stroke severity, hormone levels were correlated
with NIHSS and with lesion size using Spearman’s
rank correlation. Hormone levels were further as-
sessed fordifferent clinical strokesyndromes,andre-
sults are presented as median ± interquartile range
(IQR). In addition, hormone levels were compared
with regard to primary and secondary end-points.
Two-group comparisons were performed with the
Mann–Whitney U-test and multigroup comparisons
withKruskal–Wallis one-wayanalysisofvariance.
Second, we investigated the association between dif-
ferent hormone levels and both outcomes in univari-
ate logistic regression models, and results are re-
ported as OR. We then adjusted all hormones with
significant univariate associations for NIHSS and
age, the main outcome predictors within this cohort,
asdescribedpreviously [8].Further,weperformedre-
ceiver operating characteristics (ROC) curve analysis
to assess discrimination and results are reported as
area under the curve (AUC). To study the ability of
cortisol to predict mortality, we calculated Kaplan–
Meier survival curves and stratified patients by corti-
sol quartiles. Finally, we calculated reclassification
tables [20, 21], and results are reported as net reclas-
sification improvement for outcome and mortality
risk categories, as proposed previously [8, 22]. For
net reclassification improvement, only those changes
in estimated prediction probabilities that imply a
change from one risk category to another are consid-
ered.
All statistical tests were two-tailed, and P < 0.05was
considered to indicate statistical significance. All
statistical analysis was performed with medcalc for
windows (version 7.2.1.0.; MedCalc, Mariakerke,
Belgium), graph pad prism (version 4; GraphPAd, La
Jolla, CA, USA) or stata 9.2 (Stata Corp, College Sta-
tion,TX,USA).
Results
Baseline characteristics of the study population
A total of 281 patients were included in this analysis;
113 (40%) were male and median age was 68 years
(IQR 63–82). Median systolic blood pressure was
160 mmHg (IQR 141–180), median diastolic blood
pressure was 90 mmHg (IQR 80–100) and median
heart rate was 78 beats min)1 (IQR 68–88). A total of
58 (21%) patients were diagnosed with atrial fibrilla-
tion, 74 (26%) patients had hypercholesterolaemia,
84 (30%)hadapositive familyhistory of cardiovascu-
lar events and 98 (35%) were smokers. Median glu-
cose levels were 6.1 mmol L)1 (IQR 5.4–7.4). The
main baseline characteristics are summarized in
Table1.
Pituitary axis hormones and stroke characteristics
NIHSS. Therewas a positive correlation between the
NIHSS and levels of cortisol (r = 0.32, P < 0.0001)
andGH (r = 0.15, P = 0.004), and a negative correla-
tionwith levels of T3 (r = )0.27, P < 0.0001) andTSH
(r = )0.17, P = 0.006). fT4 levels were not correlated
with theNIHSS (r = )0.0008,P = 0.78) (Fig.1).
Lesion size. In patients for whom MRI data were
available (n = 169), cortisol levels increased with le-
sion size. Median cortisol levels in patients with
small, medium and large lesions were 461 nmol L)1
(IQR 345–585), 490 nmol L)1 (IQR 367–631) and
749 nmol L)1 (IQR 648–631), respectively (P <
0.0001). There was no difference in T3 or fT4 levels
with lesion size. However, TSH levels were lower in
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patients with large lesions compared to those with
small lesion [0.62 mIU L)1 (IQR 0.3–1.1) vs.
1.33 mIU L)1 (IQR 1.1–1.6), P < 0.01], and GH levels
increased with lesion size [0.21 ng mL)1 (IQR 0.10–
0.94) vs. 0.57 ng mL)1 (IQR 0.16–1.21) vs. 1.65 ng
mL)1 (IQR0.84–2.40),overallP = 0.003].
Clinical stroke syndrome. Cortisol values were sig-
nificantly higher in patientswith TACS654 nmol L)1
(IQR 495–839) compared with patients with PACS
472 nmol L)1 (IQR 328–624, P < 0.001), LACS
450 nmol L)1 (IQR 334–587, P < 0.001) or POCS
469 nmol L)1 (IQR 351–613, P < 0.01). Thyroid hor-
mone levels did not vary in patients with different
clinical stroke syndromes. GH levels were signifi-
cantly higher in patients with TACS [0.59 ng mL)1
(IQR 0.36–1.06)] compared to those with LACS
[0.31 ng mL)1 (IQR0.11–0.84), P < 0.05] and tended
to be higher compared to those with PACS or POCS
[0.35 ng mL)1 (IQR 0.15–1.03) and 0.43 ng mL)1
(IQR0.14–1.22), respectively,P = 0.05].
Pituitary axis hormones and outcome
Pituitary axis hormones and 90-day outcome. A total
of 172 (61%) patients had a good functional outcome
defined as an mRS £ 2, whereas 109 patients (39%)
had a bad functional outcome defined by an
mRS ‡ 3.Thirty patients died within 90 days, and
thus themortality rate was 10.7%. The comparisons
of median hormone values in patients with a good ⁄ -
bad functional outcome and in survivors ⁄nonsurvi-
vorsaresummarized inTable2.
Table 1 Baselinecharacteristicsofstrokepatients
Demographiccharacteristics
Age (years)median (IQR) 68(63–82)
Malesex (%) 59
Clinicalfindingsmedian (IQR)
Heart rate (beats min)1) 78(68–88)
Systolicbloodpressure (mmHg) 160 (141–180)
Diastolicbloodpressure (mmHg) 90(80–100)
Temperature (C) 37.0 (36.5–37.5)
Weight (kg) 72(64–82)
Height (cm) 169 (162–175)
Bodymass index
(BMI) (kg m)2)
25.2 (24–27.2)
Laboratoryfindings (median–IQR)
Cortisol (nmol L)1) (n = 281) 480 (344.5–629.8)
T3(nmol L)1) (n = 269) 1.4 (1.2–1.6)
fT4 (pmol L)1) (n = 274) 15.4 (13.8–17.2)
TSH(mIU L)1) (n = 275) 1.4 (0.9–2.2)
Growthhormone
(ng mL)1) (n = 276)
0.4 (0.2–1.1)
Total cholesterol
(mmol L)1) (n = 268)
4.4 (3.8–5.1)
High-density lipoproteins (HDL)
(mmol L)1) (n = 281)
1.3 (1.1–1.6)
Low-density lipoproteins (LDL)
(mmol L)1) (n = 281)
2.4 (1.8–3.0)
Triglycerides (mmol L)1) (n = 281) 1.1 (0.9–1.6)
C-reactiveprotein
(mg L)1) (n = 281)
3.4 (3.0–9.4)
Glucose (mmol L)1) (n = 281) 6.1 (5.4–7.4)
Prognosticscores (median–IQR)
Modifiedrankingscale (points) 2 (1–4)
NIHSS (points) 5 (2–10)
Strokesyndromeno. (%)
TACS 27(9.4)
PACS 126 (43.8)
LACS 58(20.1)
POCS 71(24.7)
Strokeaetiologyno. (%)
Small-vessel occlusive 48(16.7)
Large-vessel occlusive 54(18.8)
Cardioembolic 105 (36.5)
Other 13(4.5)
Unknown 61(21.2)
Table 1 (Continued)
Vascular risk factorsno. (%)
Hypertension 214 (74)
Atrialfibrillation 58 (20)
Smokinghistory 98 (34)
Hypercholesterolaemia 74 (26)
Diabetesmellitus 56 (19)
Coronaryheartdisease 67 (23)
Priorstroke 66 (23)
Familyhistoryof cardiovascularevent 84 (29)
fT4, free thyroxine; IQR, interquartile range; LACS, lacunar
syndrome; NIHSS, National Institutes of Health Stroke
Scale; PACS, partial anterior circulation syndrome; POCS,
posterior circulation syndrome; T3, triiodothyronine; TACS,
total anterior circulation syndrome; TSH, thyroid-stimulat-
inghormone.
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Cortisol. Median cortisol levels in patients with a
favourable outcomeand insurvivorswere lower com-
pared to levels in patients with an unfavourable out-
comeandnonsurvivors, respectively.
Time todeathwasanalysedbyKaplan–Meier survival
curves based on cortisol quartiles. Patients in the
highest two quartiles (cortisol ‡ 633 nmol L)1) had
an increased risk of death compared with patients in
the lowest twoquartiles (P < 0.001) (Fig.2).
T3, fT4 and TSH. Triiodothyronine levels in stroke
patients with a favourable outcome were higher
compared to levels in patients with an unfavourable
outcome; the reversewas found for fT4 levels. T3 ⁄ fT4
ratios were significantly higher in patients with a
Fig. 1 Correlation between the National Institutes ofHealth StrokeScale (NIHSS) and pituitary axis hormone levels. Rank corre-
lation between the NIHSS and levels of cortisol, growth hormone, triiodothyronine, free thyroxine and thyroid-stimulating
hormone.
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favourable outcome compared to ratios in patients
with anunfavourable outcome. TSH levelswerehigh-
er in patientswith a favourable outcome compared to
levels inpatientswithanunfavourableoutcome.
Patients who died had lower T3 ⁄TSH levels and high-
er fT4 levels compared to levels in patients who
survived. T3 ⁄ fT4 ratios were significantly higher in
patients who survived compared to ratios in those
whodied.
TimetodeathwasanalysedbyKaplan–Meier survival
curves based on fT4, T3 and TSH quartiles. Patients
in thehighest quartile of fT4 (P = 0.02) and the lowest
Table 2 Pituitaryaxishormone levelsandoutcomeafter90 daysand1 year
Functionaloutcome Mortality
mRS £ 2 mRS > 2 P Survivors Nonsurvivors P
Pituitaryaxishormonesand90-dayoutcome
Cortisol
(mmol L)1)
median (IQR)
444 (318.5–558.5) 582 (439.5–727) <0.0001 466 (337–598) 712 (577–1106) <0.0001
T3
(nmol L)1)
median (IQR)
1.5 (1.3–1.6) 1.3 (1.1–1.6) 0.005 1.5 (1.3–1.6) 1.2 (1.0–1.4) 0.002
fT4
(pmol L)1)
median (IQR)
15.6 (14.2–17.8) 15.3 (13.7–16.6) 0.03 15.4 (13.8–16.9) 16.3 (14.3–19.6) 0.03
T3 ⁄ fT4ratio 0.1 (0.08–0.1) 0.08(0.07–0.1) 0.0001 0.09 (0.08–0.11) 0.07 (0.06–0.08) 0.0001
TSH
(mIU L)1)
median (IQR)
1.6 (1.1–2.4) 1.1 (0.7–2.0) 0.0003 1.4 (0.9–2.3) 1.0 (0.6–2.2) 0.02
GH(ng mL)1)
median (IQR)
0.3 (0.1–1) 0.5 (0.2–1.2) 0.01 0.3 (0.2–1.0) 0.6 (0.4–1.4) 0.02
Pituitaryaxishormonesand1-yearoutcome
Cortisol
(mmol L)1)
median (IQR)
466 (333–585) 512 (377–692) 0.004 466 (337–590) 633 (455–853) <0.0001
T3
(nmol L)1)
median (IQR)
1.5 (1.3–1.7) 1.3 (1.2–1.7) 0.0008 1.5 (1.3–1.6) 1.3 (1.1–1.6) 0.06
fT4
(pmol L)1)
median (IQR)
15.4 (13.8–16.8) 15.6 (14.1–17.8) 0.11 15.4 (13.8–16.7) 17.1(14.3–19.1) 0.004
T3 ⁄ fT4ratio 0.1 (0.08–0.11) 0.08(0.07–0.1) 0.0002 0.09 (0.08–0.11) 0.08 (0.06–0.09) 0.001
TSH
(mIU L)1)
median (IQR)
1.4 (1.0–2.2) 1.2 (0.7–2.1) 0.04 1.4 (0.9–2.2) 1.1 (0.6–2.2) 0.1
GH
(ng mL)1)
median (IQR)
0.3 (0.1–1.1) 0.5 (0.2–1.1) 0.06 0.3 (0.1–1.0) 0.6 (0.4–1.5) 0.002
fT4, free thyroxine;GH,growthhormone; IQR, interquartile range;mRS,modifiedRankinScale; T3, triiodothyronine;TSH, thy-
roid-stimulatinghormone.
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quartile of T3 (P = 0.002) and TSH (P = 0.01) had a
significantly higher risk of death compared to pa-
tients in theother threequartiles.
GH. Growth hormone levels in patients with a
favourable outcome and survivors were lower com-
pared to levels in patients with an unfavourable out-
comeandnonsurvivors, respectively.
Time todeathwasanalysedbyKaplan–Meier survival
curves based onGHquartiles. Patients in the highest
two quartiles had a significantly increased risk of
death compared to patients in the lower two quartiles
(P = 0.001).
Pituitary axis hormones and outcome at 1 year. Of
the original 281 stroke patients, 268 completed the
1-year follow-up and were available for long-term
analysis. The comparisons of median hormone val-
ues in patients with a good ⁄bad functional outcome
and in survivors ⁄nonsurvivors are summarized in
Table 2.
Comparison of the pituitary axis hormones with other
markers and clinical scores. We performed ROC
curve analysis to compare the overall prognostic
accuracy of theNIHSS,cortisol, T3, fT4,TSHandGH.
The prognostic accuracy of cortisol was high com-
pared to that of glucose and white blood cell count,
butwassimilar to thatofCRPandtheCCI.TheNIHSS
was the most accurate predictor of 1-year outcome
(Table3).
The AUC to predict mortality was highest for cortisol
[0.81 (IQR 0.76–0.86)] and was similar to that of the
NIHSS [0.85 (IQR0.8–0.89), P = 0.44]. Cortisol had a
higher prognostic accuracy than the other hormones
and laboratory andclinical parameters and tended to
have a higher AUC value compared to CRP (Table 3).
Again, the NIHSS was the most accurate predictor of
mortalityat1 year (Table3).
When combining the NIHSS with initial cortisol in a
logistic regression model for 90-day outcome, we
found only a small increase in AUC from0.75 to 0.77
for functional outcome prediction, which did not
reach statistical significance (P = 0.52). Similarly, for
mortality prediction, the AUC increased from 0.85 to
0.87 (P = 0.30).
We further calculated in-sample reclassification ta-
bles (Appendix 1 and 2). In patients with poor out-
come,14wereclassified inhigher-riskcategoriesand
10 in lower categories when using themodel with the
NIHSS and cortisol. Similarly, in patients with good
outcome, only 14 were classified in higher-risk cate-
goriesand32in lowercategories.Thus, theestimated
net reclassification improvement for functional
outcomewas0.14 (P < 0.01). Amongst nonsurvivors,
seven patients were classified in higher-risk catego-
ries and three in lower categories; amongst survivors,
99 patients were classified in lower-risk categories
and 50 in higher categories when using the model
with theNIHSSscoreandcortisol (net reclassification
improvement0.33,P < 0.001).
Fig. 2 Kaplan–Meier survival based on cortisol quartiles. Time todeathwasanalysedbyKaplan–Meier curvesbasedon cortisol
quartiles.Patients in the lower twoquartiles (cortisol <345 nmol L)1andcortisol between345and480 nmol L)1) hadaminor risk
of death compared to patients with cortisol levels in the upper two quartile (cortisol between 481 and 632 and ‡633 nmol L)1,
P < 0.001).
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Association between hormones and both functional outcome
andmortality in logistic regression analysis
Univariate logistic regression models showed that
cortisol, T3 and TSHwere associated with functional
outcome. Cortisol, fT4 and T3 were also significantly
associatedwithdeath (Table2). Ina logisticmodelad-
justed for the NIHSS and age, cortisol, but not the
other pituitary axis hormones, was independently
associated with both functional outcome [OR 1.0
(1.00–1.01), P < 0.0002] and death [OR 1.62 (1.37–
1.92),P < 0.0002] (Table4).
Discussion
In this study, we simultaneously assessed anterior
pituitary axishormoneswith regard to their accuracy
to predict functional outcome and mortality in pa-
tients with acute ischaemic stroke within 90 days
and 1 year. Our main finding is that cortisol is an
independent prognostic marker of functional out-
come and death in patients with ischaemic stroke,
butaddsnosignificantadditionalpredictive informa-
tion to the clinical score of the NIHSS. We demon-
strated that cortisol levels increased with lesion size,
neurological deficit (assessed by the NIHSS) and the
clinical stroke syndrome (i.e. TACS versus PACS,
LACSandPOCS), reflecting the severity of the stroke.
Conversely, T3, fT4, TSH and GH add only limited or
no prognostic information to currently used mea-
suresandscores.
Inpreviousstudies,we foundthatcopeptin isasignif-
icant predictor of short- and long-term outcome and
mortality [8, 9]. The prognostic performance of corti-
sol within the same population was similar to that of
copeptin, but showed no significant additional pre-
dictive value to theNIHSS incontrast to copeptin [8].
Table 3 Receiveroperatingcharacteristics curveanalysis
Parameter
Functionaloutcomeat90 days Functionaloutcomeat1 year
AUC 95%confidence interval P AUC 95%confidence interval P
Cortisol 0.68 (0.63–0.74) 0.60 (0.53–0.66)
NIHSS 0.75 (0.69–0.8) 0.08 0.72 (0.66–0.78) 0.004
T3 0.56 (0.50–0.63) 0.06 0.61 (0.55–0.67) 0.71
fT4 0.58 (0.52–0.64) 0.03 0.55 (0.49–0.62) 0.38
TSH 0.60 (0.55–0.67) 0.29 0.55 (0.49–0.61) 0.35
GH 0.61 (0.55–0.67) 0.12 0.57 (0.50–0.63) 0.56
Glucose 0.55 (0.49–0.61) 0.01 0.50 (0.44–0.58) 0.05
WBC 0.56 (0.50–0.62) 0.02 0.53 (0.49–0.60) 0.18
CCI 0.62 (0.56–0.68) 0.26 0.64 (0.57–0.71) 0.45
CRP 0.60 (0.54–0.67) 0.16 0.59 (0.52–0.66) 0.84
Mortalityat90 days Mortalityat1 year
Cortisol 0.81 (0.76–0.86) 0.69 (0.63–0.75)
NIHSS 0.85 (0.80–0.89) 0.44 0.78 (0.72–0.83) 0.11
T3 0.66 (0.60–0.70) 0.02 0.59 (0.52–0.65) 0.10
fT4 0.60 (0.54–0.76) 0.003 0.63 (0.57–0.68) 0.29
TSH 0.60 (0.54–0.67) 0.001 0.56 (0.50–0.62) 0.03
GH 0.64 (0.58–0.70) 0.04 0.65 (0.58–0.71) 0.50
Glucose 0.59 (0.53–0.66) 0.002 0.55 (0.48–0.62) 0.0.2
WBC 0.66 (0.53–0.67) 0.004 0.53 (0.47–0.61) 0.01
CCI 0.59 (0.53–0.65) 0.007 0.59 (0.52–0.66) 0.08
CRP 0.69 (0.63–0.75) 0.13 0.64 (0.57–0.71) 0.27
AUC,areaunder thecurve;CCI,Charlsoncomorbidity index;CRP,C-reactiveprotein; fT4, free thyroxine;GH,growthhormone;
NIHSS, National Institutes of Health Stroke Scale; T3, triiodothyronine; TSH, thyroid-stimulating hormone;WBC, white blood
count.
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Acute ischaemic stroke acts as a stressor and thus
stimulates theHPA axis resulting in increased gluco-
corticoid levels [5,6,23].Thehighercortisol levelsob-
served in patients with worse functional outcome or
subsequent death reflect a higher degree of stress.
These results are in accordancewith the results from
other studies showing that serum cortisol levels rise
proportionally with the degree of stress and correlate
with stroke severity [5, 24–26]. A severe stroke per se
implies a poor outcome. However, there are several
other mechanisms that might explain the unfavour-
able outcome in patients with higher cortisol levels.
Hypercortisolismhasbeensuggestedtopotentiate is-
chaemic neuronal injury, especially in hippocampal
neurons [27], and the corticosterone synthesis inhib-
itor metyrapone was able to prevent ischaemia-in-
duced loss of synaptic function in the hippocampus
of rats [28]. The hippocampus has an important role
in the feedback regulation of the HPA axis. A dis-
turbed hippocampus function might result in a false
HPA axis feedback that potentiates hypercortisolism
and causes a vicious circle, explaining the worse
prognosis in stroke patients with high cortisol levels
[29]. In addition, patients with stroke and high corti-
sol levels have been shown to be more prone to ad-
verse cardiac events (e.g. arrhythmias ormyofibrillar
degeneration), which might lead to higher mortality
rates [25,30].Anothermajorcauseofabadprognosis
after stroke is the development of infectious disease
which is related to an immune dysregulation result-
ing fromneuroendocrinedisturbanceafter stroke.
In our study, T3 levels were lower in patients with a
poorer prognosis concerning functional outcomeand
death. This is in line with a previously published
study which showed that the low T3 syndrome was
an independent predictor of survival in patients with
acute stroke, and predicted disability at 1 year [7]. It
should be emphasized that low T3 levels even within
the normal range are already associated with poorer
prognosis in acute stroke patients [7]; the greater the
severity of disease, the lower the serum T3 levels. A
decrease in the peripheral production of T3 because
of decreased extra-thyroidal conversion of T4 into T3
by the enzyme type I iodothyronine-5¢-deiodinase, as
in the lowT3syndrome, isamajor contributing factor
[31]. This is reflected by the lower T3 ⁄ fT4 ratios in pa-
tientswithanunfavourableoutcome inour cohort. In
addition, it has been shown that high levels of corti-
costeroids suppress TSH secretion and the pituitary
response to thyrotropin-releasing hormone in man
[32], leading, for example, to low T3 levels. Further-
more, stress-induced elevation of glucocorticoids in
rats causes suppression of TSH and T3 levels [33].
Thus, thehigherglucocorticoid levels inpatientswith
worse outcome measured in our cohort might result
inahigherdecrease inT3levels.
Growth hormone levels in our study were higher in
patientswhodiedthan in thosewhosurvived.Several
mechanisms might explain the poorer prognosis of
patients with higher GH levels. First, GH levels in-
crease during stress and thus mirror the stress
Table 4 Univariateandmultivariateassociationbetweenhormone levelsandoutcome
Parameter
Univariateanalysis Multivariateanalysis
Oddsratio P > z 95%confidence interval Oddsratio P > z 95%confidence interval
Predictor: functionaloutcome
Cortisol (per100 nmol increase) 1.00 <0.0002 (1.00–1.00) 1.23 <0.01 (1.07–1.43)
fT4 1.07 0.08 (0.99–1.14)
T3 0.32 0.01 (0.15–0.72) 0.84 0.09 (0.68–1.02)
TSH 0.78 0.01 (0.63–0.95) 0.79 0.60 (0.33–1.90)
GH 0.99 0.81 (0.90–1.08)
Predictor:death
Cortisol (per100 nmol increase) 1.62 <0.0002 (1.37–1.92) 1.43 <0.001 (1.17–1.75)
fT4 1.10 0.02 (1.01–1.20) 1.08 0.13 (0.98–1.19)
T3 0.19 0.01 (0.05–0.71) 0.69 0.66 (0.13–3.60)
TSH 0.92 0.50 (0.72–1.17)
GH 1.04 0.41 (0.95–1.14)
Multivariate analysiswas calculated for all significant predictors inunivariate analysis, adjusted for age and theNational Insti-
tutesofHealthStrokeScale.
fT4, free thyroxine;GH,growthhormone;T3, triiodothyronine;TSH, thyroid-stimulatinghormone.
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associated with the severity and extent of illness [4].
Second, thehigher levelsofGHinnonsurvivorsmight
beanattemptby thebody toprovide energyandpost-
pone anabolism. Third, the higher GH levels in our
study observed in nonsurvivors might be related to
lower insulin-like growth factor (IGF) levels and re-
flect hepatic GH resistance. In this context, it has
beenshown thatpatientswith lower IGF levels suffer-
ing from an ischaemic or haemorrhagic stroke are at
higher risk of death compared to patientswith higher
IGF levels [34, 35]. IGF is a potent neurotrophic fac-
tor. Its expression is induced in injuredbrainregions,
and its administration reduces the extent of cortical
infarction and neuronal death from ischaemic injury
inanimalmodels [36].
Limitations
Some limitations of this observational study merit
consideration. First, cortisol improved the classifica-
tion of patients for functional outcome and for death
in net reclassification statistics as evidenced by sig-
nificantnet reclassification improvements [21].How-
ever, the lack of significance in the combined ROC
curveanalysissuggests that thesefindingsneed tobe
interpreted with caution. For this reason, we did not
further determine cut-off values for cortisol for use in
clinicalpractice.
Second, we only performed single measurements of
hormone levels in the morning after admission. GH
and cortisol levels show a large variation during the
daybecause in termsofGH, secretion ispulsatile [37]
with almost undetectable serum GH concentrations
between thepulses, and in terms of cortisol, it follows
a circadian rhythm [38]. A standardized measure-
ment ofGHwitha functional test in combinationwith
IGFmeasurement inall patientsmighthaveprovided
a higher accuracy to predict outcome. For cortisol,
however, the confounding factors are minimized as
the acute illness abolishes its diurnal variation and
as we similarly measured the level in the morning
after admission in all patients [39]. Also, standard-
ized measurements do not represent clinical routine
intheacuteemergency roomsetting.
Third, we analysed patients within 72 h of symptom
onset. When comparing initial results with results
from hormone levels of patients the next morning
after admission and within either 12–24 or 24–72 h
after symptom onset, they did not show significant
differences. We also tested for effect modification by
delay to blood sampling for cortisol measurement
and did not find evidence for interaction (between
cortisol levels and time delay) with regard to predic-
tion of death and functional outcome (data not
shown).
Conclusion
In conclusion, in this study, we simultaneously as-
sessed the prognostic accuracy of pituitary axis hor-
mones (i.e. cortisol, T3, fT4 andGH) in a large cohort
of patients with acute ischaemic stroke. We found
that cortisol levels and, to a lesser extent, T3, fT4 and
GH levels mirror stroke severity. Cortisol levels are
independently associated with an unfavourable out-
comeafteracute ischaemicstroke.
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Appendix 1 Reclassification table for functionaloutcome
ModelwithNIHSS
ModelwithNIHSSandcortisol
<3%risk
3%to
<10%risk
10%to
<18%risk
18%to
<35%risk
35%to
<40%risk
40%to
48%risk
>48%
risk
Total
no.
Patientswithgood functionaloutcome
<3%risk 0 0 0 0 0 0 0 0
3%to<10 %risk 0 0 0 0 0 0 0 0
10%to<18%risk 0 1 13 1 0 0 0 15
18%to<35%risk 0 3 22 84 8 0 0 117
35%to<40%risk 0 0 0 0 6 3 0 9
40%to48%risk 0 0 0 0 3 5 2 10
>48%risk 0 0 0 0 0 3 17 20
Totalno. 0 4 35 85 17 11 19 171
Patientswithbad functionaloutcome
<3%risk 0 0 0 0 0 0 0 0
3%to<10 %risk 0 0 0 0 0 3 0 0
10%to<18%risk 0 0 3 0 0 0 0 3
18%to<35%risk 0 0 1 29 2 3 0 35
35%to<40%risk 0 0 0 2 1 2 0 5
40%to48%risk 0 0 0 2 3 5 4 14
>48%risk 0 0 1 0 1 0 50 52
Totalno. 0 0 5 33 7 10 54 109
Appendix 2 Reclassification table formortality
ModelwithNIHSS
ModelwithNIHSSandcortisol
<1%risk
1%to
<2%risk
2%to
<4%risk
4%to
<9%risk
9%to
<18%risk
18%to
34%risk
>34%
risk
Total
no.
Survivors
<1%risk 0 0 0 0 0 0 0 0
1%to<2%risk 0 0 0 0 0 0 0 0
2%to<4%risk 24 33 44 28 0 1 0 130
4%to<9%risk 2 7 14 31 13 2 0 69
9%to<18%risk 0 1 1 5 10 3 0 20
18%to34%risk 1 0 1 1 2 11 3 19
>34%risk 0 0 1 2 2 2 5 12
Totalno. 27 41 61 67 27 19 8 250
Nonsurvivors
<1%risk 0 0 0 0 0 0 0 0
1%to<2%risk 0 0 0 0 0 0 0 0
2%to<4%risk 0 0 1 1 0 0 0 2
4%to<9%risk 0 0 2 3 1 1 0 7
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Appendix 2 (Continued)
ModelwithNIHSS
ModelwithNIHSSandcortisol
<1%risk
1%to
<2%risk
2%to
<4%risk
4%to
<9%risk
9%to
<18%risk
18%to
34%risk
>34%
risk
Total
no.
9%to<18%risk 0 0 0 0 3 2 0 5
18%to34%risk 0 0 0 0 0 2 2 4
>34%risk 0 0 0 0 0 1 11 12
Totalno. 0 0 3 4 4 6 13 30
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Copeptin adds prognostic information
after ischemic stroke
Results from the CoRisk study
ABSTRACT
Objective: To evaluate and validate the incremental value of copeptin in the prediction of outcome
and complications as compared with established clinical variables.
Methods: In this prospective, multicenter, cohort study, we measured copeptin in the emergency
room within 24 hours from symptom onset in 783 patients with acute ischemic stroke. The 2 pri-
mary end points were unfavorable functional outcome (modified Rankin Scale score 3–6) and
mortality within 90 days. Secondary end points were any of 5 prespecified complications during
hospitalization.
Results: In multivariate analysis, higher copeptin independently predicted unfavorable outcome
(adjusted odds ratio 2.17 for any 10-fold copeptin increase [95% confidence interval {CI},
1.46–3.22], p , 0.001), mortality (adjusted hazard ratio 2.40 for any 10-fold copeptin increase
[95% CI, 1.60–3.60], p , 0.001), and complications (adjusted odds ratio 1.93 for any 10-fold
copeptin increase [95%CI, 1.33–2.80], p50.001). The discriminatory accuracy, calculated with
the area under the receiver operating characteristic curve, improved significantly for all end
points when adding copeptin to the NIH Stroke Scale score and the multivariate models. More-
over, the combination of copeptin with a validated score encompassing both the NIH Stroke Scale
and age led to a net reclassification improvement of 11.8% for functional outcome and of 37.2%
for mortality.
Conclusions: In patients with ischemic stroke, copeptin is a validated blood marker that adds pre-
dictive information for functional outcome and mortality at 3 months beyond stroke severity and
age. Copeptin seems to be a promising new blood marker for prediction of in-hospital
complications. Neurology 2013;80:1–9
GLOSSARY
AUC 5 area under the curve; AVP 5 arginine vasopressin; CI 5 confidence interval; CRP 5 C-reactive protein; HR 5 hazard
ratio; mRS 5 modified Rankin Scale; IQR 5 interquartile range; NIHSS 5 NIH Stroke Scale; NRI 5 net reclassification
improvement; OR 5 odds ratio; ROC 5 receiver operating characteristic.
Accurate and prompt prediction of functional outcome, mortality, and complications in patients
with ischemic stroke is essential for patients, families, and clinicians. In this context, rapidly mea-
surable and reliable blood biomarkers may refine clinical decision-making. Several blood biomarkers
have shown the potential to predict outcome after ischemic stroke. However, to be useful in clinical
routine, blood biomarkers are expected to improve the prognostic accuracy of established clinical
variables such as stroke severity and age.1 At present, the investigated biomarkers have either failed
to further improve prognostication after stroke, or they have not been studied for their additional
prognostic value.1,2 However, a recent single-center study showed that copeptin, a hypothalamic
hormone derived from the precursor of vasopressin, predicted outcome and mortality 3 months and
1 year after ischemic stroke, improving the prognostic accuracy of established predictors.3,4
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Copeptin is a reliable prognostic marker not
only in stroke patients but also in patients with
cardiovascular events.5,6 However, before imple-
menting copeptin in clinical practice, the prog-
nostic potential of copeptin needs to be validated
in a prospective, independent, large, multicenter
study. Moreover, it is unclear whether copeptin
predicts outcome in patients with ischemic
stroke that has been treated differently, i.e., con-
servatively or with thrombolysis. The CoRisk
study aimed to validate in a multicenter, inter-
national setting the accuracy of copeptin in pre-
dicting functional outcome, mortality, and
complications as compared with established clin-
ical variables.
METHODS Ethics statement. This study (ClinicalTrials.
gov: unique identifier NCT00878813, http://www.clinicaltrials.
gov/ct2/show/NCT00878813) was conducted according to the
principles expressed in the Declaration of Helsinki and it was
approved by the Ethics Committees. All patients or their
welfare guardians provided written informed consent for the
collection of data, blood samples, and subsequent analyses.
Study design and cohort description. The primary design of
this multicenter, prospective, cohort study has been described in
detail previously.7 For the analysis of this study, we included 788
patients older than 18 years with an acute ischemic stroke within
24 hours of symptom onset, admitted consecutively to the emer-
gency department of each tertiary care center between March 24,
2009 and April 8, 2011.
We defined acute ischemic stroke according to the World
Health Organization criteria as an acute focal neurologic deficit
lasting longer than 24 hours8 with no sign of acute intracranial
bleeding on cerebral imaging. Exclusion criteria were missing
informed consent or any diagnosis different from ischemic stroke
(i.e., stroke mimics). Stroke physicians prospectively recorded the
NIH Stroke Scale (NIHSS)9 score upon admission. The clinical
stroke syndrome was assessed according to the Oxfordshire Com-
munity Stroke Project classification.10 CT or MRI was performed
upon admission. MRI with diffusion-weighted imaging was per-
formed in 537 stroke patients. Diffusion-weighted imaging lesion
volumes were measured by the consensus of 2 experienced raters
unaware of the clinical and laboratory findings. The lesion size
was calculated by a frequently used semiquantitative method val-
idated for ischemic stroke lesions.11 Lesions were categorized into
3 size classes to represent typical stroke patterns: 1) small lesion
with a volume of ,10 mm3, 2) medium lesion of 10–100 mm3,
and 3) large lesion with a volume of .100 mm3.3
Detailed information such as cardiac and neurovascular ultra-
sound and 24-hour EKGs were collected to define stroke etiology
according to the TOAST (Trial of Org 10172 in Acute Stroke
Treatment) classification.12 Comorbidities were assessed on
admission by the modified Charlson Comorbidity Index.13
Biomarker measurement. For all patients, blood was drawn in
the emergency room and within 24 hours of symptom onset. After
centrifugation for 20 minutes at 3,000g at room temperature,
plasma (from EDTA tube) was aliquoted. Tubes were frozen locally
at each center at270°C. Copeptin levels were assessed in plasma in
a blinded batch analysis by a new chemiluminescence sandwich
immunoassay. The lower detection limit was 0.4 pmol/L and the
functional assay sensitivity was,1 pmol/L (,20% interassay coef-
ficient of variation, defined as the ratio of the SD to the mean). In
359 healthy individuals, median copeptin levels were reported to be
4.2 pmol/L with a 99th percentile of 13.5 pmol/L.14
Ascertainment of outcomes. Trained stroke physicians and
study nurses assessed outcome 3 months after the acute stroke,
either during an outpatient visit (patients who underwent throm-
bolysis) or with a structured follow-up telephone interview. They
were blinded to copeptin levels and baseline clinical variables.
Primary end points. The 2 primary end points were 1) unfa-
vorable functional outcome (including mortality) defined as a
modified Rankin Scale (mRS) score of 3 to 6, and 2) mortality
within 90 days of hospital admission.
Secondary end point. The secondary outcome included any
of the following prespecified7 complications during hospital stay:
symptomatic intracerebral hemorrhage according to the Safe
Implementation of Thrombolysis in Stroke-Monitoring Study
criteria,15 space-occupying cerebral edema, pneumonia (defined
as auscultatory respiratory crackles combined with body temper-
ature $38°C, purulent sputum, or positive chest radiograph),
seizures (clinical diagnosis of focal and/or generalized seizure in
a previously nonepileptic patient), or mortality within 10 days
from stroke onset.
Statistical analysis. Univariate analysis. Statistical analysis was
performed for the primary and secondary end points separately.
Discrete variables were expressed as counts (percentages) and con-
tinuous variables as means 6 SD or medians (interquartile range
[IQR]), depending on their distribution. The distribution of raw
biomarker data was skewed. After log transformation with a base of
10, the distribution of the biomarker data approximated a normal
distribution. Comparisons for categorical baseline measurements
were performed by Fisher exact test and for continuous, not nor-
mally distributed baseline data, by the Mann-Whitney U test. For
survival analysis, we stratified patients according to copeptin ter-
tiles in Kaplan-Meier curves and compared the groups by means of
the log-rank test.
Multivariate regression models. To assess the independent
association of copeptin with functional outcome and time to fatal
outcome within 3 months, we computed a multivariate logistic
and Cox regression model, respectively. We prespecified that
models were adjusted for NIHSS score, age, lesion size, modified
Charlson Index,13 and total anterior circulation stroke10 based on
the results of the previous derivation study.3 In addition, the final
multivariate models included variables significantly associated
with an unfavorable outcome or mortality in the univariate anal-
yses. Because patients with severe stroke tend to present earlier,
time from symptom onset to blood collection was included in the
final model.16 We report odds ratios (ORs) and hazard ratios
(HRs) along with 95% confidence intervals (CIs) as measure of
association and uncertainty, respectively. OR and HR correspond
to a 1-unit increase in the explanatory variable and to any 10-fold
increase in copeptin, glucose, or C-reactive protein (CRP) levels
(log-transformed with a base of 10). Goodness-of-fit of the mul-
tivariate logistic and Cox regression models were assessed with the
Hosmer-Lemeshow test and Groennesby and Borgan test,
respectively.
Interaction analysis. We further included interaction terms
to investigate whether the predictive value of copeptin is modified
by treatment status (conservative vs thrombolysis), sex, age, stroke
severity (NIHSS scores 0–6, 7–15, and .15), time from symp-
tom onset, blood collection (dichotomized at 4.5 hours), arterial
hypertension, diabetes mellitus, and atrial fibrillation. Selection of
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variables that were tested for interaction was based on biological
plausibility on factors that might influence the prognostic value of
copeptin. NIHSS was categorized in order to represent clinically
relevant stroke severity subgroups (mild, moderate, and severe
strokes), and time from symptom onset was dichotomized to
represent the time window for IV thrombolysis.
C-statistics. The discriminatory value of copeptin was assessed
with the area under the receiver operating characteristic (ROC)
curve (AUC). The incremental discriminatory value of copeptin
was tested by comparing the AUC of the NIHSS (nested model),
our prespecified prognostic factor of reference,7 with the AUC of
the NIHSS and copeptin (whole model), as well as comparing the
logistic and Cox regression models without copeptin (nested mod-
els) with the same models with copeptin (whole models). For these
comparisons of nested to whole models, we used the likelihood
ratio test as recommended.17
Reclassification tables. For risk model of comparison, we
used the multivariate models described above. As recommended
in the statistical literature,18 we calculated continuous (category-
free) net reclassification improvement (NRI) values because our
multivariate models of comparisons have no validated risk cate-
gories. To calculate category-based NRI values, we used the
validated prognostic index by König et al.,19 encompassing admis-
sion NIHSS score and age. Four risk categories were chosen:
0%–5%, 5%–10%, 10%–15%, and .15%.
Statistics were calculated using Stata Statistical Software:
Release 12, 2011 (StataCorp LP, College Station, TX). For reclas-
sification tables, we used R version R 2.15.1 along with the Predic-
tABEL package (version 1.2-1) available from CRAN repository
(http://cran.r-project.org/). Testing was 2-sided and p values
,0.05 were considered to indicate statistical significance.
RESULTS Study population. From March 24, 2009
through April 8, 2011, we consecutively recruited
788 patients with ischemic stroke. Stroke treatment
was conservative in 465 patients (59.4%), and 318
patients (40.6%) underwent thrombolysis. Follow-up
was available in 783 patients (follow-up rate: 99.6%).
The detailed patient flow is outlined in figure 1.
The median age of the cohort was 71.0 years (IQR
60.5–80.0), and 38.1% of the patients were women.
The most common cardiovascular risk factor was arte-
rial hypertension, which was present in 68.8% of
patients. At admission, the median NIHSS score
was 6 (IQR 3–13), and the median copeptin concen-
tration was 14.2 pmol/L (IQR 5.9–46.5) (table 1).
Primary end points. Prediction of functional outcome after 3
months.A total of 300 patients (38.3%) had an unfavor-
able outcome after 3 months. Median copeptin con-
centration was more than 3-fold higher in patients
with unfavorable outcomes than in those with favorable
outcomes (table 1, figure e-1 on the Neurology® Web
site at www.neurology.org). In the multivariate logistic
regression model, higher copeptin concentrations
independently predicted an unfavorable outcome
(adjusted OR for any 10-fold copeptin increase 2.17
[95% CI, 1.46–3.22]). For instance, for a patient
with a copeptin level of 30.0 pmol/L, the odds of
unfavorable outcome are on average 2.17 times or
117% higher compared with a patient with a
copeptin level of 3.0 pmol/L, after adjustment for
the covariates included in the logistic regression
model presented in table 2. The multivariate
logistic model was well calibrated as assessed by
the Hosmer and Lemeshow goodness-of-fit test
(p 5 0.62).
The discriminatory accuracy of copeptin, assessed
with the area under the ROC curve, was 0.71 (95%
CI, 0.67–0.75). Copeptin significantly improved the
discriminatory accuracy of the NIHSS and the
Figure 1 Flowchart of patient enrollment and follow-up
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Table 1 Baseline characteristics of all patients, stratified by outcomea
All patients
(N 5 783)
Favorable outcome
(n 5 483)
Unfavorable outcome
(n 5 300) p Value
Demographic data
Age, y, median (IQR) 71.0 (60.5–80.0) 66.2 (58.0–76.0) 77.3 (68.3–83.2) ,0.001b
Women, n (%) 298 (38.1) 162 (33.5) 136 (45.3) 0.001b
Medical history, n (%)
Hypertension 539 (68.8) 312 (64.6) 227 (75.7) 0.001b
Atrial fibrillation 153 (19.5) 77 (15.9) 76 (25.3) 0.002b
Current smoking 138 (17.6) 98 (20.3) 40 (13.3) 0.01b
Diabetes mellitus 125 (16.0) 59 (12.2) 66 (22.0) ,0.001b
Coronary heart disease 149 (19.0) 75 (15.5) 74 (24.7) 0.002b
Dyslipidemia 432 (55.2) 280 (57.8) 152 (50.7) 0.001b
Previous cerebrovascular event 152 (19.4) 86 (17.8) 66 (22.0) 0.16
Kidney impairmentc 174 (22.2) 82 (17.0) 92 (30.7) ,0.001b
Modified Charlson Index (IQR) 0 (0–1) 0 (0–1) 1 (0–2) ,0.001b
Clinical data, median (IQR)
NIHSS score at admission 6 (3–13) 4 (2–7) 13 (7–18) ,0.001b
Body mass index, kg/m2 25.8 (23.2–28.4) 25.9 (23.4–28.7) 25.6 (22.6–27.8) 0.14
OCSP, n (%)
TACS 158 (20.2) 35 (7.1) 123 (41.0) ,0.001b
PACS 291 (37.2) 191 (39.5) 100 (33.3) 0.09
LACS 188 (24.0) 161 (33.3) 27 (9.0) ,0.001b
POCS 146 (18.6) 96 (19.9) 50 (16.7) 0.30
Laboratory values, median (IQR)
Copeptin, pmol/L 14.2 (5.9–46.5) 9.6 (4.7–25.8) 32.2 (11.8–103.5) ,0.001b
Time to blood collection, hd 2.8 (1.7–5.0) 2.7 (1.7–4.6) 3.0 (1.6–5.7) 0.33
Glucose, mmol/L 6.3 (5.5–7.5) 6.0 (5.4–7.2) 6.7 (5.8–8.3) ,0.001b
CRP, mg/L 3.0 (3.0–6.0) 3.0 (3.0–5.0) 3.0 (3.0–9.0) ,0.001b
Creatinine, mmol/L 81.0 (69.0–95.0) 80.0 (69.0–92.0) 82.0 (69.0–100.0) 0.27
eGFR,e mL/min/1.73 m2 75.0 (60.9–91.9) 77.6 (64.7–92.8) 70.5 (55.4–90.1) ,0.001b
Lesion size on MRI, DWI, n (%)f
None detected 39 (7.3) 32 (8.6) 7 (4.2) 0.07
Small, 1–10 mm3 233 (43.4) 197 (53.1) 36 (21.7) ,0.001b
Medium, 10–100 mm3 205 (38.2) 128 (34.5) 77 (46.4) 0.02b
Large, >100 mm3 60 (11.2) 14 (3.8) 46 (27.7) ,0.001b
TOAST subtype, n (%)
Large-vessel disease 110 (14.0) 64 (13.2) 46 (15.3) 0.46
Cardioembolic 308 (39.3) 183 (37.9) 125 (41.7) 0.29
Small-artery disease 45 (5.8) 40 (8.3) 5 (1.7) ,0.001b
Multiple causes 70 (8.9) 52 (10.8) 18 (6.0) 0.03b
Other known 29 (3.7) 17 (3.5) 12 (4.0) 0.85
Undetermined 221 (28.2) 127 (26.3) 94 (31.3) 0.14
Abbreviations: CRP 5 C-reactive protein; DWI 5 diffusion-weighted imaging; eGFR 5 estimated glomerular filtration rate; IQR 5 interquartile range
(meaning range between the first and third quartile); LACS 5 lacunar anterior circulation stroke; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale;
OCSP5 Oxfordshire Community Stroke Project classification; PACS5 partial anterior circulation stroke; POCS 5 posterior circulation stroke; TACS5 total
anterior circulation stroke; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment.12
a See the Statistical Analysis section for a description of this analysis. Because of rounding, percentages may not total 100.
b The differences between the group with a favorable outcome vs the group with an unfavorable outcome are statistically significant.
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multivariate logistic regression model both for an unfa-
vorable functional outcome, defined as mRS score 3 to
6 (table 3, figures e-2 to e-4), and disability, defined as
mRS score 3 to 5 (table e-1).
Copeptin improved classification of patients when
added to the validated prognostic index of König
et al.19 with a categorical NRI of 11.8% (table e-2).
Among patients with a favorable outcome, a total of
11.8% were correctly moved to lower risk categories,
whereas in patients with an unfavorable outcome,
zero were reclassified. Moreover, adding copeptin to
the full model improved reclassification as evidenced
by the continuous NRI of 46.8%.
Prediction of mortality within 3 months after stroke. A
total of 118 patients (15.1%) died within 3 months
after stroke. The median copeptin concentration was
more than 5-fold higher in patients who died within
3 months compared with survivors (58.8 pmol/L
[IQR 23.0–141.0] vs 11.7 pmol/L [IQR 5.6–
35.1], p , 0.001) (table e-3, figure e-1). Overall,
Kaplan-Meier survival curves of patients stratified
per copeptin tertiles differed (p , 0.001, log-rank
test) (figure 2). In the multivariate Cox model, high-
er copeptin concentrations independently predicted
mortality (adjusted HR for any 10-fold copeptin
increase 2.40 [95% CI, 1.60–3.60], p , 0.001)
(table 2). The multivariate Cox model was well cali-
brated as assessed by the Groennesby and Borgan test
(p 5 0.35). The overall discriminative ability of copep-
tin to distinguish survivors from nonsurvivors—assessed
with the area under the ROC curve—was 0.75 (95%
CI, 0.71–0.80) (figures e-5 to e-7). Copeptin signifi-
cantly improved the discriminatory accuracy of the
NIHSS and the multivariate Cox regression model
(table 3). These results were also confirmed in reclassi-
fication statistics where the categorical NRI of
copeptin on the validated prognostic index of König
et al. was 37.2% (table e-4). Among survivors,
33.0% were correctly moved to lower risk categories,
whereas in nonsurvivors 4.2% were correctly moved
to higher risk categories. Moreover, adding copeptin
to the multivariate model resulted in a continuous
NRI of 64.5%.
Interaction analysis. The predictive value of copeptin
regarding functional outcome and mortality was con-
sistent across all subgroups. We did not identify any
significant effect modifiers.
Secondary end point: Prediction of complications. A total of
185 patients (23.6%) had at least 1 of the 5 predefined
complications during hospitalization. Median copeptin
levels were more than 3-fold higher in patients develop-
ing any of the prespecified complications during hospital-
ization (39.9 pmol/L [IQR 16.4–114.0] vs 11.0 pmol/L
[IQR 5.3–32.5], p , 0.001) (table e-5). In the multi-
variate logistic model, copeptin independently predicted
the occurrence of at least 1 complication (adjusted OR
for any 10-fold copeptin increase 1.93 [95% CI, 1.33–
2.80], p5 0.001). Other significant predictors were the
NIHSS score and age. Copeptin improved the prognos-
tic accuracy of the NIHSS (AUC change from 0.79
[95% CI, 0.76–0.83] to 0.80 [95% CI, 0.77–0.84],
p 5 0.001). We found no significant interaction
between copeptin and each of the potentially effect-
modifying variables used for the primary outcomes.
Prediction of individual complications was associated
with different OR for any 10-fold copeptin increase: for
symptomatic intracerebral hemorrhage, OR 1.07 (95%
CI, 0.45–2.53, p5 0.89); for space-occupying cerebral
edema, OR 2.85 (95% CI, 1.39–5.87, p5 0.004); for
pneumonia, OR 1.79 (95% CI, 1.16–2.76, p 5
0.009); for seizures, OR 1.20 (95% CI, 0.62–2.33,
p 5 0.59); and for mortality within 10 days from
admission, OR 3.00 (95% CI, 1.67–5.39, p, 0.001).
DISCUSSION In this prospective, multicenter study,
higher copeptin blood levels independently predicted
functional outcome and mortality 3 months after ische-
mic stroke. Copeptin improved the discriminatory abil-
ity of the NIHSS and multivariate models as shown by
an increase in the respective AUCs. Despite the modest
size of the AUC increases, copeptin improved risk clas-
sification by 11.8% for functional outcome and by
37.2% for mortality compared with the validated prog-
nostic index by König et al.,19 encompassing NIHSS
score and age. Moreover, copeptin improved reclassifi-
cation compared with the multivariate models including
demographic factors, cardiovascular risk factors, lesion
size in MRI, comorbidities, and admission laboratory
variables such as CRP and glucose. The CoRisk study
confirms and extends the conclusions of the previously
published derivation study.3 Further new findings are
that 1) copeptin independently predicts complications,
and 2) the prognostic ability of copeptin was consistent
across subgroups including different acute treatments
(conservative vs thrombolysis).
c Kidney impairment was defined as eGFR ,60 mL/min/1.73 m2.40
d Time to blood collection was calculated in hours from symptom onset (if known).
e eGFR was estimated according to the Modification of Diet in Renal Disease Study.40
f Percentages refer to patients for whom information on DWI lesion was present (n5 537). Of the 537 patients undergoing an MRI on admission, 371 had a
favorable outcome (69.1%) and 166 had an unfavorable outcome (30.9%) within 3 months after stroke. The definition of stroke required an acute focal
neurologic deficit lasting longer than 24 hours, suggestive of acute stroke, and with no sign of acute intracranial bleeding on cerebral imaging (CT or MRI). A
visible ischemic lesion on MRI was not required for the diagnosis of ischemic stroke.
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Although several markers, such as N-terminal brain
natriuretic peptide,5,20,21 CRP,21–24 D-dimers,20,25,26
interleukin-6,21,24,27 von Willebrand factor,28,29
S-100b,30 and neuron-specific enolase,31 have been
associated with functional outcome or mortality, only
a few biomarkers added to prognosis based on clinical
assessment. None of these markers, however, were fully
evaluated including assessment of accuracy (i.e., cali-
bration by goodness-of-fit test), discriminatory ability
(i.e., C-statistics), reclassification improvement, and
performance in an external validation study according
to the recommendations of the American Heart Asso-
ciation for studies evaluating biomarkers in cardiovas-
cular research.32
Several prognostic models have been evaluated in the
past years. Some of these models include information
from MRI33 or CT34; others are based mostly on clinical
information such as comorbidities or stroke severity.35–37
As reference for reclassification, we chose the prognostic
index of König et al.19 because of its validation for both
functional outcome and mortality at 3 months along
with its robust prognostic power arising from 2 easily
accessible variables such as age and NIHSS score. To
be used in clinical routine, prognosis should be almost
immediate and based on only a few variables, thus
copeptin, which adds to the simple and highly accurate
prognostic index by König et al.,19 may be promising.
Measurement of copeptin in the emergency setting
(incubation time 30 minutes6) may help physicians to
more accurately inform patients and caregivers on the
overall prognosis. Copeptin might help in early decision-
making on aggressiveness of care, potential new interven-
tions, discharge planning, and rehabilitation. In the
setting of trials of new stroke therapies, it might also
be valuable to predict those with stroke recovery. For
optimal risk stratification, it is crucial that prognostic
information be available within the first hours from
symptom onset, and copeptin meets this demand. The
pathophysiologic mechanism relating copeptin with
stroke outcome and mortality is only partially under-
stood. Copeptin derives from a larger precursor peptide
along with arginine vasopressin (AVP) and is released in
an equimolar ratio to AVP. The advantage of copeptin is
that it is more stable in blood circulation and easier to
Table 2 Multivariate logistic regression analysis for functional outcome and Cox regression model for mortalitya
Functional outcome Mortality
Predictors OR 95% CI p HR 95% CI p
Age (per y) 1.07 1.04–1.09 <0.001 1.04 1.02–1.06 <0.001
Hypertension 1.00 0.60–1.68 0.99 0.90 0.53–1.51 0.68
Diabetes mellitus 1.69 0.88–3.26 0.12 1.78 1.03–3.11 <0.001
Atrial fibrillation 0.69 0.39–1.22 0.20 1.14 0.66–1.96 0.64
Modified Charlson Index (per point) 1.06 0.89–1.27 0.50 1.11 1.01–1.23 0.04
Kidney impairmentb 1.17 0.69–1.99 0.55 1.36 0.86–2.16 0.19
NIHSS score at admission (per point) 1.14 1.09–1.21 <0.001 1.05 1.02–1.08 <0.001
TACS 1.98 0.97–4.04 0.06 2.02 1.17–3.49 0.01
Log10 (copeptin [pmol/L]) 2.17 1.46–3.22 <0.001 2.40 1.60–3.60 <0.001
Log10 (glucose [mmol/L]) 0.55 0.07–4.50 0.58 0.68 0.10–4.66 0.69
Log10 (CRP [mg/L]) 1.77 0.99–3.17 0.05 1.89 1.20–2.96 0.01
Large DWI lesion (>100 mm3) 4.16 1.62–10.65 0.003 1.25 0.69–2.27 0.47
Time from symptom onset to blood
collection (per h)
1.06 1.01–1.11 0.01 1.01 0.97–1.06 0.64
Women 1.06 0.66–1.71 0.80 NA NA NA
Medium DWI lesion (10–100 mm3) 1.31 0.80–2.14 0.28 NA NA NA
Unclear cause of stroke NA NA NA 2.23 1.39–3.58 0.001
Abbreviations: CI 5 confidence interval; CRP 5 C-reactive protein; DWI 5 diffusion-weighted imaging; eGFR 5 estimated glomerular filtration rate; HR 5
hazard ratio; NA 5 not applicable (meaning that the variable was not significantly associated with an unfavorable outcome or mortality in the respective
univariate analysis); NIHSS 5 NIH Stroke Scale; OR 5 odds ratio; TACS 5 total anterior circulation stroke. Data in boldface type indicate statistically
significant predictors.
a See the Statistical Analysis section for a description of this analysis. OR and HR refer to a 1-unit increase in the explanatory variable and to any 10-fold
increase in copeptin, glucose, and CRP (log-transformed with a base of 10). For example, the odds of an unfavorable outcome are on average 2.17 times or
117% higher in a patient with a copeptin level of 30.0 pmol/L compared with a patient with a copeptin level of 3.0 pmol/L, after adjustment for the
covariates included in the presented logistic regression model.
bKidney impairment was defined as eGFR ,60 mL/min/1.73 m2.40 Coronary heart disease and eGFR/creatinine were not included in the multivariate model
because of collinearity with atrial fibrillation and kidney impairment, respectively.
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measure compared with AVP.14 The secretion of AVP
can be stimulated through brainstem and limbic path-
ways triggered by different “stressors”; it seems to act as
an endogenous barometer of integral homeostasis. Thus,
copeptin assesses the severity of damage beyond lesion
size, the effect of age, sex, and measurable clinical impair-
ment on admission. In addition AVP/copeptin might be
associated with adrenocorticotropic hormone–induced
hypercortisolism, which is thought to potentiate ische-
mic neuronal injury, especially in the long run.38 Data
from experimental studies imply that AVP has a role in
brain edema formation because blocking of AVP recep-
tors attenuates brain edema in ischemic mice models.39
Some limitations of the study merit attention. To
assess complications, a time-to-event analysis would have
been ideal. However, we were not able to document the
exact time of onset of some complications, e.g., aspiration
pneumonia, and we did not take into account the dura-
tion of hospitalization.Moreover, this study was powered
only for the combined end point of complications after
stroke, but not to assess each complication separately:
our subgroup analyses should be interpreted with caution,
and further studies are needed to elucidate the specific
association with each of the assessed complications.
In patients with ischemic stroke, copeptin is a vali-
dated blood marker that adds predictive information on
functional outcome and mortality at 3 months beyond
important clinical variables such as stroke severity and
age. Copeptin seems to be a promising blood marker
for prediction of in-hospital complications.
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ABSTRACT
Background: TIA is a strong predictor of subsequent stroke. The hypothalamic stress hormone
copeptin is an accurate prognostic marker in acute ischemic stroke. This study assessed prognos-
tic reliability of 2 distinct stress hormones, copeptin and cortisol, for the risk stratification of
re-events in patients with TIA.
Methods:We conducted a prospective study in patients admitted to the emergency department with
a TIA. Clinical risk scoring using the ABCD2 score was determined and both hormones were mea-
sured in plasma on admission. The primary endpoint was a cerebrovascular re-event within 90 days.
Results: We included 107 consecutive patients with TIA. Re-events occurred in 10 patients (9%).
Copeptin levels were higher in patients with a re-event compared with patients without re-event (p
0.02), in contrast to cortisol (p0.53). Copeptin revealed a higher area under the receiver operating
characteristics curve (AUC) to predict re-events compared to the ABCD2 score (AUC of 0.73 vs
0.43; p0.01) and improved its prognostic accuracy (AUC of combinedmodel of 0.77; p0.002).
Conclusion:Measurement of plasma copeptin but not cortisol levels in patients with TIA provides
additional prognostic information beyond the ABCD2 clinical risk score alone. If confirmed in
future studies, routine copeptin measurement may be an additional tool for risk stratification and
targeted resource allocation after TIA. Neurology® 2011;76:563–566
GLOSSARY
AUC area under the receiver operating characteristics curve; CI confidence interval; DWI diffusion-weighted imaging;
HPA axis hypothalamic-pituitary-adrenal axis; IQR interquartile range; ROC receiver operating characteristic.
The risk of a stroke after a TIA in the first 90 days ranges from 9.5% to 20%.1 The ability to
accurately identify high- and low-risk patients with TIA has important clinical implications.
The discriminatory ability of the 7-point ABCD2 score in patients with TIA to assess short-
term risk of stroke is limited.2 Therefore, it is important to find additional reliable and rapidly
measureable predictors for recurrent vascular events in patients with TIA.
Cerebral ischemia activates the hypothalamic-pituitary-adrenal axis (HPA axis).3 Vasopres-
sin is a main secretagogue of the HPA axis. Copeptin is produced in equimolar amounts to
vasopressin and can be easily determined.4
The present study evaluated copeptin and cortisol as new prognostic tools for the risk
stratification of re-events in a cohort of patients with TIA.
METHODS Standard protocol approvals, registrations, and patient consents. The design of this prospective cohort
study has been described in detail (clinicaltrials.gov NCT00390962)5 and was approved by the local ethical committee. Written
informed consent was obtained from all patients.
Study design and setting. Briefly, between November 2006 and November 2007, all patients (n  605) presenting at the
emergency department of the University Hospital Basel, Switzerland, with a suspected cerebrovascular event were screened.
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The primary endpoint of this analysis was a subsequent cere-
brovascular event (i.e., ischemic or hemorrhagic stroke, or TIA)
in the first 90 days following index TIA, assessed by a structured
follow-up telephone interview with the patient. Stroke was de-
fined as an acute deficit of focal neurologic function with symp-
toms lasting more than 24 hours, resulting from intracranial
vascular disturbance (ischemia or hemorrhage) occurring within
90 days after the index event. TIA was defined as an acute loss
of focal cerebral or ocular function with symptoms lasting less
than 24 hours of presumed ischemic origin following ade-
quate investigations.6
A total of 107 patients were diagnosed with a TIA on admis-
sion. All patients with acute neurologic dysfunction, in whom
diagnostic workup suggested a nonvascular disorder, were classi-
fied as TIA mimics.6 Risk stratification according to the ABCD2
score7 was performed. All patients underwent a standardized di-
agnostic workup including specification of stroke etiology ac-
cording to the TOAST classification8 and routine laboratory
testing. All plasma blood samples were obtained on admission
within 72 hours of symptom onset. Copeptin was measured with
a new chemiluminescence sandwich immunoassay.4 Median
copeptin levels in healthy individuals are 3.7 pmol/L and the
97.5 percentile is 16.4 pmol/L.4 Cortisol was measured with a
competitive chemiluminescence immunoassay (IMMULITE
2000; Siemens Medical Solution Diagnostics, Los Angeles, CA).
Cranial CT was performed on admission and thereafter MRI
within 24 hours after admission on a 1.5-T MR Avanto system
(Siemens, Erlangen, Germany). Diffusion-weighted imaging
Table Baseline characteristics
Characteristics Overall No re-events Re-events p Value
Demographic characteristics
TIA, n (%) 107 (100) 97 (91) 10 (9)
Death, n (%) 2 (2) 1 (1) 1 (1)
Age, y, median (IQR) 71 (60–79) 70 (59–79) 73 (69–78) 0.26
Female, n (%) 60 (100) 45 (49) 2 (20) 0.13
TIA severity, ABCD2,
median (IQR)
4 (3–5) 4 (3–5) 4(3–4) 0.50
Clinical findings, median (IQR)
Heart rate, bpm 74 (66–84) 75 (66–85) 67 (65–69) 0.14
Arterial pressure, mm Hg
Systolic 163 (141–182) 165 (143–184) 155 (137–176) 0.62
Diastolic 88 (81–98) 90 (82–98) 82 (73–86) 0.11
Body temperature (°C) 37.0 (36.6–37.5) 37.1 (36.8–37.5) 36.3 (36.0–36.9) 0.02
Laboratory findings,
median (IQR)
Copeptin, pmol/L 4.61 (2.83–10.14) 4.55 (2.80–7.8) 11.25 (9.11–24.78) 0.0016
Cortisol, nmol/L 408 (317–538) 408 (317–557) 382 (349–427) 0.53
C-reactive protein, mmol/L 3 (3–5.8) 3 (3–6) 3 (3–4) 0.33
Glucose level, mmol/L 5.9 (5.2–7.1) 5.9 (5.3–7.3) 6.1 (4.8–6.8) 0.58
TIA etiology, n (%)
Small vessel occlusive 8 (7) 7 (7) 1 (10) 0.95
Large vessel occlusive 10 (9) 6 (6) 4 (40) 0.053
Cardioembolic 10 (9) 9 (9) 1 (10) 0.92
Unknown 79 (74) 75 (78) 4 (40) 0.59
Comorbidity, median (IQR)
Charlson Index 0 (0–2) 0 (0–2) 1 (0–3) 0.38
Vascular risk factors, n (%)
Hypertension 74 (69) 68 (70) 6 (60) 0.85
Atrial fibrillation 11 (10) 9 (9) 2 (20) 0.64
Smoking history 36 (34) 32 (33) 4 (40) 0.96
Hypercholesterolemia 35 (33) 29 (30) 6 (60) 0.63
Diabetes mellitus 16 (15) 15 (15) 1 (10) 0.76
Coronary hearth disease 19 (18) 14 (14) 5 (50) 0.25
Prior TIA or stroke 34 (32) 32 (33) 2 (20) 0.77
Family history of stroke
or myocardial infarction, n (%)
39 (36) 37 (38) 2 (20) 0.60
Abbreviation: IQR interquartile range.
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(DWI) was available in 88 patients (82%). In 19 patients (17%)
only cranial CT was performed (one patient had no neuroimag-
ing against medical advice). DWI results were classified as nega-
tive or positive based on the presence or absence of an acute
DWI lesion after neuroradiologic review.
Statistical analysis. Discrete variables are expressed as fre-
quency (percentage) and continuous variables as medians and
interquartile ranges (IQR). Two group comparisons were made
using the Mann-Whitney U test. Receiver operating characteris-
tics (ROC) were calculated. The area under the ROC curve
(AUC) is a summary measure over criteria and cutpoint choices.
To test whether the copeptin level improves ABCD2 score per-
formance, we compared the nested logistic regression model
with ABCD2 score and copeptin with a model limited to the
ABCD2 score alone. Finally, time to re-event was analyzed in
Kaplan-Meier survival curves and patients were stratified based
on a priori defined median copeptin levels. Analyses were per-
formed with STATA 9.2 (StataCorp., College Station, TX).
RESULTS Baseline characteristics. Cerebrovascular
re-events after a TIA within 90 days were observed in
10 (9%) patients; 8 (8%) out of the 10 patients pre-
sented with a new TIA, and 2 (2%) had an ischemic
stroke; of these 2 patients, 1 died. Of the 97 patients
without a re-event, 1 (1%) patient died.
The median ABCD2 score on admission was 4
(IQR 3–5). A 50% stenosis in a large vessel refer-
able to the patients’ symptoms was found in 10 pa-
tients (9%), and a cardioembolic source warranting
anticoagulation was detected in 10 patients (9%).
Small vessel disease was found in 8 patients (7%).
Detailed baseline characteristics are presented in the
table.
Copeptin, cortisol, and the ABCD2 score to predict
re-events. Patients with a cerebrovascular re-event
had higher median copeptin levels than patients
without a re-event (11.25 [IQR 9.11–24.78] pmol/L
vs 4.55 [IQR 2.8–7.8] pmol/L, p  0.016). The
median ABCD2 score was comparable in patients
with and without a re-event (4 [IQR 3–4] vs 4 [IQR
3–5], p  0.56).
The AUC for copeptin to predict a re-event was
0.73 (95% confidence interval [CI] 0.545–0.922).
At a copeptin cutoff of 9.0 pmol/L, sensitivity was
80% with a specificity of 76% to diagnose re-event.
Similarly, at a cutoff of 18 pmol/L, the respective
sensitivity and specificity was 40% and 88%. Com-
bining copeptin and the ABCD2 score in a com-
bined logistic regression model showed an AUC of
0.77 (95% CI 0.596–0.949). This combination of
the clinical score and the biomarker showed a higher
overall prognostic accuracy compared with the
ABCD2 score alone (0.43 [95% CI 0.291–0.570],
p  0.002).
Median basal cortisol levels in patients developing
a cerebrovascular re-event compared to those with-
out a re-event were similar (382.0 [IQR 331.0–
437.5] nmol/L vs 408 [IQR 317–557] nmol/L, p 
0.53). The AUC for cortisol to predict a re-event was
0.57 (95% CI 0.438–0.697).
Copeptin and time to re-event. Patients with copeptin
levels below the median value of 4.60 pmol/L had a
minimal risk of cerebrovascular re-events, in contrast
to patients with copeptin levels above the median
value of 4.60 pmol/L, who were at higher risk to
develop a new cerebrovascular event (log rank p 
0.02) (figure).
Copeptin and DWI. In the MRI subgroup of patients
(n  88) in whom the DWI showed ischemic cere-
bral lesions (n 7) (6%), copeptin levels were higher
compared to the patients without DWI lesions
(12.65 [3.75–43.55] pmol/L vs 4.50 [2.70–7.57]
pmol/L, p  0.045).
DISCUSSION As principal finding of this study, we
found that copeptin, but not cortisol levels, may pro-
vide additional prognostic information beyond the
ABCD2 score in patients with a TIA to predict cere-
brovascular re-events within 90 days.
Serum cortisol levels have been reported to rise
proportionately with the degree of stress and to pre-
dict outcome in several diseases.9 However, in our
study cortisol levels showed no additional informa-
tion for the risk stratification after a TIA. The lack of
prognostic accuracy after TIA might be due to the
fact that cortisol, but not copeptin, underlies a circa-
dian rhythm and changes with food intake.10
Recently, we demonstrated that copeptin levels
were significantly lower in healthy controls without
apparent stress, compared to hospitalized patients
with moderate or high stress, thereby reflecting sub-
tle differences in individual stress level even better
than cortisol.9 This suggests that moderate stress sit-
Figure Time to re-event based on the median of copeptin
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uations contribute to a notable copeptin release. We
hypothesize that the activation of the stress axis in
patients with a more severe “ischemic threat” (re-
flected by the patients who showed a DWI and/or
the patients with longer lasting and more severe
symptoms) might be more pronounced. These pa-
tient groups are known to have a higher risk for cere-
brovascular re-events11 and mortality. However,
although copeptin in stroke patients was associated
with lesion size,5 it was still an independent predictor
for functional outcome and mortality within 90
days. This suggests that copeptin not only reflects the
visible DWI lesion but provides additional prognos-
tic information by yet unknown mechanisms.
Despite the strength of our prospective enroll-
ment and the detailed patient characterization, our
study has limitations. First, the ability to accurately
identify high- and low-risk patients with TIA with
the ABCD2 score was very limited. It is, however,
known that the discriminatory ability of the ABCD2
score especially to identify low-risk patients and to
stratify patients with TIA is not optimal.2 Second,
our sample size is too small to draw definitive conclu-
sions. A larger cohort of patients with TIA will be
necessary to validate our results. Nevertheless, the re-
sults of this study should encourage and propagate
further investigation in this direction.
AUTHOR CONTRIBUTIONS
Statistical analysis was conducted by Dr. P. Schuetz.
DISCLOSURE
Dr. Katan has received speaker honoraria from B • R • A • H • M • S
GmbH.Ms. Nigro reports no disclosures. Dr. Fluri reports no disclosures.
Dr. Schuetz has received funding for travel and speaker honoraria from
B • R • A • H • M • S GmbH and BioMerieux. Dr. Morgenthaler is VP
Global Medical Affairs for B • R • A • H • M • S GmbH (part of
Thermo-Fisher Scientific). Dr. Jax reports no disclosures. Dr. Meckel
serves on a scientific advisory board for Chestnut Medical Technologies,
Inc. and has received fellowship support from the Swiss Radiological So-
ciety. Dr. Gass serves on the editorial board of Cerebrovascular Diseases.
Dr. Bingisser reports no disclosures. Dr. Steck has served on a scientific
advisory board for Pfizer Inc; has received funding for travel and speaker
honoraria from Talecris Biotherapeutics; and serves on the editorial
boards of Swiss Archives of Neurology and Psychiatry, Muscle and Nerve,
Journal of Neurology, Journal of the Peripheral Nervous System, European
Neurology, and Aktuelle Neurologie. Dr. Kappos serves on the editorial
board of the International MS Journal; receives research support from the
Swiss National Research Foundation, the Swiss MS Society, and the Gi-
anni Rubatto Foundation (Zurich); has served on scientific advisory
boards and his Department at the University Hospital Basel has received
research support from Acorda Therapeutics Inc., Actelion Pharmaceuti-
cals Ltd, Abbott, AstraZeneca, Bayhill Therapeutics, Bayer Schering
Pharma, Biogen Idec, Boehringer Ingelheim, Centocor Ortho Biotech
Inc., Eisai Inc., Genzyme Corporation, GlaxoSmithKline, The Immune
Response Corporation, MediciNova, Inc., Neurocrine Biosciences, No-
vartis, sanofi-aventis, Merck Serono, Roche, Teva Pharmaceutical Indus-
tries Ltd., UCB, and Wyeth. Dr. Engelter and Dr. Mueller report no
disclosures. Dr. Christ-Crain has received speaker honoraria from B • R •
A • H • M • S GmbH.
Received March 31, 2010. Accepted in final form October 4, 2010.
REFERENCES
1. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson
LW, Schopflocher DP. The high risk of stroke immedi-
ately after transient ischemic attack: a population-based
study. Neurology 2004;62:2015–2020.
2. Cucchiara BL, Messe SR, Taylor RA, et al. Is the ABCD
score useful for risk stratification of patients with acute
transient ischemic attack? Stroke 2006;37:1710–1714.
3. Fassbender K, Schmidt R, Mossner R, Daffertshofer M,
Hennerici M. Pattern of activation of the hypothalamic-
pituitary-adrenal axis in acute stroke: relation to acute con-
fusional state, extent of brain damage, and clinical
outcome. Stroke 1994;25:1105–1108.
4. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a
stable peptide derived from the vasopressin precursor, is
elevated in serum of sepsis patients. Peptides 2005;26:
2500–2504.
5. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a
novel, independent prognostic marker in patients with
ischemic stroke. Ann Neurol 2009;66:799–808.
6. Dennis MS, Bamford JM, Sandercock PA, Warlow CP.
A comparison of risk factors and prognosis for transient
ischemic attacks and minor ischemic strokes: The Ox-
fordshire Community Stroke Project. Stroke 1989;20:
1494–1499.
7. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al.
Validation and refinement of scores to predict very early
stroke risk after transient ischaemic attack. Lancet 2007;
369:283–292.
8. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classifica-
tion of subtype of acute ischemic stroke: definitions for use
in a multicenter clinical trial TOAST Trial of Org 10172
in Acute Stroke Treatment. Stroke 1993;24:35–41.
9. Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a
stable peptide derived from the vasopressin precursor, cor-
relates with the individual stress level. Neuro Endocrinol
Lett 2008;29:341–346.
10. Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Bra-
bant G. Circadian secretion pattern of copeptin, the
C-terminal vasopressin precursor fragment. Clin Chem
Epub 2010 Apr 22.
11. Lavallee PC, Meseguer E, Abboud H, et al. A transient
ischaemic attack clinic with round-the-clock access (SOS-
TIA): feasibility and effects. Lancet Neurol 2007;6:953–
960.
566 Neurology 76 February 8, 2011
DOI 10.1212/WNL.0b013e31820b75e6
; Published online before print January 12, 2011; 2011;76;563Neurology
M. Katan, N. Nigro, F. Fluri, et al.
Stress hormones predict cerebrovascular re-events after transient ischemic attacks
 
March 28, 2013This information is current as of 
 
 Services
Updated Information &
 http://www.neurology.org/content/76/6/563.full.html
including high resolution figures, can be found at:
 Supplementary Material
 3e31820b75e6.DC2.html
http://www.neurology.org/content/suppl/2011/08/17/WNL.0b01
 3e31820b75e6.DC1.html
http://www.neurology.org/content/suppl/2011/02/06/WNL.0b01
Supplementary material can be found at: 
References
 http://www.neurology.org/content/76/6/563.full.html#ref-list-1
This article cites 10 articles, 5 of which can be accessed free at:
Subspecialty Collections
 http://www.neurology.org/cgi/collection/outcome_research
Outcome research
 ional_study_cohort_case_control
http://www.neurology.org/cgi/collection/clinical_trials_observat
Clinical trials Observational study (Cohort, Case control)
 sease_stroke
http://www.neurology.org/cgi/collection/all_cerebrovascular_di
All Cerebrovascular disease/Stroke
following collection(s):
This article, along with others on similar topics, appears in the
Permissions & Licensing
 http://www.neurology.org/misc/about.xhtml#permissions
tables) or in its entirety can be found online at: 
Information about reproducing this article in parts (figures,
 Reprints
 http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
Biomarkers in Stroke
Midregional Pro-Atrial Natriuretic Peptide and
Outcome in Patients With Acute Ischemic Stroke
Mira Katan, MD,*† Felix Fluri, MD,† Philipp Schuetz, MD,* Nils G. Morgenthaler, MD, PHD,‡
Christian Zweifel, MD,§ Roland Bingisser, MD, Ludwig Kappos, MD,† Andreas Steck, MD,†
Stefan T. Engelter, MD,† Beat Müller, MD,*¶ Mirjam Christ-Crain, MD*
Basel and Aarau, Switzerland; and Hennigsdorf/Berlin, Germany
Objectives The purpose of this study was to examine the prognostic value of midregional pro-atrial natriuretic peptide (MR-
proANP) in patients with acute ischemic stroke.
Background The rapid and reliable estimation of prognosis in acute ischemic stroke is pivotal to optimize clinical care. MR-
proANP, a recently described, stable fragment of the ANP precursor hormone, may be useful in this setting.
Methods In a prospective observational study, we measured MR-proANP on admission in plasma of 362 consecutive pa-
tients presenting with acute ischemic stroke. The prognostic value of MR-proANP to predict mortality within 90
days and functional outcome (defined as a modified Rankin Scale of 2 or 3) was evaluated and compared
with the National Institutes of Health Stroke Scale (NIHSS) score.
Results The discriminatory accuracy, calculated with the area under the curve (AUC) of the receiver operating character-
istics curve, of MR-proANP to predict death was comparable to the NIHSS (AUC: 0.86 [95% confidence interval
(CI): 0.82 to 0.90] and 0.85 [95% CI: 0.81 to 0.89; p  0.7]). Combined, the accuracy significantly improved
(0.92 [95% CI: 0.88 to 0.96; p  0.01]). The AUC of MR-proANP to predict functional outcome was 0.70 (95%
CI: 0.65 to 0.75), similar to the NIHSS (0.75 [95% CI: 0.70 to 0.80]; p  0.16). The prognostic value of MR-
proANP for both outcomes was independent of the NIHSS. Higher MR-proANP concentrations were found in
stroke of cardioembolic etiology.
Conclusions MR-proANP is a prognostic marker in the acute phase of stroke, improving the discriminatory value of the
NIHSS, independently predicting post-stroke mortality and functional outcome. (The “COSMOS”-Study [Copeptin
in Osmoregulation and Stress Assessment]; NCT00390962) (J Am Coll Cardiol 2010;56:1045–53) © 2010 by
the American College of Cardiology Foundation
Stroke is the third leading cause of death and the primary
cause of long-term disability worldwide (1). The direct and
indirect cost of stroke amounted to $65.5 billion in 2008
(2). Each year, over 5 million people die as a consequence of
stroke, and at least 1 in 6 patients who survives a stroke will
suffer another stroke within 5 years (3). An early risk
assessment with estimate of the severity of disease and
prognosis could facilitate optimized care and allocation of
health care resources (4). Thus, there is the need to develop a
credible evidence base of prognostic information for out-
See page 1054
comes that are meaningful to patients, including mortality
and level of independency. In this context, prognostic
markers available during the initial phase after acute stroke
would aid in the timely estimation of disease severity,
functional outcome, and mortality.
A-type natriuretic peptide (ANP) is a family member of
the natriuretic peptides. Its physiological role is mainly the
regulation of blood pressure ascribed to its natriuretic,
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diuretic, and vasodilating action.
ANP emerged as reliable prog-
nostic marker for congestive
heart failure and risk of cardio-
vascular events and death (5,6).
In the acute phase of ischemic
stroke, levels of ANP have been
reported to be elevated (7) and to
predict mortality (8). Immuno-
histochemical studies suggest
that cerebral ischemia directly in-
duces ANP secretion in brain
tissue (9,10). Interestingly, indi-
viduals with a homozygous geno-
type for the ANP stop codon
mutation have an increased risk
of ischemic stroke (11). Thus,
ANP is likely to play a role in the
hemodynamic regulation during
the acute phase of ischemic
stroke.
Midregional pro-ANP (MR-
proANP) derives from the pre-
cursor hormone of ANP. MR-
proANP is released in an equimolar
ratio to ANP. The present assay
for MR-proANP was designed
to detect the midregion of the
prohormone, which is more sta-
ble than the N- or C-terminal
part of the precursor (12). Other
proANP assays may underesti-
mate the release of the precursor
due to an early degradation of crucial epitopes at the
extreme ends of the molecule. The midregional fragment of
proANP is also more stable in blood ex vivo, which renders
it generally more applicable in clinical practice (13). Frag-
ments of natriuretic prohormones (i.e., MR-proANP and
pro-brain natriuretic peptide [proBNP], respectively) pre-
dict poor outcomes in patients after acute myocardial
infarction and in patients with heart failure (14–18). We
hypothesize that MR-proANP, measured in the acute phase
after an ischemic stroke, is a good prognostic marker for
functional outcome and mortality within 90 days.
Methods
Study design and setting. We conducted a prospective
cohort study at the University Hospital Basel, Basel, Swit-
zerland. From November 2006 to November 2007, consec-
utive patients presenting with an acute ischemic cerebrovas-
cular event were included. The primary end point of this
study was to evaluate prognostic biomarkers, particularly the
arginine vasopressin (AVP) precursor (copeptin) and the
precursor hormone of ANP (MR-proANP) to predict
outcome in ischemic stroke. A complete description of
copeptin and stroke outcome has been reported previously
(19). In brief, after approval from the Ethics Committee of
the University Hospital Basel was received, written in-
formed consent was obtained from study participants or, if
not feasible, from next of kin. A total of 605 consecutive
patients with a suspicion of stroke within 72 h before
admission at the emergency department were examined.
For the purpose of this study, we evaluated all patients
with the final diagnosis of ischemic stroke (n  362),
confirmed by computed tomography and/or magnetic res-
onance imaging on admission. The other 243 patients had
either transient ischemic attack, intracerebral hemorrhage,
or other final diagnoses and were excluded from the final
analysis. Neurological deficits were assessed using the Na-
tional Institutes of Health Stroke Scale (NIHSS) prospec-
tively on admission in all patients. Blood samples were
collected within 0 to 3 h (n  78), 3 to 12 h (n  189), 12
to 24 h (n  55), and 24 to 72 h (n  40) from symptom
onset. The clinical stroke syndrome was determined by
applying the criteria of the Oxfordshire Community Stroke
Project; that is, total anterior circulation syndrome (TACS),
partial anterior circulation syndrome (PACS), lacunar syn-
drome (LACS), and posterior circulation syndrome
(POCS) (20). Stroke etiology was determined according to
the criteria of the TOAST (Trial of Org 10172 in Acute
Stroke Treatment) classification (21), which distinguishes
large artery arteriosclerosis, cardioembolism, small artery
occlusion, other etiology, and undetermined etiology. At
discharge from the hospital, each patient received an etio-
logic diagnosis of stroke.
Follow-up and end points. All patients underwent a
structured telephone interview after 90 days in order to
identify occurrence and timing of mortality of any cause and
functional outcome. Ninety-day outcome was measured by
the modified Rankin Scale (mRS), and a favorable outcome
was defined as a mRS score of 0 to 2.
Assays. Blood was obtained from a venous catheter. Re-
sults of the routine blood analyses were recorded. Plasma
was frozen at 70°C. MR-proANP was detected in plasma
from all patients with a new sandwich immunoassay
(BRAHMS AG, Hennigsdorf/Berlin, Germany), as de-
scribed in detail elsewhere (13). In brief, the lower detection
limit of the assay is 6.0 pmol/l. The intra-assay coefficient of
variation was 10% for samples containing 23 to 3,000
pmol/l MR-proANP and 20% for samples containing 18 to
22.8 pmol/l. The interassay coefficient of variation was 10%
at the concentration of 65 pmol/l MR-proANP and 20% at
a concentration of 18 pmol/l MR-proANP. In 325 healthy
individuals, the range of MR-proANP concentrations was
9.6 to 313 pmol/l. The median was 45 pmol/l (95%
confidence interval [CI]: 43.0 to 49.1 pmol/l) (13).
Statistical analysis. Discrete variables are expressed as
counts (percentage), and continuous variables as medians
and interquartile ranges (IQRs). Two-group comparison of
not normally distributed data was performed using Mann-
Whitney U test and a Kruskal-Wallis 1-way analysis of
Abbreviations
and Acronyms
AF  atrial fibrillation
ANP  A-type natriuretic
peptide
AUC  area under the
curve
AVP  arginine vasopressin
CE  cardioembolism
CI  confidence interval
IQR  interquartile range
LACS  lacunar syndrome
MR-proANP  midregional
pro-atrial natriuretic
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mRS  modified Rankin
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NIHSS  National
Institutes of Health Stroke
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OR  odds ratio
PACS  partial anterior
circulation syndrome
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variance was used for multigroup comparisons. First, the
relation of MR-proANP with outcomes (i.e., death and
functional outcome in stroke patients) was assessed using
logistic regression models. All baseline parameters were
analyzed. Thereby, common logarithmic transformation
(i.e., base 10) was performed to obtain normal distribution
for skewed variables (i.e., MR-proANP concentrations) as
the resulting model yielded a smaller Akaike Information
Criterion, which was chosen to compare the results. We
used crude models and only report odds ratios (ORs) of
biological important or significant predictors in our tables.
Multivariate models were adjusted for 3 biologically impor-
tant outcome predictors for the end point mortality (n 44)
to avoid overfitting. For the end point functional outcome,
we adjusted for all significant predictors, and then for the 4
main predictors. Note that the OR corresponds to an
increase by 1 U in the explanatory variable. In terms of
log-transformed MR-proANP values, the OR corresponds
to a 10-fold increase.
Second, we compared the overall discriminatory ability of
different predictors by calculating receiver-operating char-
acteristic curve (ROC) analysis with the method by DeLong
et al. (22). Thereby, the area under the ROC (AUC) is a
summary measure over criteria and cut-point choices. The
AUC summary equals the probability that the underlying
classifier will score a randomly drawn positive sample higher
than a randomly drawn negative sample. To test whether
the MR-proANP level improves the performance of the
NIHSS score, we compared ROCs of the logistic regression
model combining the NIHSS score with MR-proANP with
a ROC limited to the NIHSS. We also compared ROCs of
MR-proANP and copeptin, which is a recently published
prognostic biomarker in acute ischemic stroke.
Finally, to study the ability of MR-proANP to predict
mortality, we calculated Kaplan-Meier survival curves and
stratified patients by quartiles. All testing was 2-tailed, and
p values 0.05 were considered to indicate statistical
significance. All calculations were performed using STATA
version 9.2 (Stata Corp, College Station, Texas).
Results
Baseline characteristics. Of the 362 consecutively en-
rolled patients with an ischemic stroke, 359 patients
completed the 90-day follow-up and were analyzed; 2
patients were lost to follow-up, and 1 patient withdrew
informed consent.
The median age of patients was 75 years (IQR 63 to 83
years), and 41% were women. Vital signs assessed on
admission revealed a median systolic blood pressure of 160
mm Hg (IQR 140 to 180 mm Hg) and a body temper-
ature of 37.0°C (IQR 36.5°C to 37.4°C). Regarding the
neurological deficits on admission, the median NIHSS was
5 points (IQR 2 to 10 points). A total of 275 patients (77%)
had a history of hypertension, 93 (26%) had hypercholes-
terolemia, 71 (20%) had a history of diabetes mellitus, 124
(35%) were smokers, 75 (21%) were diagnosed with atrial
fibrillation (AF), 88 (25%) had a history of a previous
vascular event, 91 (25%) had coronary heart disease, and 54
(15%) had a history of heart failure. According to the
Oxfordshire Community Stroke Project classification, 162
(45%) had a PACS, 41 (11%) a TACS, 74 (21%) a LACS,
and 83 (23%) a POCS. Baseline characteristics of the study
population are provided in Table 1.
Outcome evaluation of the stroke population after 90
days showed a mortality rate of 12% (n  44). The
functional outcome assessment revealed a median mRS of 2
(IQR 1 to 4) in the whole stroke population, and 42% (n 
151) of patients had an unfavorable functional outcome
defined as (mRS 2).
MR-proANP and severity of stroke on admission according
to the NIHSS. MR-proANP concentrations increased
with increasing severity of stroke as defined by the NIHSS
(Fig. 1). MR-proANP levels in patients with a NIHSS of 0
to 6 points (n 217) were 122.0 pmol/l (IQR 73.4 to 203.5
pmol/l), in patients with a NIHSS of 7 to 15 points (n 
90) 168.5 pmol/l (IQR 100.0 to 286.0 pmol/l), and in
patients with a NIHSS 15 points (n  55) 251.5 pmol/l
(IQR 129.0 to 372.5 pmol/l) (p  0.0001).
MR-proANP and death within 90 days. MR-proANP
levels on admission in the 44 patients who subsequently
died were about 3-fold increased as compared with survivors
(345.0 pmol/l [IQR 232.0 to 465.0 pmol/l] vs. 130.5 pmol/l
[IQR 78.2 to 216.5 pmol/l]; p  0.001) (Fig. 2A). Univar-
iate analysis identified MR-proANP concentrations, age,
presence of TACS and POCS, history of heart failure,
coronary artery disease, renal insufficiency, small vessel
disease, and the NIHSS as predictors for death (Table 2).
Thereby, the unadjusted OR of log-transformed MR-
proANP was 128.7 (95% CI: 29.7 to 557.1), and for
MR-proANP quartiles, it was 4.7 (95% CI: 2.8 to 8.0).
After combining MR-proANP in bivariate logistic re-
gression analysis with each predictor alone, it remained
an independent predictor. In addition, multivariate anal-
ysis restricted to the 4 main predictors, age, the NIHSS,
and TACS, MR-proANP remained an independent pre-
dictor for mortality with an adjusted OR of 61.01 (95%
CI: 9.87 to 377.93); similarly after adjustment for age,
the NIHSS, and heart failure, the adjusted OR was 62.83
(95% CI: 9.60 to 411.28) (Table 3). ROCs demonstrated
a discriminatory accuracy (AUC) to predict mortality for
MR-proANP of 0.86 (95% CI: 0.82 to 0.86), which was
in the range of the NIHSS (AUC: 0.85 [95% CI: 0.78 to
0.91]) and copeptin (AUC: 0.82 [95% CI: 0.76 to 0.89]).
MR-proANP had a better predictive value as compared
with CRP (AUC: 0.70 [95% CI: 0.60 to 0.70]; p  0.05)
and glucose (AUC: 0.57 [95% CI: 0.47 to 0.66]; p 
0.01). The combination of MR-proANP and the NIHSS
in a combined logistic model had a significantly higher
discriminatory accuracy (AUC: 0.92 [95% CI: 0.88 to
0.96]) than the AUC of the NIHSS or MR-proANP
alone (p  0.01 and p  0.01, respectively) (Fig. 3). Also,
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the combination of the MR-proANP and copeptin im-
proved the discriminatory accuracy of copeptin alone (AUC:
0.89 [95% CI: 0.84 to 0.93]; p  0.04). Adding copeptin to
the logistic model of MR-proANP and the NIHSS did not
further improve the model’s discriminatory ability and
revealed an AUC of 0.92 (95% CI: 0.88 to 0.96).
The time to death in the 90-day follow-up was analyzed
using Kaplan-Meier survival curves based on MR-proANP
quartiles. As demonstrated in Figure 4, patients in higher
MR-proANP quartiles had an increase in the risk of
mortality.
MR-proANP and functional outcome of stroke patients
within 90 days. MR-proANP levels in patients with an
unfavorable outcome were about 2-fold higher compared
with patients with a favorable outcome (213.0 pmol/l [IQR
119.0 to 333.0 pmol/l] vs. 119.0 pmol/l [IQR 72.8 to 187.0
Baseline CharacteristicsTable 1 Baseline Characteristics
All
Favorable Outcome
(mRS 0–2)
Unfavorable Outcome
(mRS 3–6) p Value*
n 359 208 151
Demographic data
Age, yrs 75 (63–83) 71 (59–80) 80 (71–86) 0.001
Female sex 41% (149) 35% (73) 49% (76) 0.01
Stroke severity, NIHSS 5 (2–10) 4 (2–6) 8 (4–17) 0.001
Laboratory findings
MR-proANP, pmol/l† 141.5 (84.1–237.8) 119.0 (72.8–187.0) 213.0 (119.0–332.0) 0.0001
Glucose level, mmol/l 6.1 (5.5–7.4) 6.0 (5.3–7.2) 6.3 (5.6–7.7) 0.05
C-reactive protein, mmol/l 3.6 (3.0–9.9) 3.0 (3.0–6.5) 4.90 (3.0–19.9) 0.001
Creatinine, mol/l 76.0 (63.0–89.0) 76.0 (63.5–89.0) 76.0 (62.5–91.0) NS
Vital parameters on admission
Arterial pressure, mm Hg systolic 160 (140–180) 162 (143–180) 159 (132–180) NS
Arterial pressure mm Hg diastolic 90 (80–100) 91 (81–102) 90 (79–98) NS
Body temperature, °C 37.0 (36.5–37.4) 37.0 (36.7–37.5) 37 (36.4–37.4) NS
Stroke etiology‡
Small vessel occlusive 15% (55) 18% (38) 11% (17) NS
Large vessel occlusive 18% (65) 18% (38) 18% (27) NS
Cardioembolic 37% (131) 36% (75) 37% (56) NS
Other 4% (16) 5% (11) 3% (5) NS
Unknown 26% (92) 22% (46) 30% (46) NS
Stroke syndrome
TACS 11% (41) 5% (11) 20% (30) 0.0001
PACS 45% (162) 44% (92) 47% (69) NS
LACS 21% (74) 23% (47) 18% (27) NS
POCS 23% (83) 28% (58) 16% (24) 0.01
Comorbidities
Charlson Index 1 (0–2) 0 (0–2) 1 (0–2) <0.0001
Hypertension 77% (275) 73% (152) 81% (123) <0.05
Atrial fibrillation 21% (75) 16% (34) 27% (41) <0.05
Heart failure 15% (54) 10% (21) 21% (33) <0.05
Renal insufficiency 11% (39) 7% (14) 17% (25) <0.05
Smoking history 35% (124) 38% (79) 30% (45) NS
Hypercholesterolemia 26% (93) 28% (58) 23% (35) NS
Diabetes mellitus 20% (71) 19% (39) 21% (32) NS
Coronary heart disease 25% (91) 23% (48) 28% (43) NS
Prior stroke 25% (88) 23% (48) 26% (40) NS
Therapies
Antihypertensive (prior to admission) 59% (213) 57% (119) 62% (94) NS
ASA (prior to admission) 37% (133) 36% (74) 39% (59) NS
Clopidogrel (prior to admission) 5% (18) 3% (7) 7% (11) NS
Anticoagulant (prior to admission) 11% (38) 9% (18) 13% (20) NS
Statins (prior to admission) 22% (78) 23% (47) 21% (31) NS
Thrombolysis (on admission) 16% (59) 17% (36) 15% (23) NS
Values are median (interquartile range) or % (n). *p values were assessed using the Mann-Whitney U test; †9 patients had missing values for MR-proANP; ‡some patients had 2 etiologies at the same time,
and because of rounding, percentages may not sum to 1. Bold values indicate statistical significance.
ASA  acetyl salicylic acid; IQR  interquartile range; LACS  lacunar syndrome; mRS modified Rankin Scale; NIHSS  National Institutes of Health Stroke Scale; PACS  partial anterior circulation
syndrome; POCS  posterior circulation syndrome; TACS  total anterior circulation syndrome.
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pmol/l], p  0.0001) (Fig. 2B). In univariate logistic
regression analysis, we calculated the predictive value of
MR-proANP as compared with the NIHSS and other risk
factors (Table 2). With an unadjusted OR of 10.06 (95%
CI: 4.71 to 21.52), for log-transformed MR-proANP levels
and 1.9 (95% CI: 1.6 to 2.4) for MR-proANP quartiles,
MR-proANP was a strong predictor of outcome. Compar-
ing MR-proANP with each significant outcome predictors
in a bivariate regression model, MR-proANP remained an
independent predictor (adjustment for the NIHSS revealed
an OR of 5.78 [95% CI: 2.60 to 12.97; p  0.001], for age
an OR of 4.88 [95% CI: 2.08 to 11.46; p  0.001], for
female sex an OR of 9.30 [95% CI: 4.33 to 19.97; p 
0.001], for heart failure an OR of 9.07 [95% CI: 4.10 to
20.05; p 0.001], for AF an OR of 10.08 [95% CI: 4.45 to
22.87; p  0.001], for renal insufficiency an OR of 7.73
[95% CI: 3.44 to 17.35; p 0.001], for CRP an OR of 6.47
[95% CI: 2.82 to 14.83; p  0.001], for the Charlson Index
an OR of 8.41 [95% CI: 3.84 to 18.41], and for the presence
of TACS an OR of 9.34 [95% CI: 4.28 to 20.34; p 
0.001]). When combining all significant predictors in a
multivariate model, only age, the Charlson score, and the
NIHSS remained independent predictors for functional
outcome.
With an AUC of 0.70 (95% CI: 0.65 to 0.75) to predict
functional outcome, MR-proANP had a significantly
higher prognostic discriminatory capacity as compared with
TACS and sex, and was within the range of copeptin, the
NIHSS, and age (Table 4). In addition, MR-proANP
tended to improve the NIHSS with an AUC of the
combined model of 0.79 (95% CI: 0.74 to 0.83; p  0.05).
MR-proANP in different stroke etiologies. When divid-
ing patients into 4 subgroups based on stroke etiology, 18%
(n  65) of patients were allocated to the large artery
atherosclerosis group, 36% (n 131) to the cardioembolism
(CE) group, 15% (n  55) to the small vessel occlusion
group, 4% (n  16) to the group of other etiologies (e.g.,
dissection), and 26% (n  92) to the group with undeter-
mined etiology. MR-proANP levels were highest in pa-
tients with CE etiology (206 pmol/l [IQR 119 to 326
pmol/l]), significantly higher as compared with other etiol-
ogies (124 pmol/l [IQR 73 to 207 pmol/l]; p  0.0001).
Logistic regression analysis revealed that MR-proANP was
significantly associated with CE etiology (unadjusted OR of
7.1 [95% CI: 2.6 to 19.4]), independent of history of
chronic heart failure (adjusted OR: 6.0 [95% CI: 2.3 to
13.9]) and atrial fibrillation (adjusted OR: 14.8 [95% CI:
1.2 to 6.1]) and hypertension (OR: 1.5 [95% CI: 0.80 to
2.91]). ROC analysis showed an AUC of 0.68 (95% CI:
0.62 to 0.74) for cardioembolic etiology. The optimal
biomarker cutoff point for discriminating the presence or
absence of a cardioembolic source was determined to be
180 pg/ml with a specificity of 60.3% (95% CI: 51.2 to
68.9), sensitivity of 71% (95% CI: 64.6 to 76.8), a positive
likelihood ratio of 2.0, and a negative likelihood ratio of 0.6.
Figure 2 Log MR-proANP Levels
(A) Log MR-proANP levels in survivors and nonsurvivors of stroke. (B) Log MR-
proANP levels in stroke patients with favorable and unfavorable functional out-
come. All data are medians and IQR, with dot plots representing all values. The
p value refers to a Mann-Whitney U test. Abbreviations as in Table 1.
Figure 1 MR-proANP Levels and Stroke Severity
According to the NIHSS
All data are medians and interquartile range (IQR) with dot plots representing
all values. The p value refers to a Kruskal-Wallis 1-way analysis of variance.
MR-proANP  midregional pro-atrial natriuretic peptide; NIHSS  National Insti-
tutes of Health Stroke Scale.
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To estimate whether MR-proANP improved the diag-
nosis of CE etiology by already known clinical information,
we calculated logistic models based on clinical information
(age, known heart failure, and known AF on admission) and
combined models based on clinical information plus MR-
proANP concentrations. The model including MR-
proANP (AUC: 0.81 [95% CI: 0.77 to 0.86]) was signifi-
cantly better than the model based on clinical information
alone (AUC: 0.76 [95% CI: 0.71 to 0.81]; p  0.001).
MR-proANP levels in the subgroup of patients with
heart failure or AF. In 54 (15%) patients with known
chronic heart failure on admission, MR-proANP levels
were higher as compared with patients without chronic
heart failure (271 pmol/l [IQR 162.5 to 383.8] vs. 132.0
pmol/l (IQR 78.1 to 216.6]; p  0.001). MR-proANP
remained a significant predictor for both mortality and
functional outcome after adjustment for heart failure with
ORs of 148.83 (95% CI: 32.16 to 688.67) and 9.07 (95%
CI: 4.10 to 20.05), respectively. In addition, ROC analysis
showed a similar predictive value of MR-proANP for both
Figure 3 ROC Area to Predict Mortality
Area under the receiver-operating characteristics curve (ROC) of the NIHSS and
MR-proANP, and the combined AUC. The combined model (AUC of the NIHSS
and AUC of MR-proANP) was more accurate to discriminate survivors from non-
survivors as compared with the clinical score (NIHSS) or the biomarker (MR-
proANP) alone (p  0.01 and p  0.01, respectively). Abbreviations as in
Figure 1.
Univariate AnalysesTable 2 Univariate Analyses
Mortality Functional Outcome
Odds Ratio R2 95% CI p Value Odds Ratio R2 95% CI p Value
Laboratory parameters
MR-proANP* 128.31 0.25 29.71–554.22 <0.0001 10.07 0.09 4.71–21.52 <0.0001
C-reactive protein 1.10 0.03 0.99–1.21 0.05 1.01 0.02 1.00–1.02 0.01
Creatinine 1.00 0.0006 0.99–1.01 0.68 1.00 0.0006 0.99–1.00 0.59
Demographic data
Age 1.09 0.12 1.05–1.14 <0.0001 1.06 0.09 1.04–1.08 <0.0001
Female sex 1.35 0.003 0.72–2.54 0.93 1.78 0.01 1.17–2.74 0.01
Stroke severity, NIHSS 1.20 0.28 1.14–1.25 <0.0001 1.16 0.15 1.12–1.21 <0.0001
Comorbidities
Charlson Index 1.16 0.008 0.96–1.40 0.13 1.34 0.03 1.15–1.56 <0.0001
Heart failure 2.44 0.02 1.16–5.10 0.02 2.49 0.003 1.38–4.51 0.003
Atrial fibrillation 3.16 0.001 0.92–6.15 0.09 1.91 0.01 1.14–3.19 0.01
Coronary heart disease 2.07 0.017 1.07–4.00 0.03 1.33 0.003 0.82–2.14 0.25
Renal insufficiency 3.64 0.046 1.65–8.04 0.001 2.92 0.02 1.46–5.83 0.002
Stroke syndrome
TACS 4.44 0.10 2.15–9.19 <0.0001 6.67 0.05 3.39–13.99 <0.0001
PACS 1.12 0.0001 0.74–1.69 0.74 0.81 0.0002 0.41–1.54 0.53
LACS 0.75 0.02 0.44–1.26 0.28 0.35 0.0001 0.12–1.02 0.54
POCS 0.49 0.006 0.29–0.83 0.01 0.50 0.01 0.20–1.23 0.20
Stroke etiology
Small vessel occlusive 0.11 0.03 0.02–0.84 0.03 0.58 0.007 0.30–1.05 0.07
Large vessel occlusive 0.55 0.006 0.21–1.45 0.23 0.97 0.00001 0.56–1.68 0.93
Cardioembolic 1.54 0.007 0.82–2.92 0.43 1.05 0.0001 0.68–1.62 0.84
Other 0.47 0.002 0.06–3.64 0.46 0.61 0.001 0.21–1.80 0.37
Unknown 1.96 0.01 1.02–3.79 0.05 1.54 0.007 0.96–2.49 0.08
p values in bold indicate statistical significance. *Note that the odds ratio corresponds to a unit increase in the explanatory variable; for MR-proANP this corresponds to an increase per unit of the log
transformation of MR-proANP (thus a log-transformed increase of 1 corresponds to a MR-proANP increase of 10 pmol/l).Bold values indicate statistical significance.
Multivariate Analysis for MortalityTable 3 Multivariate Analysis for Mortality
Predictors Odds Ratio 95% CI p Value
MR-proANP 62.83 9.60–411.28 <0.001
Age 1.04 0.99–1.09 0.07
Stroke severity, NIHSS 1.19 1.12–1.26 <0.001
Chronic heart failure 0.76 0.26–2.23 0.60
p values in bold indicate statistical significance; p values in italics indicate nonsignificance.
Abbreviations as in Tables 1 and 2.
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outcomes in patients with and without heart failure (data
not shown).
Similarly, in 75 (21%) patients with AF, MR proANP
levels were higher (258.5 pmol/l [IQR 181.8 to 380.0
pmol/l]) as compared with patients without AF (123.5
pmol/l [IQR 74.2 to 213.0 pmol/l]; p  0.001). Again,
MR-proANP remained a significant predictor for both
outcomes after adjustment for AF. ROC analysis showed a
similar predictive value of MR-proANP for both outcomes
in patients with and without AF (data not shown).
Discussion
MR-proANP levels on admission were increased in stroke
patients, with particularly prominently elevated levels in
patients with cardioembolic strokes. MR-proANP proved
to accurately predict 90-day mortality and functional out-
come, independent of other comorbidities such as chronic
heart failure and AF, age, and clinical scores. Importantly,
MR-proANP improved the prognostic value of the NIHSS.
To our knowledge, this is the first prospective study evalu-
ating MR-proANP levels in a large cohort of stroke
patients.
Elevated concentrations of natriuretic peptides, especially
BNP, have been shown to be of prognostic value in patients
with congestive heart failure and myocardial ischemia (as-
sessed by electrocardiographic changes) (18,23,24). Re-
cently, MR-proANP levels were also evaluated in patients
with heart failure showing comparable prognostic capabili-
ties to BNP values with respect to 1-year all-cause mortality
(25). Hence, higher natriuretic peptide levels reflect a
greater degree of hemodynamic dysfunction and explain the
increased mortality in patients with acute cardiac disease. A
role of natriuretic peptides in the hemodynamic regulation
has also been shown during the acute phase of ischemic
stroke (7,26–28). Clinical studies have revealed elevated
levels of natriuretic peptides in the acute phase of ischemic
stroke (8,28–30). One study (8) reported elevated levels of
BNP and ANP in 51 ischemic stroke patients compared
with healthy controls and higher levels of natriuretic pep-
tides in patients who died as compared with those who
survived. BNP and its N-terminal peptide (NT-proBNP)
has been demonstrated to be excellent markers for vas-
cular mortality and re-events in stroke (6) although
NT-proBNP levels on admission were not significantly
associated with functional outcome within 3 months (30)
if adjusted for vascular risk factors in another study.
Estrada et al. (7) investigated ANP concentrations in 37
patients with acute ischemic stroke. Compared with
healthy controls, concentration of ANP increased imme-
diately after stroke and remained elevated for 7 days. We
Figure 4 Kaplan-Meier Survival Curves
Estimates by midregional pro-atrial natriuretic peptide (MR-proANP) quartiles and numbers at risk. Note that in 9 patients, we had missing values for MR-proANP.
ROC Analysis of Functional OutcomeTable 4 ROC Analysis of Functional Outcome
Parameter AUC 95% CI p Value*
MR-proANP 0.71 0.65–0.75
Copeptin 0.73 0.67–0.78 0.62
NIHSS 0.75 0.70–0.80 0.21
Age 0.70 0.65–0.75 0.88
Charlson score 0.63 0.58–0.69 0.06
Sex 0.58 0.52–0.63 0.002
Combined score (Copeptin and MR-proANP) 0.73 0.68–0.80 0.78
Combined score (NIHSS and MR-proANP) 0.79 0.74–0.83 0.016
*p values indicate significance of area under the curve (AUC) between predictors and MR-proANP.
p values in bold indicate statistical significance.
ROC  receiver-operating characteristic curve; other abbreviations as in Tables 1 and 2.
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found no published data on ANP or its precursor protein
on the independent predictive value concerning mortality
as well as functional outcome after an acute ischemic
stroke.
The relation of natriuretic peptides and stroke prognosis
seems not to be monocausal and is complex. First, it has
been demonstrated that a higher level of NT-proBNP in
stroke patients is associated with increased sympathetic
activation. Sympathetic activation by itself is a prognostic
determinant after an acute thromboembolic stroke (31,32).
Second, previous studies have shown that heart failure is
associated with dependency after stroke (27) and that it is an
independent predictor for mortality after first cerebral in-
farction (33–35).
In our study, unadjusted and adjusted logistic regression
analysis revealed that levels of MR-proANP were predictors
for 90-day mortality and functional outcome, independently
of the presence of heart failure or AF. The pathophysiolog-
ical mechanism explaining this independent predictive value
of MR-proANP observed in our study remains to be
clarified. It may be hypothesized that high MR-proANP
concentrations indicate the presence of a profound neuro-
hormonal dysfunction, and thus a worse outcome. Further-
more, increased MR-proANP levels might mirror, not only
manifest heart failure, but also a beginning cardiac pathol-
ogy (e.g., subclinical heart failure) in which intracardial
thrombus development might be more likely. This would
explain the additional diagnostic value of MR-proANP
levels to differentiate CE etiologies from others. It is
essential to identify the CE etiology in stroke because
recurrent stroke occurs within 2 weeks in up to 12% of
patients who initially experience embolic stroke from car-
diac sources (36). AF might be no longer present when
patients are examined by 24-h electrocardiography moni-
toring. Thus, anticoagulant therapy might be delayed even
when the neurologist suspects an embolic origin due to
distinct patterns of lesions. Using biomarkers may be a
reasonable strategy to improve the identification of cardio-
embolic stroke already in the acute phase, thus rapidly point
to need of other diagnostic tests and accelerating the start of
optimal secondary prevention (26).
Other known mediators involved in the ischemic cascade
are markers for neuronal cell death, such as protein S-100
(37), inflammation markers, such as interleukin-6 (38), or
markers for oxidative stress and blood-brain barrier disrup-
tion, such as matrix metalloproteinase-9 (39,40). Although
these biomarkers reliably mirror the initial stroke severity
(NIHSS and lesion size) and some even bear an association
with outcome, they were not able to independently predict
functional outcome and death within 3 months as well as to
improve the NIHSS. To our knowledge, only 1 circulation
biomarker, copeptin, the c-terminal part of the AVP pro-
hormone, was able to significantly improve prediction of
clinical outcome after stroke for death and functional
outcome (19). Copeptin is released in an equimolar ratio to
AVP and is more stable in the circulation and easier to
determine as AVP (41). Interestingly, MR-proANP seems
to be a better predictor for mortality, whereas copeptin had
a higher prognostic accuracy to predict functional outcome.
One reason for the absence of a “unique” biomarker pre-
eminently mirroring all aspects of prognosis might be that
the complexity of brain ischemia and recovery capacities is
less amenable to the use of a single biochemical marker. In
the difficult task of outcome prediction, it seems, therefore,
reasonable to rely on several parameters, each mirroring
different pathophysiological aspects. The approach of using
a multiple biomarker panel has already been well established
in the clinical setting of patients with cardiovascular disease
(6,42). A model combining biomarkers and clinical param-
eters might also be the most promising approach to predict
outcome in stroke patients.
Study limitations. We are aware of the following limita-
tions. First, our study is a single-center study and should be
externally validated in a large cohort of patients. Second, we
did not directly compare the prognostic value of MR-
proANP with other natriuretic peptides, especially B-type
natriuretic peptides. However, this study shows promising
data for a further multicenter trial including MR-proANP
in a prognostic biomarker panel.
Conclusions
The present study shows that MR-proANP is a new,
valuable marker for the prognosis in patients with ischemic
stroke. It also seems to act as a diagnostic marker by
differentiating patients with a CE etiology of stroke from
other etiologies, especially when combining it with clinical
information. Early risk assessment in acute ischemic stroke
may allow for better and earlier intervention and improved
care strategies to effectively change the dismal natural
history of stroke.
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Abstract
Background: Early predictors for the development of stroke-associated infection may identify patients at high risk and
reduce post-stroke infection and mortality.
Methods: In 383 prospectively enrolled acute stroke patients we assessed time point and type of post-stroke infections (i.e.
pneumonia, urinary tract infection (UTI) other infection (OI)). Blood samples were collected on admission, and days 1, and 3
to assess white blood cells (WBC), monocytes, C-reactive protein (CRP), procalcitonin (PCT), and copeptin. To determine the
magnitude of association with the development of infections, odds ratios (OR) were calculated for each prognostic blood
marker. The discriminatory ability of different predictors was assessed, by calculating area under the receiver operating
characteristic curves (AUC). Prognostic models including the three parameters with the best performance were identified.
Results: Of 383 patients, 66 (17.2%) developed an infection after onset of stroke. WBC, CRP, copeptin and PCT were all
independent predictors of any infection, pneumonia and UTI developed at least 24 hours after measurements. The
combination of the biomarkers WBC, CRP and copeptin (AUC: 0.92) and WBC, CRP and PCT (AUC: 0.90) showed a better
predictive accuracy concerning the development of pneumonia during hospitalization compared to each marker by itself
(p-Wald ,0.0001).
Conclusion: Among ischemic stroke patients, copeptin, PCT, WBC and CRP measured on admission were predictors of
infection in general, and specifically for pneumonia and UTI within 5 days after stroke. The combination of these biomarkers
improved the prediction of patients who developed an infection.
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Introduction
Infection during the first days after ischemic stroke (IS) occurs in
25–65% of patients [1,2]. Pneumonia and urinary tract infection
(UTI) are the most common infectious complications after IS [3].
It has been suggested that the predominance of infections during
the acute phase of stroke [1] is due to stroke-induced immuno-
suppression (SIS) [4]. The central nervous system modulates the
activity of the immune system through complex pathways that
include the hypothalamic pituitary adrenal axis (HPAA), the vagus
nerve, and the sympathetic nervous system [5,6]. Several studies
found an independent association between stroke-associated
infections (SAI) and poor functional outcome after IS [7–9].
Therefore, early initiation of antibiotic treatments is recom-
mended if infection is present [10]. However, gold-standard
clinical diagnostics are time-consuming and delay early antibiotic
therapy. Thus, accurate and simply available prognostic markers
for optimal risk stratification are needed. We therefore selected C-
reactive protein (CRP), white blood cells (WBC), monocytes
(Mcyt), as they represent the most commonly measured and well-
established inflammatory markers in clinical routine. Procalcitonin
(PCT) was selected to better discriminate infections from general
inflammation [11,12]. Copeptin, a reliable stress marker [13] was
selected because SIS may be mediated by changes in the
neuroendocrine system. All these biomarkers are available
immediately due to rapid analytic procedure.
We hypothesize that these blood markers are predictive for
the development of post-stroke infections. First we planned to
evaluate the prognostic value of each blood biomarker to
predict infections in the acute phase of IS. Second, we aimed to
identify the best prognostic model consisting of a batch of the
best prognostic biomarkers. Thereafter, the prognostic value of
this batch was compared to that of each prognostic biomarker
alone.
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Patients and Methods
Ethics Statement
The study has been approved by the local Ethics Committee at
the University Hospital of Basel. All participants or their
representative gave written informed consent for the study.
Study Population
We performed a post-hoc analysis of a prospective cohort study
[14]. All patients with IS within 72 hours before admission at the
Emergency Department, University Hospital of Basel, were
eligible and prospectively enrolled (11/2006–11/2007). IS was
confirmed by CT and/or MRI on admission. Neurological deficits
were measured at presentation with the National Institutes of
Health Stroke Scale (NIHSS) score.
Definition of Stroke-associated Infections
SAI was defined as any infection occurring within the first 5
days of hospital admission [13]. Infections were diagnosed
according to the criteria of the U.S. Centers for Disease Control
and Prevention (CDC) [15]. We distinguished between pneumo-
nia, urinary tract infection (UIT) and ‘‘other infections’’ (OI).
Pneumonia was diagnosed when at least one of each of the first
and latter criteria was fulfilled: i) abnormal respiratory examina-
tion, pulmonary infiltrates in chest x-rays; ii) productive cough
with purulent sputum, positive microbiological cultures from lower
respiratory tract or blood cultures. Diagnosis of UTI was based on
two of the following criteria: fever ($38.0uC), urine sample
positive for nitrite, leukocyturia (.40/mL), or significant bacteri-
uria ($104/mL of an uropathogen). OI was defined if temperature
was $38.0uC, white blood cell count was $11000/mL or
CRP$10 mg/L and an infectious manifestation was present.
Diagnosis of infection was done by the treating physician during
hospitalization and was then validated post-hoc using charts, both
diagnosis by treating physicians as well as secondary validation was
blinded to biomarker levels with the exception of WBC and CRP
for the diagnosis of (OI). Time point of diagnosis was referred to
the beginning of clinical symptoms, which lead to diagnostic work-
up and resulted in the diagnosis of infection.
In order to exclude acute infections preceding stroke, patients
with admission temperature $38uC, or patients reporting an
infection lasting up to 3 days before onset of stroke or patients who
required mechanical intubation were not included in the study.
Laboratory Methods
Blood samples were collected on admission (baseline) within 72
hours from symptom onset, and 1, and 3 days after admission to
assess WBC and Mcyt count, CRP level, PCT and copeptin. PCT
serum concentration was measured using a commercially available
time-resolved amplified cryptate emission technology assay
(Kryptor PCT, Brahms, Hennigsdorf, Germany) [16]. Measure-
ment of copeptin was performed in a single batch with a
commercial sandwich immunoluminometric assay (LUMItest
CT-proAVP, B.R.A.H.M.S, Hennigsdorf/Berlin, Germany)
[17]. In patients who died within 5 days after admission, or in
patients who were discharged before day 5, only data from
admission or until the day of discharge were collected.
Statistical Analysis
Descriptive statistics were expressed as means 6 standard
deviations, medians and quartiles or absolute and relative
frequencies depending on their distribution. Group differences
were assessed using the Kruskal-Wallis test or Chi 2-test.
Logarithmic transformation was performed to obtain an approx-
imately normal distribution for all parameters except temperature
and Mcyt.
First, the association of the biomarkers measured at admission
with the presences of infections developed within 5 days was
assessed using simple logistic regression.
Second we calculated pooled logistic regression considering
patients to be at risk until the manifestation of an infection or until
day 5 whichever occurred first. Each of these models had one time
dependent predictor variable, i.e., the measurement of a given
blood parameter 1 or 2 days before the respective day of diagnosis
of infection. To adjust for potential clustering of data within
subjects, robust standard errors were computed using the method
of Huber-White. Odds ratios (OR) and associated 95% confidence
intervals (95%CI) refer to an increase of the respective parameter
from the lowest to the highest quartile.
Third, we compared the discriminatory ability of different
predictors by calculating receiver operating characteristic (ROC)
analysis. Bootstrap methods were used to derive 95%CIs for
AUCs, index of Youden and optimal cutpoints to statistically
compare AUC’s of different predictors.
Forth, to assess the prognostic independence from age, NIHSS
score (as indicator of stroke severity) and Charlson index (as
indicator of comorbidity burden) as well as infratentorial and
supratentorial infarct localization, we performed bivariate logistic
regression (to avoid over-fitting) with these potential confounders.
Finally, we calculated 2 prediction models (batch 1 and 2) by
including established inflammatory parameters (WBC and CRP)
and either Copeptin or PCT, the 2 new makers. Since robust
precision estimates were used, model comparisons could not be
done using likelihood ratio tests but were based on Wald p-values.
P-values less than 0.05 were considered to indicate statistical
significance. All calculations were performed using SAS software,
version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline Data
Of 383 patients with stroke, 66 (17.2%) developed an infection
within 5 days after onset of stroke. Twenty (5.2%) patients suffered
from pneumonia, 25 (6.5%) patients had UTI and 21 (5.5%)
patients an OI (sepsis: 7 patients; phlebitis: 6 patients; gastroen-
teritis: 4 patients, erysipelas: 1 patient; panniculitis: 1 patient,
colpitis: 2 patients). Baseline data are summarized in table 1.
Blood Biomarkers as Predictors of Post-stroke Infections
Copeptin, PCT, WBC and CRP-levels on admission predicted
any infection, pneumonia and UTI in the acute phase of stroke.
ORs and AUCs for each marker measured on admission (i.e. day
0) are provided in table 2. ORs to predict infections associated
with nearest predictor measurements over time (i.e. performed 1
or 2 days prior to the onset of infection) are presented in table 3.
After adjusting for either age, NIHSS, CI or infarct localization
(infra2/supratentorial) in a bivariate model all biomarkers
remained significant predictors (table 4).
Copeptin as a new prognostic marker for SAI was a strong
predictor of any infection, pneumonia and UTI (table 3). Copeptin
had the same prognostic accuracy compared to WBC, CRP, and
the only statistical significant difference in AUCs was found when
comparing WBC and copeptin regarding the outcome of OI
(p = 0.02) (table 5).
Predictive Models for Post-stroke Infections
We defined two batches of the three parameters with highest
AUC values for any infection, pneumonia, UTI and OI by
Predictors of Stroke-Associated Infection
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combining WBC, CRP and copeptin (batch 1) as well as WBC,
CRP and PCT (batch 2).
Batch 1 (WBC, CRP, copeptin) better predicted any infection
(Wald-p,0.001) and pneumonia (Wald-p,0.001) than the best
single predictor alone. However, batch 1 was not a better predictor
of UTI (Wald-p = 0.058) and OI (Wald-p = 0.25) than WBC
(table 6).
Table 1. Baseline Data.
All patients
Patients without
infection
Patients with any
infection Pneumonia UTI
Other
infections
N 383 317 66 20 25 21
Age
Median (6SD) 71.4613.7 70.5614.1 75.6610.6 77.0610.5 77.3610.8 74.4
Gender (male)
% (n) 57.7 (221) 60.8 (192) 43.3 (29) 45.0 (9) 32.0 (8) 50 (13)
Laboratory Findings on admission
CRP (mg/ml)
median 3.0 3.0 5.1 5.6 4.9 4.5
(IQR) (3.0–6.7) (3.0–5.8) (3.0–15.8) (3.0–19.7) (3.0–24.3) (3.0–8.8)
WBC (109/l)
median 8.0 7.8 9.7 9.8 9.9 9.2
(IQR) (6.6–9.8) (6.5–9.4) (7.5–11.4) (7.5–13.5) (8.3–11.2) (7.4–11.3)
Monocyte (109/l)
Mean (6SD) 0.41060.167 0.39860.143 0.46360.243 0.55760.357 0.47160.277 0.41360.152
Procalcitonin (mg/l)
median 0.017 0.016 0.018 0.022 0.017 0.027
(IQR) (0.01–0.02) (0.01–0.02) (0.01–0.03) (0.02–0.03) (0.01–0.04) (0.01–0.03)
Copeptin (pmol/l)
median 8.19 7.68 19.6 24.1 24.5 15.0
(IQR) (4.4–31.4) (4.2–16.5) (6.2–61.9) (8.6–42.4) (5.2–73.5) (5.7–62.3)
Temperature (6C)
Mean (6SD) 37.060.6 37.060.6 36.960.7 37.060.9 36.860.7 37.060.7
Risk factors % (n)
Heart failure 13.4 (48/357) 11.6 (34/293) 21.9 (14/64) 25.0 (5/20) 17.4 (4/23) 20.0 (5/25)
AH 80.0 (286/358) 77.7 (227/292) 89.4 (59/66) 85.0 (17/20) 91.7 (22/24) 88.5 (23/26)
PAD 8.3 (30/363) 8.4 (25/298) 7.7 (5/65) 10.0 (2/20) 4.3 (1/23) 7.7 (2/26)
Diabetes mellitus 19.3 (71/367) 18.9 (57/301) 21.2 (14/66) 35.0 (7/20) 25.0 (6/24) 7.7 (2/26)
CHD 21.0 (76/363) 21.2 (63/297) 19.7 (13/66) 25.0 (5/20) 16.7 (4/24) 19.2 (5/26)
Atrial fibrillation 19.4 (69/355) 15.9 (46/289) 34.8 (23/66) 45.0 (9/20) 25.0 (6/24) 38.5 (10/26)
Hyperchol 29.2 (99/339) 29.1 (82/282) 29.8 (17/57) 41.2 (7/17) 25.0 (5/20) 21.7 (5/23)
Family history of stroke 30.1 (106/352) 31.3 (90/288) 25.0 (16/64) 25.0 (5/20) 24.0 (6/25) 21.7 (5/23)
NIHSS
Median 5 4 11 12 9 11
(IQR) (2–10) (2–7) (5–18) (5–19) (3–15.5) (5.5–19)
Charlson Index
Median 1 0 1 1.5 1 0.5
(IQR) (0–2) (0–2) (0–2) (0–2.5) (0–2) (0–2)
BP on admission
Systolic BP
Mean (6SD) 160629 161634 158634 153636 158636 159634
Diastolic BP
Mean (6SD) 86621 85620 92623 103630 89622 92618
UTI: urinary tract infection; CRP: C-reactive protein; WBC: white blood cells; NIHSS: National Institutes of Health Stroke Scale; BP: blood pressure; IQR: interquartile range
(log transformed), AH: arterial hypertension; PAD: peripheral artery disease; CHD: coronary heart disease; Hyperchol: Hypercholestrolemia.
doi:10.1371/journal.pone.0048309.t001
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Batch 2 (WBC, CRP, PCT) better predicted any infection
(Wald-p,0.001), pneumonia (Wald-p,0.001) and UTI (Wald-
p = 0.014) than the best single predictor alone. However, batch 2
was not better in predicting OI compared to the best single
predictor (Wald-p = 0.25) (table 6).
Discussion
The value of rapidly available blood markers as predictors for
SAI has not been studied extensively, although WBC, CRP and
Mcyt are routinely measured within the first hours of admission.
Copeptin and PCT measured on admission were good predictors
of any infection, pneumonia and UTI in the present cohort. They
showed a similar predictive value for future infection compared to
WBC and CRP. In a recent study neither WBC, CRP, Mcyt nor
PCT measured on admission were sensitive enough to reliably be
associated with SAI [18]. In another study, WBC and Mcyt count
on admission did not differ between infected and non-infected
stroke patients [19]. Only on day 1 after stroke onset, body
temperature [18] and WBC [18,19] became significantly associ-
ated with infections after stroke. However, in these studies the time
point of diagnosis in relation to biomarker measurements was not
taken into account. Therefore, they could not really establish the
predictive value of these markers but rather their diagnostic
accuracy at the time of infection. Moreover the sample size was
somewhat small and associations might have been missed due to
lack of power. To our knowledge our study is the first to assess the
predictive value of these markers taking into account the time
point of measurements as well as diagnosis.
In the present study, each laboratory parameter remained a
strong predictor after adjusting for NIHSS, age and CI and infarct
localization. This is an unexpected finding because age and stroke
severity may also contribute to SIS and thus infection after acute
ischemic stroke [20–22]. However, these biomarkers seem to add
prognostic information beyond age, stroke severity and a higher
CI as well as infarct localization.
Copeptin was a strong predictor for SAI on admission and
during the acute phase of stroke. The predictive value of copeptin
Table 2. OR/AUC to predict infections (measurements on
admission (day 0)).
Univariate analyses
variables
Odds
Ratio CI (95%) p-value AUC
Any Infection (n=66)
Temperature 0.88 0.59–1.33 0.055 0.51
PCT 1.91 1.38–2.63 ,.001 0.68
CRP 1.50 1.22–1.84 ,.001 0.65
WBC 3.35 2.14–5.23 ,.001 0.74
Mcyt 1.43 1.03–2.00 0.035 0.56
Copeptin 2.51 1.68–3.75 ,.001 0.73
Pneumonia (n =20)
Temperature 0.90 0.48–1.69 0.75 0.49
PCT 1.96 1.34–2.86 ,.001 0.69
CRP 1.67 1.25–2.24 ,.001 0.77
WBC 3.38 1.85–6.20 ,.001 0.76
Mcyt 2.00 1.28–3.11 0.002 0.63
Copeptin 2.35 1.29–4.28 0.005 0.75
Urinary Tract Infection (n =25)
Temperature 0.77 0.40–1.48 0.43 0.56
PCT 1.90 1.30–2.78 ,.001 0.70
CRP 1.61 1.20–2.16 0.002 0.65
WBC 3.23 1.75–5.96 ,.001 0.77
Mcyt 1.46 0.89–2.40 0.14 0.54
Copeptin 2.99 1.60–5.60 ,.001 0.77
Other Infection (n =21)
Temperature 0.99 0.48–2.04 0.97 0.46
PCT 1.48 0.96–2.28 0.08 0.66
CRP 1.36 0.96–1.91 0.08 0.60
WBC 4.14 2.13–8.02 ,.001 0.78
Mcyt 1.72 1.07–2.76 0.02 0.71
Copeptin 1.70 0.86–3.37 0.13 0.67
OR referred to an increment to predict values from the 1st to the 3th
interquartile range (IQR). IQRs for the parameters are given in Table 1.
PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cells; Mcyt:
monocytes.
doi:10.1371/journal.pone.0048309.t002
Table 3. Odds ratios/AUC to predict infections associated
with nearest predictor measurements*.
Univariate analyses
variables
Odds
Ratio CI (95%) p-value AUC
Any Infection
Temperature 2.30 1.46–3.63 0.0003 0.64
PCT 1.69 1.30–2.20 ,.0001 0.67
CRP 2.28 1.75–2.96 ,.0001 0.74
WBC 4.91 3.38–7.14 ,.0001 0.82
Mcyt 1.72 1.40–2.11 ,.0001 0.65
Copeptin 2.40 1.81–3.20 ,.0001 0.75
Pneumonia
Temperature 3.00 1.22–7.37 0.02 0.67
PCT 1.95 1.36–2.79 0.0003 0.71
CRP 2.65 1.83–3.84 ,.0001 0.80
WBC 4.29 2.52–7.31 ,.0001 0.81
Mcyt 2.17 1.71–2.77 ,.0001 0.72
Copeptin 3.32 2.32–4.76 ,.0001 0.86
Urinary Tract Infection
Temperature 1.64 0.77–3.48 0.20 0.57
PCT 1.61 1.18–2.20 0.003 0.63
CRP 2.26 1.52–3.37 ,.0001 0.74
WBC 4.65 2.85–7.58 ,.0001 0.83
Mcyt 2.04 1.60–2.60 ,.0001 0.69
Copeptin 2.09 1.39–3.13 0.0004 0.71
Other Infection
Temperature 6.82 2.34–19.89 0.0004 0.80
PCT 1.33 0.95–1.85 0.09 0.58
CRP 2.31 1.50–3.55 0.0001 0.74
WBC 5.69 3.44–9.39 ,.0001 0.84
Mcyt 1.32 0.93–1.87 0.12 0.61
Copeptin 2.22 1.39–3.55 0.0008 0.75
OR referred to an increment to predict values from the 1st to the 3th
interquartile range (IQR). IQRs for the parameters are given in Table 1.
PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cells; Mcyt:
monocytes performed 1 or 2 days prior to the onset of infection.
doi:10.1371/journal.pone.0048309.t003
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in respect of SAI was similar to that of established biomarkers of
infection (i.e. WBC, CRP). This finding might be due to the
association of copeptin with the activation of the HPAA: increased
copeptin-levels probably indicate a high degree of stress and SIS,
which means a higher susceptibility to develop an infection. The
prognostic value of PCT was also in the range of WBC and CRP.
In the literature PCT is a superior diagnostic marker in
pneumonia and other bacterial infections when compared to
WBC and CRP [23]. However, the prognostic accuracy of a single
PCT valueis limited [24]. PCT might be rather a specific than a
sensitive prognostic marker in predicting infections.
The combination of established inflammatory makers (WBC,
CRP) combined with a biomarker of stress, i.e. copeptin or a
biomarker of bacterial infection, i.e. PCT [16] improves prediction
of SAI compared to the strongest prognostic marker alone. The
combination of biomarkers probably reflects better the complexity
of an infection than one biomarker alone and may lead to a more
accurate prediction of a beginning but not yet clinically apparent
infection.
The investigated biomarkers seem to detect infections before
clinical or paraclinical signs prompt further diagnostic work-up
leading to the diagnosis of infection. Thus, these markers may help
in risk stratification and may select high-risk patients for
intervention studies.
We are aware of the following limitations: First, our results are
based ona single cohort and our findings need to be validated in an
independent and larger cohort. Second, the sample size was
relatively small when assessing subgroups of infection. The
bivariate analysis may have a limited statistical power and validity
underestimating possible effects of biomarkers and other potential
predictors. Third, although WBC and CRP was not a criterion for
making the diagnosis of pneumonia, any infection and UTI, one
must take into account that WBC was one of three criteria for the
diagnosis of the subgroup of OI. Therefore, the good predictive
value of WBC - in the case of OI - is most probably due to
incorporation bias. This, on the other hand, strengthens the
predictive value of copeptin that might be underestimated
compared to WBC in this study. Fourth, we are not able to proof
causalities or provide more insights into pathomechanisms, to
explain why these markers are good predictors of infections even
before clinical signs occur. But even if these markers are only
surrogates of underlying processes which predispose patients for
Table 4. OR to predict infections associated with nearest predictor measurements adjusted for age, NIHSS and CI as well as supra-
or infratentorial infarct localization.
OR (95%CI)
adjusted for age
OR (95%CI)
adjusted for NIHSS
OR (95%CI)
adjusted for CI
OR (95%CI) adjusted for supra2/
infratentorial infarctions
Any Infection
Temperature 2.36 (1.48–3.75) 2.10 (1.35–3.28) 2.82 (1.46–3.56) 2.30 (1.45–3.65)
PCT 1.64 (1.27–2.12) 1.62 (1.26–2.07) 1.81 (1.37–2.40) 1.69 (1.30–2.20)
CRP 2.23 (1.72–2.90) 1.96 (1.47–2.60) 2.22 (1.70–2.90) 2.28 (1.75–2.96)
WBC 4.97 (3.42–7.21) 4.22 (2.86–6.21) 4.90 (3.34–7.20) 4.80 (3.33–6.91)
Mcyt 1.69 (1.37–2.07) 1.70 (1.37–2.10) 1.68 (1.37–2.06) 1.72 (1.40–2.11)
Copeptin 2.22 (1.64–3.02) 1.84 (1.21–2.79) 2.30 (1.72–3.70) 2.43 (1.81–3.25)
Pneumonia
Temperature 3.11 (1.23–7.86) 2.64 (1.11–6.29) 2.95 (1.23–7.09) 2.95 (1.24–7.00)
PCT 1.89 (1.33–2.67) 1.88 (1.33–2.65) 2.15 (1.40–3.32) 1.95 (1.37–2.79)
CRP 2.58 (1.79–3.71) 2.25 (1.48–3.42) 2.60 (1.77–3.80) 2.67(1.86–3.82)
WBC 4.17 (2.41–7.22) 3.73 (2.17–6.41) 4.32 (2.58–7.23) 4.30 (2.55–7.28)
Mcyt 2.09 (1.63–2.67) 2.13 (1.65–2.75) 2.15 (1.71–2.71) 2.19 (1.72–2.79)
Copeptin 3.07 (2.08–4.53) 2.95 (1.70–5.11) 3.28 (2.24–4.81) 3.37 (2.28–4.98)
Urinary Tract Infection
Temperature 1.66 (0.78–3.55) 1.48 (0.76–2.88) 1.61 (0.76–3.42) 1.63 (0.78–3.42)
PCT 1.56 (1.16–2.10) 1.54 (1.12–2.11) 1.74 (1.19–2.53) 1.67 (1.21–2.29)
CRP 2.21 (1.49–3.29) 1.98 (1.31–3.00) 2.21 (1.45–3.36) 2.46 (1.64–3.69)
WBC 4.50 (2.82–7.18) 4.18 (2.48–7.06) 4.76 (2.75–8.25) 4.86 (2.99–7.92)
Mcyt 1.97 (1.56–2.49) 1.99 (1.56–2.53) 2.02 (1.48–2.77) 2.08 (1.63–2.67)
Copeptin 1.86 (1.20–2.89) 1.65 (0.85–3.20) 1.92 (1.19–3.09) 2.02 (1.32–3.10)
Other Infection
Temperature 6.94 (2.52–19.12) 5.75 (2.10–15.71) 6.57 (2.50–17.29) 6.52 (2.23–19.06)
PCT 1.29 (0.93–1.78) 1.24 (0.87–1.77) 1.37 (0.97–1.92) 1.36 0.99–1.88)
CRP 2.25 (1.50–3.37) 1.91 (1.16–3.14) 2.30 (1.53–3.44) 2.44 (1.56–3.81)
WBC 5.54 (3.49–8.78) 5.01 (2.93–8.56) 5.62 (3.48–9.08) 6.08 (3.75–9.88)
Mcyt 1.32 (0.96–1.82) 1.30 (0.95–1.79) 1.33 (0.95–1.84) 1.34 (0.95–1.91)
Copeptin 2.28 (1.36–3.79) 1.60 (0.75–3.42) 2.37 (1.50–3.74) 2.17 (1.31–3.59)
PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cells; Mcyt: monocytes.
doi:10.1371/journal.pone.0048309.t004
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infections, from a clinical standpoint we belief that the observed
associations are very interesting since we identified accurate
prognostic markers for risk stratification. Finally, the distinction
between prediction and early diagnosis of infection is difficult. We
are not able to differentiate whether the biomarkers investigated in
this study might rather detect infections at an early state or predict
vulnerability for future post-stroke infections, although we
excluded patients with possible infection prior to the onset of
stroke.
In summary, copeptin, PCT, WBC and CRP were good
predictors of the development of any infection, pneumonia and
UTI. The combination of the 3 biomarkers even improved the
prognostic value by accurately separating patients with and
without future infections already on admission. If validated in
larger prospective studies the combination of these 3 biomarkers
with best AUC values may add significant information for the
early identification of high-risk patients. Future intervention
studies could select patients with high-risk profiles according to
these biomarker levels and these high-risk patients may proof to
benefit from prophylactic antibiotic treatment.
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Table 5. Comparison of AUCs for developing infection
between the predictors WBC, Mcyt, CRP and Copeptin.
Variables AUC p-value
Any Infection
WBC vs Mcyt 0.82 vs 0.65 ,.001
WBC vs CRP 0.82 vs 0.74 0.16
WBC vs Copeptin 0.82 vs 0.75 0.07
CRP vs Copeptin 0.74 vs 0.75 0.75
CRP vs Mcyt 0.74 vs 0.65 0.04
Copeptin vs Mcyt 0.75 vs 0.65 0.05
Pneumonia
WBC vs Mcyt 0.81 vs 0.72 0.13
WBC vs CRP 0.81 vs 0.80 0.78
WBC vs Copeptin 0.81 vs 0.86 0.72
CRP vs Copeptin 0.80 vs 0.86 0.98
CRP vs Mcyt 0.80 vs 0.72 0.36
Copeptin vs Mcyt 0.86 vs 0.72 0.28
Urinary Tract Infection
WBC vs Mcyt 0.83 vs 0.69 0.09
WBC vs CRP 0.83 vs 0.74 0.24
WBC vs Copeptin 0.83 vs 0.71 0.14
CRP vs Copeptin 0.74 vs 0.71 0.86
CRP vs Mcyt 0.74 vs 0.69 0.64
Copeptin vs Mcyt 0.71 vs 0.69 0.68
Other Infection
WBC vs Mcyt 0.84 vs 0.61 0.008
WBC vs CRP 0.84 vs 0.74 0.10
WBC vs Copeptin 0.84 vs 0.75 0.02
CRP vs Copeptin 0.74 vs 0.75 0.80
CRP vs Mcyt 0.74 vs 0.61 0.28
Copeptin vs Mcyt 0.75 vs 0.61 0.30
PCT: procalcitonin; CRP: C-reactive protein; WBC: white blood cells; Mcyt:
monocytes.
doi:10.1371/journal.pone.0048309.t005
Table 6. Comparison of batches with best predictors of
specific type of infection alone.
Adjusted
OR* CI (95%) p-value AUC Wald-p**
Batches 1: WBC+CRP+Copeptin
Any infection
WBC 3.70 2.26–6.08 ,0.001 0.86 ,0.001
CRP 1.66 1.24–2.21 ,0.001
Copeptin 1.53 1.07–2.18 0.019
Pneumonia
WBC 4.12 1.63–10.39 0.003 0.92 ,0.001
CRP 1.92 1.30–2.84 0.001
Copeptin 2.06 1.19–3.57 0.010
Urinary Tract infection
WBC 3.11 1.55–6.24 0.001 0.85 0.058
CRP 1.62 1.01–2.61 0.047
Copeptin 1.26 0.73–2.19 0.411
Other Infections
WBC 6.84 3.00–15.60 ,0.001 0.90 0.43
CRP 1.29 0.87–1.93 0.208
Copeptin 1.18 0.69–2.03 0.550
Batch 2: WBC+CRP+PCT
Any infection
WBC 3.67 2.42–5.58 ,0.001 0.84 ,0.001
CRP 1.56 1.16–2.11 0.003
PCT 1.25 0.99–1.57 0.064
Pneumonia
WBC 4.25 2.27–7.97 ,0.001 0.90 ,0.001
CRP 1.87 1.39–2.52 ,0.001
PCT 1.36 1.00–1.85 0.052
Urinary Tract Infection
WBC 2.89 1.69–4.95 ,0.001 0.82 0.014
CRP 1.59 0.90–2.81 0.114
PCT 1.19 0.82–1.70 0.359
Other Infections
WBC 5.74 3.33–9.87 ,0.001 0.89 0.25
CRP 1.53 0.92–2.55 0.103
PCT 0.85 0.59–1.24 0.407
WBC: white blood cells; CRP: C-reactive protein; PCT: procalcitonin. AUC: Area
under the curve to predict infection using the combined model of all
predictors.g.
*adjusted for all predictors in the respective model.
**Wald-p: refers to the comparison of the combined model with the model of
the strongest predictor, alone which always was WBC.
doi:10.1371/journal.pone.0048309.t006
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